


B5 2300-19199



(11) Publication number:

**0 388 232  
A1**

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 90302866.0

(51) Int. Cl.<sup>5</sup> C12N 15/51, A61K 39/29,  
G01N 33/576, C12Q 1/70

(22) Date of filing: 16.03.90

(30) Priority: 17.03.89 US 325338  
20.04.89 US 341334  
18.05.89 US 355002(43) Date of publication of application:  
19.09.90 Bulletin 90/38(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE(71) Applicant: CHIRON CORPORATION  
4560 Horton Street  
Emeryville California 94608(US)(72) Inventor: Houghton, Michael  
53 Rosemead Court  
Danville, California 94526(US)  
Inventor: Choo, Qui-Lim  
5700 Fern Street  
El Cerrito, California 94530(US)  
Inventor: Kuo, George  
1370 Sixth Avenue  
San Francisco, California 94122(US)(74) Representative: Goldin, Douglas Michael et al  
J.A. KEMP & CO. 14, South Square Gray's Inn  
London WC1R 5EU(GB)

(54) NANBV diagnostics and vaccines.

(57) A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. The initial work on this virus, which includes a partial genomic sequence of the prototype HCV isolate, is described in EPO Pub. No. 318,216, and PCT Pub. No. WO/89/04669. The present invention, which in part is based on new HCV sequences and polypeptides which are not disclosed in the above-cited publications, includes the application of these new sequences and polypeptides in immunoassays, probe diagnostics, anti-HCV antibody production, PCR technology, and recombinant DNA technology. Included within the invention also are novel immunogenic polypeptides encoded within clones containing HCV cDNA, novel methods for purifying an immunogenic HCV polypeptide, and antisense polynucleotides derived from HCV cDNA.

**EP 0 388 232 A1**

## EP 0 388 232 A1

## NANBV DIAGNOSTICS AND VACCINES

Technical Field

The invention relates to materials and methodologies for managing the spread of non-A, non-B hepatitis virus (NANBV) infection. More specifically, it relates to polynucleotides derived from the genome of an etiologic agent of NANBV, hepatitis C virus (HCV), to polypeptides encoded therein, and to antibodies directed to the polypeptides. These reagents are useful as screening agents for HCV and its infection, and as protective agents against the disease.

References Cited in the Application

- Barr et al. (1986), *Biotechniques* 4:428.
- Botstein (1979), *Gene* 8:17.
- Brinton, M.A. (1986) in *THE VIRUSES: THE TOGAVIRIDAE AND FLAVIVIRIDAE* (Series eds. Fraenkel-Conrat and Wagner, vol. eds. Schlesinger and Schlesinger, Plenum Press), p.327-374.
- Broach (1981) in: *Molecular Biology of the Yeast Saccharomyces*, Vol. 1, p.445. Cold Spring Harbor Press.
- Broach et al. (1983), *Meth. Enz.* 101:307.
- Chang et al. (1977), *Nature* 198:1056.
- Chirgwin et al. (1979), *Biochemistry* 18:5294.
- Chomczynski and Sacchi (1987), *Analytical Biochemistry* 162:156.
- Clewell et al. (1969), *Proc. Natl. Acad. Sci. USA* 62:1159.
- Clewell (1972), *J. Bacteriol.* 110:667.
- Cohen (1972), *Proc. Natl. Acad. Sci. USA* 69:2110.
- Cousens et al. (1987), *gene* 61:265.
- De Boer et al. (1983), *Proc. Natl. Acad. Sci. USA* 292:128.
- Dreesman et al. (1985), *J. Infect. Disease* 151:761.
- Feinstone, S.M. and Hoofnagle, J.H. (1984), *New Engl. J. Med.* 311:185.
- Fields & Knipe (1986), *FUNDAMENTAL VIROLOGY* (Raven Press, N.Y.).
- Fiers et al. (1978), *Nature* 273:113.
- Gerety, R.J. et al., in *VIRAL HEPATITIS AND LIVER DISEASE* (Vyas, B.N., Dienstag, J.L., and Hoofnagle, J.H., eds, Grune and Stratton, Inc., 1984) pp 23-47.
- Goeddel et al. (1980), *Nucleic Acids Res.* 8:4057.
- Graham and Van der Eb (1978), *Virology* 52:546.
- Grunstein and Hogness (1975), *Proc. Natl. Acad. Sci. USA* 73:3961.
- Grych et al. (1985), *Nature* 316:74.
- Gubler and Hoffman (1983), *Gene* 25:263.
- Hahn (1988) *Virology* 162:167.
- Hammerling et al. (1981), *MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS*.
- Han (1987), *Biochemistry* 26:1617.
- Helfman (1983), *Proc. Natl. Acad. Sci. USA* 80:31.
- Hess et al. (1968), *J. Adv. Enzyme Reg* 7:149.
- Hinnen et al. (1978), *Proc. Natl. Acad. Sci.* 75:1929.
- Hitzeman et al. (1980), *J. Biol. Chem.* 255:2073.
- Holland et al. (1978), *Biochemistry* 17:4900.
- Holland (1981), *J. Biol. Chem.* 256: 1385.
- Houghton et al. (1981), *Nucleic Acids Res.* 9:247.
- Hunyh, T.V. et al. (1985) in *DNA CLONING TECHNIQUES; A PRACTICAL APPROACH* (D. Glover, Ed., IRL Press, Oxford, U.K.) pp. 49-78.
- Immun. Rev. (1982) 62:185.
- Iwarson (1987), *British Medical J.* 295:946.
- Kennett et al. (1980) *MONOCLONAL ANTIBODIES*.
- Kyte and Doolittle (1982), *J. Mol. Biol.* 157:105-132.
- Laemmli (1970), *Nature* 227, 680.
- Lee et al. (1988), *Science* 239:1288.
- Maniatis, T., et al. (1982) *MOLECULAR CLONING; A LABORATORY MANUAL* (Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).

## EP 0 388 232 A1

- Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London).
- Maxam et al. (1980), *Methods in Enzymology* 65:499.
- MacNamara et al. (1984), *Science* 226:1325.
- 5 Messing et al. (1981), *Nucleic Acids Res.* 9:309.
- Messing (1983), *Methods in Enzymology* 101:20-37. METHODS IN ENZYMOLOGY (Academic Press).
- Michelle et al., Int. Symposium on Viral Hepatitis.
- Monath (1986) in THE VIRUSES: THE TOGAVIRIDAE AND FLAVIVIRIDAE (Series eds. Fraenkel-Conrat and Wagner, vol. eds. Schlesinger and Schlesinger, Plenum Press), p.375-440.
- 10 Nagahuma et al. (1984), *Anal. Biochem.* 141:74.
- Neurath et al. (1984), *Science* 224:392.
- Nisonoff et al. (1981), *Clin. Immunol. Immunopathol.* 21:397-406.
- Overby, L.R. (1985), *Curr. Hepatol.* 5:49.
- 15 Overby, L.R. (1986), *Curr. Hepatol.* 6:65.
- Overby, L.R. (1987), *Curr. Hepatol.* 7:35.
- Peleg (1969), *Nature* 221:193.
- Pfeferkorn and Shapiro (1974), in COMPREHENSIVE VIROLOGY, Vol. 2 (Fraenkel-Conrat & Wagner, eds., Plenum, N.Y.) pp. 171-230.
- 20 Prince, A.M. (1983), *Annu. Rev. Microbiol.* 37:217.
- Rice et al. (1985), *Science* 229:726.
- Rice et al. (1986) in THE VIRUSES: THE TOGAVIRIDAE AND FLAVIVIRIDAE (Series eds. Fraenkel-Conrat and Wagner, vol. eds. Schlesinger and Schlesinger, Plenum Press), p.279-328.
- Roehrig (1986) in THE VIRUSES: THE TOGAVIRIDAE AND FLAVIVIRIDAE (Series eds. Fraenkel-Conrat and Wagner, vol. eds. Schlesinger and Schlesinger, Plenum Press)
- 25 Sadler et al. (1980), *Gene* 8, 279.
- Saiki et al. (1986), *Nature* 324: 183.
- Saiki et al. (1988), *Science* 239:487.
- Sanger et al. (1977), *Proc. Natl. Acad. Sci. USA* 74:5463.
- 30 Schlesinger et al. (1986), *J. Virol.* 60:1153.
- Schreier, M., et al. (1980) HYBRIDOMA TECHNIQUES
- Scopes (1984), PROTEIN PURIFICATION, PRINCIPLES AND PRACTICE, SECOND EDITION (Springer-Verlag, N.Y.).
- Shimatake et al. (1981), *Nature* 292:128.
- 35 Sippel (1973), *Eur. J. Biochem.* 37:31.
- Steimer et al. (1986), *J. Virol.* 58:9.
- Stollar (1980), in THE TOGAVIRUSES (R.W. Schlesinger, ed., Academic Press, N.Y.), pp. 584-622.
- Sumiyoshi et al. (1987), *Virology* 161:497.
- Taylor et al. (1976), *Biochem. Biophys. Acta* 442:324.
- 40 Towbin et al. (1979), *Proc. Natl. Acad. Sci. USA* 76, 4350.
- Tsu and Herzenberg (1980), in SELECTED METHODS IN CELLULAR IMMUNOLOGY (W.H. Freeman and Co.) pp. 373-391.
- Vytdehaag et al. (1985), *J. Immunol.* 134:1225.
- Valenzuela, P., et al. (1982), *Nature* 298:344.
- 45 Valenzuela, P., et al. (1984), in HEPATITIS B (Millman, I., et al., ed, Plenum Press) pp. 225-236.
- Warner (1984), *DNA* 3:401.
- Wu and Grossman (1987), *Methods in Enzymology* Vol. 154, RECOMBINANT DNA, Part E.
- Wu (1987), *Methods in Enzymology* vol 155, RECOMBINANT DNA, part F.
- Zoller (1982), *Nucleic Acids Res.* 10:6487. Cited Patents
- 50 EPO Pub. No. 318,216
- PCT Pub. No. WO 89/04669
- U.S. Patent No. 4,341,761
- U.S. Patent No. 4,399,121
- U.S. Patent No. 4,427,763
- 65 U.S. Patent No. 4,444,887
- U.S. Patent No. 4,466,917
- U.S. Patent No. 4,472,500
- U.S. Patent No. 4,491,632

## EP 0 388 232 A1

U.S. Patent No. 4,493,890

Background Art

5 Non-A, Non-B hepatitis (NANBH) is a transmissible disease or family of diseases that are believed to be viral-induced, and that are distinguishable from other forms of viral-associated liver diseases, including that caused by the known hepatitis viruses, i.e., hepatitis A virus (HAV), hepatitis B virus (HBV), and delta hepatitis virus (HDV), as well as the hepatitis induced by cytomegalovirus (CMV) or Epstein-Barr virus (EBV). NANBH was first identified in transfused individuals. Transmission from man to chimpanzee and serial passage in chimpanzees provided evidence that NANBH is due to a transmissible infectious agent or agents.

Epidemiologic evidence is suggestive that there may be three types of NANBH: the water-borne epidemic type; the blood or needle associated type; and the sporadically occurring (community acquired) type. However, the number of agents which may be the causative of NANBH are unknown.

15 Clinical diagnosis and identification of NANBH has been accomplished primarily by exclusion of other viral markers. Among the methods used to detect putative NANBV antigens and antibodies are agar-gel diffusion, counterimmunoelectrophoresis, immunofluorescence microscopy, immune electron microscopy, radioimmunoassay, and enzyme-linked immunosorbent assay. However, none of these assays has proved to be sufficiently sensitive, specific, and reproducible to be used as a diagnostic test for NANBH.

20 Previously there was neither clarity nor agreement as to the identity or specificity of the antigen-antibody systems associated with agents of NANBH. This was due, at least in part, to the prior or co-infection of HBV with NANBV in individuals, and to the known complexity of the soluble and particulate antigens associated with HBV, as well as to the integration of HBV DNA into the genome of liver cells. In addition, there is the possibility that NANBH is caused by more than one infectious agent, as well as the possibility that NANBH has been misdiagnosed. Moreover, it is unclear what the serological assays detect in the serum of patients with NANBH. It has been postulated that the agar-gel diffusion and counterimmunoelectrophoresis assays detect autoimmune responses or nonspecific protein interactions that sometimes occur between serum specimens, and that they do not represent specific NANBV antigen-antibody reactions. The immunofluorescence, and enzyme-linked immunosorbent, and radioimmunoassays appear to detect low levels of a rheumatoid-factor-like material that is frequently present in the serum of patients with NANBH as well as in patients with other hepatic and nonhepatic diseases. Some of the reactivity detected may represent antibody to host-determined cytoplasmic antigens.

25 There have been a number of candidate NANBV. See, for example the reviews by Prince (1983), Feinstone and Hoofnagle (1984), and Overby (1985, 1986, 1987) and the article by Iwarson (1987). However, there is no proof that any of these candidates represent the etiological agent of NANBH.

The demand for sensitive, specific methods for screening and identifying carriers of NANBV and NANBV contaminated blood or blood products is significant. Post-transfusion hepatitis (PTH) occurs in approximately 10% of transfused patients, and NANBH accounts for up to 90% of these cases. The major problem in this disease is the frequent progression to chronic liver damage (25-55%).

30 Patient care as well as the prevention of transmission of NANBH by blood and blood products or by close personal contact require reliable screening, diagnostic and prognostic tools to detect nucleic acids, antigens and antibodies related to NANBV. In addition, there is also a need for effective vaccines and immunotherapeutic therapeutic agents for the prevention and/or treatment of the disease.

45 Applicant discovered a new virus, the Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH (BB-NANBH). Applicant's initial work, including a partial genomic sequence of the prototype HCV isolate, CDC/HCV1 (also called HCV1), is described in EPO Pub. No. 318,216 (published 31 May 1989) and PCT Pub. No. WO 89/04669 (published 1 June 1989). The disclosures of these patent applications, as well as any corresponding national patent applications, are incorporated herein by reference. These applications teach, inter alia, recombinant DNA methods of cloning and expressing HCV sequences, HCV polypeptides, HCV immunodiagnostic techniques, HCV probe diagnostic techniques, anti-HCV antibodies, and methods of isolating new HCV sequences, including sequences of new HCV isolates.

55

Disclosure of the Invention

The present invention is based, in part, on new HCV sequences and polypeptides that are not disclosed

## EP 0 388 232 A1

in EPO Pub. No. 318,216, or in PCT Pub. No. WO 89/04669. Included within the invention is the application of these new sequences and polypeptides in, inter alia, immunodiagnostics, probe diagnostics, anti-HCV antibody production, PCR technology and recombinant DNA technology. Included within the invention, also, are new immunoassays based upon the immunogenicity of HCV polypeptides disclosed herein. The new subject matter claimed herein, while developed using techniques described in, for example, EPO Pub. No. 318,216, has a priority date which antecedes that publication, or any counterpart thereof. Thus, the invention provides novel compositions and methods useful for screening samples for HCV antigens and antibodies, and useful for treatment of HCV infections.

Accordingly, one aspect of the invention is a recombinant polynucleotide comprising a sequence derived from HCV cDNA, wherein the HCV cDNA is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

Another aspect of the invention is a purified polypeptide comprising an epitope encoded within HCV cDNA wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

Yet another aspect of the invention is an immunogenic polypeptide produced by a cell transformed with a recombinant expression vector comprising an ORF of DNA derived from HCV cDNA, wherein the HCV cDNA is comprised of a sequence derived from the HCV cDNA sequence in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33C or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, and wherein the ORF is operably linked to a control sequence compatible with a desired host.

Another aspect of the invention is a peptide comprising an HCV epitope, wherein the peptide is of the formula

AA<sub>x</sub>-AA<sub>y</sub>,

wherein x and y designate amino acid numbers shown in Fig. 17, and wherein the peptide is selected from the group consisting of AA1-AA25, AA1-AA50, AA1-AA84, AA9-AA177, AA1-AA10, AA5-AA20, AA20-AA25, AA35-AA45, AA50-AA100, AA40-AA90, AA45-AA65, AA65-AA75, AA80-90, AA99-AA120, AA95-AA110, AA105-AA120, AA100-AA150, AA150-AA200, AA155-AA170, AA190-AA210, AA200-AA250, AA220-AA240, AA245-AA265, AA250-AA300, AA290-AA330, AA290-305, AA300-AA350, AA310-AA330, AA350-AA400, AA380-AA395, AA405-AA495, AA400-AA450, AA405-AA415, AA415-AA425, AA425-AA435, AA437-AA582, AA450-AA500, AA440-AA460, AA460-AA470, AA475-AA495, AA500-AA550, AA511-AA690, AA515-AA550, AA550-AA600, AA550-AA625, AA575-AA605, AA585-AA600, AA600-AA650, AA600-AA625, AA635-AA665, AA650-AA700, AA645-AA680, AA700-AA750, AA700-AA725, AA700-AA750, AA725-AA775, AA770-AA790, AA750-AA800, AA800-AA815, AA825-AA850, AA850-AA875, AA800-AA850, AA920-AA990, AA850-AA900, AA920-AA945, AA940-AA965, AA970-AA990, AA950-AA1000, AA1000-AA1060, AA1000-AA1025, AA1000-AA1050, AA1025-AA1040, AA1040-AA1055, AA1075-AA1175, AA1050-AA1200, AA1070-AA1100, AA1100-AA1130, AA1140-AA1165, AA1192-AA1457, AA1195-AA1250, AA1200-AA1225, AA1225-AA1250, AA1250-AA1300, AA1260-AA1310, AA1260-AA1280, AA1266-AA1428, AA1300-AA1350, AA1290-AA1310, AA1310-AA1340, AA1345-AA1405, AA1345-AA1365, AA1350-AA1400, AA1365-AA1380, AA1380-AA1405, AA1400-AA1450, AA1450-AA1500, AA1460-AA1475, AA1475-AA1515, AA1475-AA1500, AA1500-AA1550, AA1500-AA1515, AA1515-AA1550, AA1550-AA1600, AA1545-AA1560, AA1569-AA1931, AA1570-AA1590, AA1595-AA1610, AA1590-AA1650, AA1610-AA1645, AA1650-AA1690, AA1685-AA1770, AA1689-AA1805, AA1690-AA1720, AA1694-AA1735, AA1720-AA1745, AA1745-AA1770, AA1750-AA1800, AA1775-AA1810, AA1795-AA1850, AA1850-AA1900, AA1900-AA1950, AA1900-AA1920, AA1916-AA2021, AA1920-AA1940, AA1949-AA2124, AA1950-AA2000, AA1950-AA1985, AA1980-AA2000, AA2000-AA2050, AA2005-AA2025, AA2020-AA2045, AA2045-AA2100, AA2045-AA2070, AA2054-AA2223, AA2070-AA2100, AA2100-AA2150, AA2150-AA2200, AA2200-AA2250, AA2200-AA2325, AA2250-AA2330, AA2255-AA2270, AA2265-AA2280, AA2280-AA2290, AA2287-AA2385, AA2300-AA2350, AA2290-AA2310, AA2310-AA2330, AA2330-AA2350, AA2350-AA2400, AA2348-AA2464, AA2345-AA2415, AA2345-AA2375, AA2370-AA2410, AA2371-AA2502, AA2400-AA2450, AA2400-AA2425, AA2415-AA2450, AA2445-AA2500, AA2445-AA2475, AA2470-AA2490, AA2500-AA2550, AA2505-AA2540, AA2535-AA2560, AA2550-AA2600, AA2560-AA2580, AA2600-AA2650, AA2605-AA2620, AA2620-AA2650, AA2640-AA2660, AA2650-AA2700, AA2655-AA2670, AA2670-AA2700, AA2700-AA2750, AA2740-AA2760, AA2750-AA2800, AA2755-AA2780, AA2780-AA2830, AA2785-AA2810, AA2796-AA2886, AA2810-AA2825, AA2800-AA2850, AA2850-AA2900, AA2850-AA2865, AA2885-AA2905, AA2900-AA2950, AA2910-AA2930, AA2925-AA2950, AA2945-end(C terminal).

Still another aspect of the invention is a monoclonal antibody directed against an epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or

## EP 0 388 232 A1

8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

Yet another aspect of the invention is a preparation of purified polyclonal antibodies directed against a polypeptide comprised of an epitope encoded within HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

Still another aspect of the invention is a polynucleotide probe for HCV, wherein the probe is comprised of an HCV sequence derived from an HCV cDNA sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or from the complement of the HCV cDNA sequence.

Yet another aspect of the invention is a kit for analyzing samples for the presence of polynucleotides from HCV comprising a polynucleotide probe containing a nucleotide sequence of about 8 or more nucleotides, wherein the nucleotide sequence is derived from HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, wherein the polynucleotide probe is in a suitable container.

Another aspect of the invention is a kit for analyzing samples for the presence of an HCV antigen comprising an antibody which reacts immunologically with an HCV antigen, wherein the antigen contains an epitope encoded within HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or wherein the HCV cDNA is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

Yet another aspect of the invention is a kit for analyzing samples for the presence of an HCV antibody comprising an antigenic polypeptide containing an HCV epitope encoded within HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

Another aspect of the invention is a kit for analyzing samples for the presence of an HCV antibody comprising an antigenic polypeptide expressed from HCV cDNA in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33C or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, wherein the antigenic polypeptide is present in a suitable container.

Still another aspect of the invention is a method for detecting HCV nucleic acids in a sample comprising:

(a) reacting nucleic acids of the sample with a polynucleotide probe for HCV, wherein the probe is comprised of an HCV sequence derived from an HCV cDNA sequence is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, and wherein the reacting is under conditions which allow the formation of a polynucleotide duplex between the probe and the HCV nucleic acid from the sample; and (b) detecting a polynucleotide duplex which contains the probe, formed in step (a).

Yet another aspect of the invention is an immunoassay for detecting an HCV antigen comprising:

(a) incubating a sample suspected of containing an HCV antigen with an antibody directed against an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the incubating is under conditions which allow formation of an antigen-antibody complex; and (b) detecting an antibody-antigen complex formed in step (a) which contains the antibody.

Still another aspect of the invention is an immunoassay for detecting antibodies directed against an HCV antigen comprising:

(a) incubating a sample suspected of containing anti-HCV antibodies with an antigen polypeptide containing an epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the incubating is under conditions which allow formation of an antigen-antibody complex; and detecting an antibody-antigen complex formed in step (a) which contains the antigen polypeptide.

Another aspect of the invention is a vaccine for treatment of HCV infection comprising an immunogenic polypeptide containing an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence

## EP 0 388 232 A1

indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17 or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the immunogenic polypeptide is present in a pharmacologically effective dose in a pharmaceutically acceptable excipient.

Yet another aspect of the invention is a method for producing antibodies to HCV comprising administering to an individual an isolated immunogenic polypeptide containing an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is of the sequence present in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33C or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, and wherein the immunogenic polypeptide is present in a pharmacologically effective dose in a pharmaceutically acceptable excipient.

Still another aspect of the invention is an antisense polynucleotide derived from HCV cDNA, wherein the HCV cDNA is that shown in Fig. 17.

Yet another aspect of the invention is a method for preparing purified fusion polypeptide C100-3 comprising:

- (a) providing a crude cell lysate containing polypeptide C100-3,
- (b) treating the crude cell lysate with an amount of acetone which causes the polypeptide to precipitate, and solubilizing the precipitated
- (c) isolating material,
- (d) isolating the C100-3 polypeptide by anion exchange chromatography, and
- (e) further isolating the C100-3 polypeptide of step (d) by gel filtration.

#### 25 Brief Description of the Drawings

Fig. 1 shows the sequence of the HCV cDNA in clone 12f, and the amino acids encoded therein.

Fig. 2 shows the HCV cDNA sequence in clone k9-1, and the amino acids encoded therein.

Fig. 3 shows the sequence of clone 15e, and the amino acids encoded therein.

Fig. 4 shows the nucleotide sequence of HCV cDNA in clone 13i, the amino acids encoded therein, and the sequences which overlap with clone 12f.

Fig. 5 shows the nucleotide sequence of HCV cDNA in clone 26j, the amino acids encoded therein, and the sequences which overlap clone 13i.

Fig. 6 shows the nucleotide sequence of HCV cDNA in clone CA59a, the amino acids encoded therein, and the sequences which overlap with clones 26j and K9-1.

Fig. 7 shows the nucleotide sequence of HCV cDNA in clone CA84a, the amino acids encoded therein, and the sequences which overlap with clone CA59a.

Fig. 8 shows the nucleotide sequence of HCV cDNA in clone CA156e, the amino acids encoded therein, and the sequences which overlap with CA84a.

Fig. 9 shows the nucleotide sequence of HCV cDNA in clone CA167b, the amino acids encoded therein, and the sequences which overlap CA156e.

Fig. 10 shows the nucleotide sequence of HCV cDNA in clone CA216a, the amino acids encoded therein, and the overlap with clone CA167b.

Fig. 11 shows the nucleotide sequence of HCV cDNA in clone CA290a, the amino acids encoded therein, and the overlap with clone CA216a.

Fig. 12 shows the nucleotide sequence of HCV cDNA in clone ag30a and the overlap with clone CA290a.

Fig. 13 shows the nucleotide sequence of HCV cDNA in clone CA205a, and the overlap with the HCV cDNA sequence in clone CA290a.

Fig. 14 shows the nucleotide sequence of HCV cDNA in clone 18g, and the overlap with the HCV cDNA sequence in clone ag30a.

Fig. 15 shows the nucleotide sequence of HCV cDNA in clone 16jh, the amino acids encoded therein, and the overlap of nucleotides with the HCV cDNA sequence in clone 15e.

Fig. 16 shows the ORF of HCV cDNA derived from clones pi14a, CA167b, CA156e, CA84a, CA59a, K9-1, 12f, 14i, 11b, 7f, 7e, 8h, 33c, 40b, 37b, 35, 36, 81, 32, 33b, 25c, 14c, 8f, 33f, 33g, 39c, 35f, 19g, 26g, and 15e.

Fig. 17 shows the sense strand of the compiled HCV cDNA sequence derived from the above-described clones and the compiled HCV cDNA sequence published in EPO Pub. No. 318,216. The clones

## EP 0 388 232 A1

from which the sequence was derived are b114a, 18g, ag30a, CA205a, CA290a, CA216a, pi14a, CA167b, CA156e, CA84a, CA59a, K9-1 (also called k9-1), 26j, 13i, 12f, 14i, 11b, 7f, 7e, 8h, 33c, 40b, 37b, 35, 36, 81, 32, 33b, 25c, 14c, 8f, 33f, 33g, 39c, 35f, 19g, 26g, 15e, b5a, and 16jh. In the figure the three horizontal dashes above the sequence indicate the position of the putative initiator methionine codon; the two vertical dashes indicate the first and last nucleotides of the published sequence. Also shown in the figure is the amino acid sequence of the putative polyprotein encoded in the HCV cDNA.

Fig. 18 is a diagram of the immunological colony screening method used in antigenic mapping studies.

Fig. 19 shows the hydrophobicity profiles of polyproteins encoded in HCV and in West Nile virus.

Fig. 20 is a tracing of the hydrophilicity/hydrophobicity profile and of the antigenic Index of the putative HCV polyprotein.

Fig. 21 shows the conserved co-linear peptides in HCV and Flaviviruses.

### Modes for Carrying Out the Invention

#### I. Definitions

The term "hepatitis C virus" has been reserved by workers in the field for an heretofore unknown etiologic agent of NANBH. Accordingly, as used herein, "hepatitis C virus" (HCV) refers to an agent causative of NANBH, which was formerly referred to as NANBV and/or BB-NANBV. The terms HCV, NANBV, and BB-NANBV are used interchangeably herein. As an extension of this terminology, the disease caused by HCV, formerly called NANB hepatitis (NANBH), is called hepatitis C. The terms NANBH and hepatitis C may be used interchangeably herein.

The term "HCV", as used herein, denotes a viral species of which pathogenic strains cause NANBH, and attenuated strains or defective interfering particles derived therefrom. As shown infra., the HCV genome is comprised of RNA. It is known that RNA containing viruses have relatively high rates of spontaneous mutation, i.e., reportedly on the order of  $10^{-3}$  to  $10^{-4}$  per incorporated nucleotide (Fields & Knipe (1986)). Therefore, there are multiple strains, which may be virulent or avirulent, within the HCV species described infra. The compositions and methods described herein, enable the propagation, identification, detection, and isolation of the various HCV strains or isolates. Moreover, the disclosure herein allows the preparation of diagnostics and vaccines for the various strains, as well as compositions and methods that have utility in screening procedures for anti-viral agents for pharmacologic use, such as agents that inhibit replication of HCV.

The information provided herein, although derived from the prototype strain or isolate of HCV, hereinafter referred to as CDC/HCV1 (also called HCV1), is sufficient to allow a viral taxonomist to identify other strains which fall within the species. The information provided herein allows the belief that HCV is a Flavi-like virus. The morphology and composition of Flavivirus particles are known, and are discussed in Brinton (1986). Generally, with respect to morphology, Flaviviruses contain a central nucleocapsid surrounded by a lipid bilayer. Virions are spherical and have a diameter of about 40-50 nm. Their cores are about 25-30 nm in diameter. Along the outer surface of the virion envelope are projections that are about 5-10 nm long with terminal knobs about 2 nm in diameter.

Different strains or isolates of HCV are expected to contain variations at the amino acid and nucleic acids compared with the prototype isolate, HCV1. Many isolates are expected to show much (i.e. more than about 40%) homology in the total amino acid sequence compared with HCV1. However, it may also be found that other less homologous HCV isolates. These would be defined as HCV strains according to various criteria such as an ORF of approximately 9,000 nucleotides to approximately 12,000 nucleotides, encoding a polyprotein similar in size to that of HCV1, an encoded polyprotein of similar hydrophobic and antigenic character to that of HCV1, and the presence of co-linear peptide sequences that are conserved with HCV1. In addition, the genome would be a positive-stranded RNA.

HCV encodes at least one epitope which is immunologically identifiable with an epitope in the HCV genome from which the cDNAs described herein are derived; preferably the epitope is contained an amino acid sequence described herein. The epitope is unique to HCV when compared to other known Flaviviruses. The uniqueness of the epitope may be determined by its immunological reactivity with anti-HCV antibodies and lack of immunological reactivity with antibodies to other Flavivirus species. Methods for determining immunological reactivity are known in the art, for example, by radioimmunoassay, by Elisa assay, by hemagglutination, and several examples of suitable techniques for assays are provided herein.

In addition to the above, the following parameters of nucleic acid homology and amino acid homology



## EP 0 388 232 A1

are applicable, either alone or in combination, in identifying a strain or isolate as HCV. Since HCV strains and isolates are evolutionarily related, it is expected that the overall homology of the genomes at the nucleotide level probably will be about 40% or greater, probably about 60% or greater, and even more probably about 80% or greater; and in addition that there will be corresponding contiguous sequences of at least about 13 nucleotides. The correspondence between the putative HCV strain genomic sequence and the CDC/HCV1 cDNA sequence can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide from the putative HCV, and the HCV cDNA sequence(s) described herein. For example, also, they can be determined by hybridization of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to S<sub>1</sub> digestion), followed by digestion with single stranded specific nuclease(s), followed by size determination of the digested fragments.

Because of the evolutionary relationship of the strains or isolates of HCV, putative HCV strains or isolates are identifiable by their homology at the polypeptide level. Generally, HCV strains or isolates are expected to be more than about 40% homologous, probably more than about 70% homologous, and even more probably more than about 80% homologous, and some may even be more than about 90% homologous at the polypeptide level. The techniques for determining amino acid sequence homology are known in the art. For example, the amino acid sequence may be determined directly and compared to the sequences provided herein. Alternatively the nucleotide sequence of the genomic material of the putative HCV may be determined (usually via a cDNA intermediate), the amino acid sequence encoded therein can be determined, and the corresponding regions compared.

As used herein, a polynucleotide "derived from" a designated sequence refers to a polynucleotide sequence which is comprised of a sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about 15-20 nucleotides corresponding to a region of the designated nucleotide sequence. "Corresponding" means homologous to or complementary to the designated sequence. Preferably, the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is unique to an HCV genome. Whether or not a sequence is unique to the HCV genome can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., Genbank, to determine whether it is present in the uninfected host or other organisms. The sequence can also be compared to the known sequences of other viral agents, including those which are known to induce hepatitis, e.g., HAV, HBV, and HDV, and to other members of the Flaviviridae. The correspondence or non-correspondence of the derived sequence to other sequences can also be determined by hybridization under the appropriate stringency conditions. Hybridization techniques for determining the complementarity of nucleic acid sequences are known in the art, and are discussed *infra*. See also, for example, Maniatis et al. (1982). In addition, mismatches of duplex polynucleotides formed by hybridization can be determined by known techniques, including for example, digestion with a nuclease such as S<sub>1</sub> that specifically digests single-stranded areas in duplex polynucleotides. Regions from which typical DNA sequences may be "derived" include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.

The derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use.

Similarly, a polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.

A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence, for example, the HCV cDNA sequences described herein, or from an HCV genome; it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system, or isolation from mutated HCV. A recombinant or derived polypeptide may include one or more analogs of amino acids or unnatural amino acids in its sequence. Methods of inserting analogs of amino acids into a sequence are known in the art. It also may include one or more labels, which are known to those of skill in the art.

The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation which: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide

## EP 0 388 232 A1

other than that to which it is linked in nature, or (3) does not occur in nature.

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA, as well as double- and single stranded RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide.

The term "purified viral polynucleotide" refers to an HCV genome or fragment thereof which is essentially free, i.e., contains less than about 50%, preferably less than about 70%, and even more preferably less than about 90% of polypeptides with which the viral polynucleotide is naturally associated. Techniques for purifying viral polynucleotides from viral particles are known in the art, and include for example, disruption of the particle with a chaotropic agent, differential extraction and separation of the polynucleotide(s) and polypeptides by ion-exchange chromatography, affinity chromatography, and sedimentation according to density.

The term "purified viral polypeptide" refers to an HCV polypeptide or fragment thereof which is essentially free, i.e., contains less than about 50%, preferably less than about 70%, and even more preferably less than about 90%, of cellular components with which the viral polypeptide is naturally associated. Techniques for purifying viral polypeptides are known in the art, and examples of these techniques are discussed infra. The term "purified viral polynucleotide" refers to an HCV genome or fragment thereof which is essentially free, i.e., contains less than about 20%, preferably less than about 50%, and even more preferably less than about 70% of polypeptides with which the viral polynucleotide is naturally associated. Techniques for purifying viral polynucleotides from viral particles are known in the art, and include for example, disruption of the particle with a chaotropic agent, and separation of the polynucleotide(s) and polypeptides by ion-exchange chromatography, affinity chromatography, and sedimentation according to density.

"Recombinant host cells", "host cells", "cells", "cell lines", "cell cultures", and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

A "replicon" is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.

"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers. The term "control sequences" is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.

A "coding sequence" is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop

## EP 0 388 232 A1

codon at the 3'-terminus. A coding sequence can include, but is not limited to mRNA, cDNA, and recombinant polynucleotide sequences.

"Immunologically identifiable with/as" refers to the presence of epitope(s) and polypeptides(s) which are also present in the designated polypeptide(s), usually HCV proteins. Immunological identity may be determined by antibody binding and/or competition in binding; these techniques are known to those of average skill in the art, and are also illustrated infra.

As used herein, "epitope" refers to an antigenic determinant of a polypeptide; an epitope could comprise 3 amino acids in a spatial conformation which is unique to the epitope, generally an epitope consists of at least 5 such amino acids, and more usually, consists of at least 8-10 such amino acids. Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance.

A polypeptide is "immunologically reactive" with an antibody when it binds to an antibody due to antibody recognition of a specific epitope contained within the polypeptide. Immunological reactivity may be determined by antibody binding, more particularly by the kinetics of antibody binding, and/or by competition in binding using as competitor(s) a known polypeptide(s) containing an epitope against which the antibody is directed. The techniques for determining whether a polypeptide is immunologically reactive with an antibody are known in the art.

As used herein, the term "immunogenic polypeptide" is a polypeptide that elicits a cellular and/or humoral response, whether alone or linked to a carrier in the presence or absence of an adjuvant.

The term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

"Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

"Treatment" as used herein refers to prophylaxis and/or therapy.

An "individual", as used herein, refers to vertebrates, particularly members of the mammalian species, and includes but is not limited to domestic animals, sports animals, and primates, including humans.

As used herein, the "sense strand" of a nucleic acid contains the sequence that has sequence homology to that of mRNA. The "anti-sense strand" contains a sequence which is complementary to that of the "sense strand".

As used herein, a "positive stranded genome" of a virus is one in which the genome, whether RNA or DNA, is single-stranded and which encodes a viral polypeptide(s). Examples of positive stranded RNA viruses include Togaviridae, Coronaviridae, Retroviridae, Picornaviridae, and Caliciviridae. Included also, are the Flaviviridae, which were formerly classified as Togaviridae. See Fields & Knipe (1986).

As used herein, "antibody-containing body component" refers to a component of an individual's body which is a source of the antibodies of interest. Antibody containing body components are known in the art, and include but are not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, white blood cells, and myelomas.

As used herein, "purified HCV" refers to a preparation of HCV which has been isolated from the cellular constituents with which the virus is normally associated, and from other types of viruses which may be present in the infected tissue. The techniques for isolating viruses are known to those of skill in the art, and include, for example, centrifugation and affinity chromatography; a method of preparing purified HCV is discussed infra.

The term "HCV particles" as used herein include entire virion as well as particles which are intermediates in virion formation. HCV particles generally have one or more HCV proteins associated with the HCV nucleic acid.

As used herein, the term "probe" refers to a polynucleotide which forms a hybrid structure with a sequence in a target region, due to complementarity of at least one sequence in the probe with a sequence in the target region. The probe, however, does not contain a sequence complementary to sequence(s) used to prime the polymerase chain reaction.

As used herein, the term "target region" refers to a region of the nucleic acid which is to be amplified

## EP 0 388 232 A1

and/or detected:

As used herein, the term "viral RNA", which includes HCV RNA, refers to RNA from the viral genome, fragments thereof, transcripts thereof, and mutant sequences derived therefrom.

As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of *in vitro* cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components).

## II. Description of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Maniatis, Fritsch & Sambrook, MOLECULAR CLONING: A LABORATORY MANUAL (1982); DNA CLONING, VOLUMES I AND II (D.N. Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed. 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes. (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES I-IV (D.M. Weir and C. C. Blackwell eds 1988). All patents, patent applications, and publications mentioned herein, both *supra* and *infra*, are hereby incorporated herein by reference.

The useful materials and processes of the present invention are made possible by the provision of a family of nucleotide sequences isolated from cDNA libraries which contain HCV cDNA sequences. These cDNA libraries were derived from nucleic acid sequences present in the plasma of an HCV-infected chimpanzee. The construction of one of these libraries, the "c" library (ATCC No. 40394), was reported in EPO Pub. No. 318,216. Several of the clones containing HCV cDNA reported herein were obtained from the "c" library. Although other clones reported herein were obtained from other HCV cDNA libraries, the presence of clones containing the sequences in the "c" library was confirmed. As discussed in EPO Pub. No. 318,216, the family of HCV cDNA sequences isolated from the "c" library are not of human or chimpanzee origin, and show no significant homology to sequences contained within the HBV genome.

The availability of the HCV cDNAs described herein permits the construction of polynucleotide probes which are reagents useful for detecting viral polynucleotides in biological samples, including donated blood. For example, from the sequences it is possible to synthesize DNA oligomers of about 8-10 nucleotides, or larger, which are useful as hybridization probes to detect the presence of HCV RNA in, for example, donated blood, sera of subjects suspected of harboring the virus, or cell culture systems in which the virus is replicating. In addition, the cDNA sequences also allow the design and production of HCV specific polypeptides which are useful as diagnostic reagents for the presence of antibodies raised during HCV infection. Antibodies to purified polypeptides derived from the cDNAs may also be used to detect viral antigens in biological samples, including, for example, donated blood samples, sera from patients with NANBH, and in tissue culture systems being used for HCV replication. Moreover, the immunogenic polypeptides disclosed herein, which are encoded in portions of the ORF of HCV cDNA shown in Fig. 17, are also useful for HCV screening, diagnosis, and treatment, and for raising antibodies which are also useful for these purposes.

In addition, the novel cDNA sequences described herein enable further characterization of the HCV genome. Polynucleotide probes and primers derived from these sequences may be used to amplify sequences present in cDNA libraries, and/or to screen cDNA libraries for additional overlapping cDNA sequences, which, in turn, may be used to obtain more overlapping sequences. As indicated *infra*, and in EPO Pub. No. 318,216, the genome of HCV appears to be RNA comprised primarily of a large open reading frame (ORF) which encodes a large polypeptide.

The HCV cDNA sequences provided herein, the polypeptides derived from these sequences, and the

## EP 0 388 232 A1

immunogenic polypeptides described herein, as well as antibodies directed against these polypeptides are also useful in the isolation and identification of the blood-borne NABV (BB-NANBV) agent(s). For example, antibodies directed against HCV epitopes contained in polypeptides derived from the cDNAs may be used in processes based upon affinity chromatography to isolate the virus. Alternatively, the antibodies may be used to identify viral particles isolated by other techniques. The viral antigens and the genomic material within the isolated viral particles may then be further characterized.

In addition to the above, the information provided infra allows the identification of additional HCV strains or isolates. The isolation and characterization of the additional HCV strains or isolates may be accomplished by isolating the nucleic acids from body components which contain viral particles and/or viral RNA, creating cDNA libraries using polynucleotide probes based on the HCV cDNA probes described infra., screening the libraries for clones containing HCV cDNA sequences described infra., and comparing the HCV cDNAs from the new isolates with the cDNAs described infra. The polypeptides encoded therein, or in the viral genome, may be monitored for immunological cross-reactivity utilizing the polypeptides and antibodies described supra. Strains or isolates which fit within the parameters of HCV, as described in the Definitions section, supra., are readily identifiable. Other methods for identifying HCV strains will be obvious to those of skill in the art, based upon the information provided herein.

#### Isolation of the HCV cDNA Sequences

The novel HCV cDNA sequences described infra. extend the sequence of the cDNA to the HCV genome reported in EPO Pub. No. 318,216. The sequences which are present in clones b114a, 18g, ag30a, CA205a, CA290a, CA216a, pi14a, CA167b, CA156e, CA84a, and CA59a lie upstream of the reported sequence, and when compiled, yield nucleotides nos. -319 to 1348 of the composite HCV cDNA sequence. (The negative number on a nucleotide indicates its distance upstream of the nucleotide which starts the putative initiator MET codon.) The sequences which are present in clones b5a and 16jh lie downstream of the reported sequence, and yield nucleotides nos. 8659 to 8866 of the composite sequence. The composite HCV cDNA sequence which includes the sequences in the aforementioned clones, is shown in Fig. 17.

The novel HCV cDNAs described herein were isolated from a number of HCV cDNA libraries, including the "c" library present in lambda gt11 (ATCC No. 40394). The HCV cDNA libraries were constructed using pooled serum from a chimpanzee with chronic HCV infection and containing a high titer of the virus, i.e., at least  $10^6$  chimp infectious doses/ml (CID/ml). The pooled serum was used to isolate viral particles; nucleic acids isolated from these particles was used as the template in the construction of cDNA libraries to the viral genome. The procedures for isolation of putative HCV particles and for constructing the "c" HCV cDNA library is described in EPO Pub. No. 318,216. Other methods for constructing HCV cDNA libraries are known in the art, and some of these methods are described infra., in the Examples. Isolation of the sequences was by screening the libraries using synthetic polynucleotide probes, the sequences of which were derived from the 5'-region and the 3'-region of the known HCV cDNA sequence. The description of the method to retrieve the cDNA sequences is mostly of historical interest. The resultant sequences (and their complements) are provided herein, and the sequences, or any portion thereof, could be prepared using synthetic methods, or by a combination of synthetic methods with retrieval of partial sequences using methods similar to those described herein.

#### Preparation of Viral Polypeptides and Fragments

The availability of HCV cDNA sequences, or nucleotide sequences derived therefrom (including segments and modifications of the sequence), permits the construction of expression vectors encoding antigenically active regions of the polypeptide encoded in either strand. These antigenically active regions may be derived from coat or envelope antigens or from core antigens, or from antigens which are non-structural including, for example, polynucleotide binding proteins, polynucleotide polymerase(s), and other viral proteins required for the replication and/or assembly of the virus particle. Fragments encoding the desired polypeptides are derived from the cDNA clones using conventional restriction digestion or by synthetic methods, and are ligated into vectors which may, for example, contain portions of fusion sequences such as beta-galactosidase or superoxide dismutase (SOD), preferably SOD. Methods and vectors which are useful for the production of polypeptides which contain fusion sequences of SOD are described in European Patent Office Publication number 0196056, published October 1, 1986. Vectors for the expression of fusion polypeptides of SOD and HCV polypeptides encoded in a number of HCV clones

## EP 0 388 232 A1

are described infra., in the Examples. Any desired portion of the HCV cDNA containing an open reading frame, in either sense strand, can be obtained as a recombinant polypeptide, such as a mature or fusion protein; alternatively, a polypeptide encoded in the cDNA can be provided by chemical synthesis.

The DNA encoding the desired polypeptide, whether in fused or mature form, and whether or not containing a signal sequence to permit secretion, may be ligated into expression vectors suitable for any convenient host. Both eukaryotic and prokaryotic host systems are presently used in forming recombinant polypeptides, and a summary of some of the more common control systems and host cell lines is given infra. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use. Purification may be by techniques known in the art, for example, differential extraction, salt fractionation, chromatography on ion exchange resins, affinity chromatography, centrifuga-  
tion, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins. Such polypeptides can be used as diagnostics, or those which give rise to neutralizing antibodies may be formulated into vaccines. Antibodies raised against these polypeptides can also be used as diagnostics, or for passive immunotherapy. In addition, as discussed infra., antibodies to these polypeptides are useful for isolating and identifying HCV particles.

#### Preparation of Antigenic Polypeptides and Conjugation with Carrier

An antigenic region of a polypeptide is generally relatively small--typically 8 to 10 amino acids or less in length. Fragments of as few as 5 amino acids may characterize an antigenic region. These segments may correspond to regions of HCV antigen. Accordingly, using the cDNAs of HCV as a basis, DNAs encoding short segments of HCV polypeptides can be expressed recombinantly either as fusion proteins, or as isolated polypeptides. In addition, short amino acid sequences can be conveniently obtained by chemical synthesis. In instances wherein the synthesized polypeptide is correctly configured so as to provide the correct epitope, but is too small to be immunogenic, the polypeptide may be linked to a suitable carrier.

A number of techniques for obtaining such linkage are known in the art, including the formation of disulfide linkages using N-succinimidyl-3-(2-pyridylthio)propionate (SPDP) and succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) obtained from Pierce Company, Rockford, Illinois, (if the peptide lacks a sulfhydryl group, this can be provided by addition of a cysteine residue.) These reagents create a disulfide linkage between themselves and peptide cysteine residues on one protein and an amide linkage through the epsilon-amino on a lysine, or other free amino group in the other. A variety of such disulfide/amide-forming agents are known. See, for example, Immun. Rev. (1982) 62:185. Other bifunctional coupling agents form a thioether rather than a disulfide linkage. Many of these thio-ether-forming agents are commercially available and include reactive esters of 6-maleimidocaproic acid, 2-bromoacetic acid, 2-iodoacetic acid, 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid, and the like. The carboxyl groups can be activated by combining them with succinimide or 1-hydroxyl-2-nitro-4-sulfonic acid, sodium salt. Additional methods of coupling antigens employs the rotavirus/"binding peptide" system described in EPO Pub. No. 259,149, the disclosure of which is incorporated herein by reference. The foregoing list is not meant to be exhaustive, and modifications of the named compounds can clearly be used.

Any carrier may be used which does not itself induce the production of antibodies harmful to the host. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins; polysaccharides, such as latex functionalized sepharose, agarose, cellulose, cellulose beads and the like; polymeric amino acids, such as polyglutamic acid, polylysine, and the like; amino acid copolymers; and inactive virus particles. Especially useful protein substrates are serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, and other proteins well known to those skilled in the art.

In addition to full-length viral proteins, polypeptides comprising truncated HCV amino acid sequences encoding at least one viral epitope are useful immunological reagents. For example, polypeptides comprising such truncated sequences can be used as reagents in an immunoassay. These polypeptides also are candidate subunit antigens in compositions for antiserum production or vaccines. While these truncated sequences can be produced by various known treatments of native viral protein, it is generally preferred to make synthetic or recombinant polypeptides comprising an HCV sequence. Polypeptides comprising these truncated HCV sequences can be made up entirely of HCV sequences (one or more epitopes, either contiguous or noncontiguous), or HCV sequences and heterologous sequences in a fusion protein. Useful heterologous sequences include sequences that provide for secretion from a recombinant host, enhance the immunological reactivity of the HCV epitope(s), or facilitate the coupling of the polypeptide to an immunoassay support or a vaccine carrier. See, e.g., EPO Pub. No. 116,201; U.S. Pat. No. 4,722,840; EPO

## EP 0 388 232 A1

Pub. No. 259,149; U.S. Pat. No. 4,629,783, the disclosures of which are incorporated herein by reference.

The size of polypeptides comprising the truncated HCV sequences can vary widely, the minimum size being a sequence of sufficient size to provide an HCV epitope, while the maximum size is not critical. For convenience, the maximum size usually is not substantially greater than that required to provide the desired HCV epitopes and function(s) of the heterologous sequence, if any. Typically, the truncated HCV amino acid sequence will range from about 5 to about 100 amino acids in length. More typically, however, the HCV sequence will be a maximum of about 50 amino acids in length, preferably a maximum of about 30 amino acids. It is usually desirable to select HCV sequences of at least about 10, 12 or 15 amino acids, up to a maximum of about 20 or 25 amino acids.

Truncated HCV amino acid sequences comprising epitopes can be identified in a number of ways. For example, the entire viral protein sequence can be screened by preparing a series of short peptides that together span the entire protein sequence. An example of antigenic screening of the regions of the HCV polypeptide is shown infra. In addition, by starting with, for example, 100mer polypeptides, it would be routine to test each polypeptide for the presence of epitope(s) showing a desired reactivity, and then testing progressively smaller and overlapping fragments from an identified 100mer to map the epitope of interest. Screening such peptides in an immunoassay is within the skill of the art. It is also known to carry out a computer analysis of a protein sequence to identify potential epitopes, and then prepare oligopeptides comprising the identified regions for screening. Such a computer analysis of the HCV amino acid sequence is shown in Fig. 20, where the hydrophilic/hydrophobic character is displayed above the antigen index. The amino acids are numbered from the starting MET (position 1) as shown in Fig. 17. It is appreciated by those of skill in the art that such computer analysis of antigenicity does not always identify an epitope that actually exists, and can also incorrectly identify a region of the protein as containing an epitope. Examples of HCV amino acid sequences that may be useful, which are expressed from expression vectors comprised of clones 5-1-1, 81, CA74a, 35f, 279a, C36, C33b, CA290a, C8f, C12f, 14c, 15e, C25c, C33c, C33f, 33g, C39c, C40b, CA167b are described infra. Other examples of HCV amino acid sequences that may be useful as described herein are set forth below. It is to be understood that these peptides do not necessarily precisely map one epitope, and may also contain HCV sequence that is not immunogenic. These non-immunogenic portions of the sequence can be defined as described above using conventional techniques and deleted from the described sequences. Further, additional truncated HCV amino acid sequences that comprise an epitope or are immunogenic can be identified as described above. The following sequences are given by amino acid number (i.e., "AA<sub>n</sub>") where n is the amino acid number as shown in Fig. 17:

AA1-AA25; AA1-AA50; AA1-AA84; AA9-AA177; AA1-AA10; AA5-AA20; AA20-AA25; AA35-AA45; AA50-AA100; AA40-AA90; AA45-AA65; AA65-AA75; AA80-90; AA99-AA120; AA95-AA110; AA105-AA120; AA100-AA150; AA150-AA200; AA155-AA170; AA190-AA210; AA200-AA250; AA220-AA240; AA245-AA265; AA250-AA300; AA290-AA330; AA290-305; AA300-AA350; AA310-AA330; AA350-AA400; AA380-AA395; AA405-AA495; AA400-AA450; AA405-AA415; AA415-AA425; AA425-AA435; AA437-AA582; AA450-AA500; AA440-AA460; AA460-AA470; AA475-AA495; AA500-AA550; AA511-AA690; AA515-AA550; AA550-AA600; AA550-AA625; AA575-AA605; AA585-AA600; AA600-AA650; AA600-AA625; AA635-AA665; AA650-AA700; AA645-AA680; AA700-AA750; AA700-AA725; AA700-AA750; AA725-AA775; AA770-AA790; AA750-AA800; AA800-AA815; AA825-AA850; AA850-AA875; AA800-AA850; AA920-AA990; AA850-AA900; AA920-AA945; AA940-AA965; AA970-AA990; AA950-AA1000; AA1000-AA1060; AA1000-AA1025; AA1000-AA1050; AA1025-AA1040; AA1040-AA1055; AA1075-AA1175; AA1050-AA1200; AA1070-AA1100; AA1100-AA1130; AA1140-AA1165; AA1192-AA1457; AA1195-AA1250; AA1200-AA1225; AA1225-AA1250; AA1250-AA1300; AA1260-AA1310; AA1260-AA1280; AA1266-AA1428; AA1300-AA1350; AA1290-AA1310; AA1310-AA1340; AA1345-AA1405; AA1345-AA1365; AA1350-AA1400; AA1365-AA1380; AA1380-AA1405; AA1400-AA1450; AA1450-AA1500; AA1460-AA1475; AA1475-AA1515; AA1475-AA1500; AA1500-AA1550; AA1500-AA1515; AA1515-AA1550; AA1550-AA1600; AA1545-AA1560; AA1569-AA1931; AA1570-AA1590; AA1595-AA1610; AA1590-AA1650; AA1610-AA1645; AA1650-AA1690; AA1685-AA1770; AA1689-AA1805; AA1690-AA1720; AA1694-AA1735; AA1720-AA1745; AA1745-AA1770; AA1750-AA1800; AA1775-AA1810; AA1795-AA1850; AA1850-AA1800; AA1900-AA1950; AA1900-AA1920; AA1916-AA2021; AA1920-AA1940; AA1949-AA2124; AA1950-AA2000; AA1950-AA1985; AA1980-AA2000; AA2000-AA2050; AA2005-AA2025; AA2020-AA2045; AA2045-AA2100; AA2045-AA2070; AA2054-AA2223; AA2070-AA2100; AA2100-AA2150; AA2150-AA2200; AA2200-AA2250; AA2200-AA2325; AA2250-AA2330; AA2255-AA2270; AA2265-AA2280; AA2280-AA2290; AA2287-AA2385; AA2300-AA2350; AA2290-AA2310; AA2310-AA2330; AA2330-AA2350; AA2350-AA2400; AA2348-AA2464; AA2345-AA2415; AA2345-AA2375; AA2370-AA2410; AA2371-AA2502; AA2400-AA2450; AA2400-AA2425; AA2415-AA2450; AA2445-AA2500; AA2445-AA2475; AA2470-AA2490; AA2500-AA2550; AA2505-AA2540; AA2535-AA2560; AA2550-AA2600; AA2560-AA2580; AA2600-AA2650; AA2605-AA2620; AA2620-AA2650; AA2640-AA2660; AA2650-AA2700; AA2655-AA2670; AA2670-AA2700; AA2700-AA2750; AA2740-

## EP 0 388 232 A1

AA2760; AA2750-AA2800; AA2755-AA2780; AA2780-AA2830; AA2785-AA2810; AA2796-AA2886; AA2810-AA2825; AA2800-AA2850; AA2850-AA2900; AA2850-AA2865; AA2885-AA2905; AA2900-AA2950; AA2910-AA2930; AA2925-AA2950; AA2945-end(C' terminal).

The above HCV amino acid sequences can be prepared as discrete peptides or incorporated into a larger polypeptide, and may find use as described herein. Additional polypeptides comprising truncated HCV sequences are described in the examples.

The observed relationship of the putative polyproteins of HCV and the Flaviviruses allows some prediction of the putative domains of the HCV "non-structural" (NS) proteins. The locations of the individual NS proteins in the putative Flavivirus precursor polyprotein are fairly well-known. Moreover, these also coincide with observed gross fluctuations in the hydrophobicity profile of the polyprotein. It is established that NS5 of Flaviviruses encodes the virion polymerase, and that NS1 corresponds with a complement fixation antigen which has been shown to be an effective vaccine in animals. Recently, it has been shown that a flaviviral protease function resides in NS3. Due to the observed similarities between HCV and the Flaviviruses, described infra., deductions concerning the approximate locations of the corresponding protein domains and functions in the HCV polyprotein are possible. The expression of polypeptides containing these domains in a variety of recombinant host cells, including, for example, bacteria, yeast, insect, and vertebrate cells, should give rise to important immunological reagents which can be used for diagnosis, detection, and vaccines.

Although the non-structural protein regions of the putative polyproteins of the HCV isolate described herein and of Flaviviruses appear to have some similarity, there is less similarity between the putative structural regions which are towards the N-terminus. In this region, there is a greater divergence in sequence, and in addition, the hydrophobic profile of the two regions show less similarity. This "divergence" begins in the N-terminal region of the putative NS1 domain in HCV, and extends to the presumed N-terminus. Nevertheless, it may still be possible to predict the approximate locations of the putative nucleocapsid (N-terminal basic domain) and E (generally hydrophobic) domains within the HCV polyprotein. In the Examples the predictions are based on the changes observed in the hydrophobic profile of the HCV polyprotein, and on a knowledge of the location and character of the flaviviral proteins. From these predictions it may be possible to identify approximate regions of the HCV polyprotein that could correspond with useful immunological reagents. For example, the E and NS1 proteins of Flaviviruses are known to have efficacy as protective vaccines. These regions, as well as some which are shown to be antigenic in the HCV isolate described herein, for example those within putative NS3, C, and NS5, etc., should also provide diagnostic reagents. Moreover, the location and expression of viral-encoded enzymes may also allow the evaluation of anti-viral enzyme inhibitors, i.e., for example, inhibitors which prevent enzyme activity by virtue of an interaction with the enzyme itself, or substances which may prevent expression of the enzyme, (for example, anti-sense RNA, or other drugs which interfere with expression).

#### Preparation of Hybrid Particle Immunogens Containing HCV Epitopes

The immunogenicity of the epitopes of HCV may also be enhanced by preparing them in mammalian or yeast systems fused with or assembled with particle-forming proteins such as, for example, that associated with hepatitis B surface antigen. Constructs wherein the NANBV epitope is linked directly to the particle-forming protein coding sequences produce hybrids which are immunogenic with respect to the HCV epitope. In addition, all of the vectors prepared include epitopes specific to HBV, having various degrees of immunogenicity, such as, for example, the pre-S peptide. Thus, particles constructed from particle forming protein which include HCV sequences are immunogenic with respect to HCV and HBV.

Hepatitis surface antigen (HBSAg) has been shown to be formed and assembled into particles in *S. cerevisiae* (Valenzuela et al. (1982)), as well as in, for example, mammalian cells (Valenzuela, P., et al. (1984)). The formation of such particles has been shown to enhance the immunogenicity of the monomer subunit. The constructs may also include the immunodominant epitope of HBSAg, comprising the 55 amino acids of the presurface (pre-S) region. Neurath et al. (1984). Constructs of the pre-S-HBSAg particle expressible in yeast are disclosed in EPO 174,444, published March 19, 1988; hybrids including heterologous viral sequences for yeast expression are disclosed in EPO 175,261, published March 26, 1986. These constructs may also be expressed in mammalian cells such as Chinese hamster ovary (CHO) cells using an SV40-dihydrofolate reductase vector (Michelle et al. (1984)).

In addition, portions of the particle-forming protein coding sequence may be replaced with codons encoding an HCV epitope. In this replacement, regions which are not required to mediate the aggregation of the units to form immunogenic particles in yeast or mammals can be deleted, thus eliminating additional



## EP 0 388 232 A1

HBV antigenic sites from competition with the HCV epitope.

### Preparation of Vaccines

5 Vaccines may be prepared from one or more immunogenic polypeptides derived from HCV cDNA, including the cDNA sequences described in the Examples. The observed homology between HCV and Flaviviruses provides information concerning the polypeptides which may be most effective as vaccines, as well as the regions of the genome in which they are encoded. The general structure of the Flavivirus  
10 genome is discussed in Rice et al (1986). The flavivirus genomic RNA is believed to be the only virus-specific mRNA species, and it is translated into the three viral structural proteins, i.e., C, M, and E, as well as two large nonstructural proteins, NS4 and NS5, and a complex set of smaller nonstructural proteins. It is known that major neutralizing epitopes for Flaviviruses reside in the E (envelope) protein (Roehrig (1986)). Thus, vaccines may be comprised of recombinant polypeptides containing epitopes of HCV E. These  
15 polypeptides may be expressed in bacteria, yeast, or mammalian cells, or alternatively may be isolated from viral preparations. It is also anticipated that the other structural proteins may also contain epitopes which give rise to protective anti-HCV antibodies. Thus, polypeptides containing the epitopes of E, C, and M may also be used, whether singly or in combination, in HCV vaccines.

In addition to the above, it has been shown that immunization with NS1 (nonstructural protein 1), results  
20 in protection against yellow fever (Schlesinger et al (1986)). This is true even though the immunization does not give rise to neutralizing antibodies. Thus, particularly since this protein appears to be highly conserved among Flaviviruses, it is likely that HCV NS1 will also be protective against HCV infection. Moreover, it also shows that nonstructural proteins may provide protection against viral pathogenicity, even if they do not cause the production of neutralizing antibodies.

25 The information provided in the Examples concerning the immunogenicity of the polypeptides expressed from cloned HCV cDNAs which span the various regions of the HCV ORF also allows predictions concerning their use in vaccines.

In view of the above, multivalent vaccines against HCV may be comprised of one or more epitopes from one or more structural proteins, and/or one or more epitopes from one or more nonstructural proteins.  
30 These vaccines may be comprised of, for example, recombinant HCV polypeptides and/or polypeptides isolated from the virions. In particular, vaccines are contemplated comprising one or more of the following HCV proteins, or subunit antigens derived therefrom: E, NS1, C, NS2, NS3, NS4 and NS5. Particularly preferred are vaccines comprising E and/or NS1, or subunits thereof.

The preparation of vaccines which contain an immunogenic polypeptide(s) as active ingredients, is  
35 known to one skilled in the art. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol,  
40 ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A,  
45 referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing an HCV antigenic sequence  
50 resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and  
55 carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the

## EP 0 388 232 A1

like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.

The proteins may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

#### Dosage and Administration of Vaccines

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered, which is generally in the range of 5 micrograms to 250 micrograms of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be peculiar to each subject.

The vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reenforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. The dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgment of the practitioner.

In addition, the vaccine containing the immunogenic HCV antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immune globulins.

#### Preparation of Antibodies Against HCV Epitopes

The immunogenic polypeptides prepared as described above are used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an immunogenic polypeptide bearing an HCV epitope(s). Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an HCV epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987).

Alternatively, polyclonal antibodies may be isolated from a mammal which has been previously infected with HCV. An example of a method for purifying antibodies to HCV epitopes from serum from an infected individual, based upon affinity chromatography and utilizing a fusion polypeptide of SOD and a polypeptide encoded within cDNA clone 5-1-1, is presented in EPO Pub. No. 318,216.

Monoclonal antibodies directed against HCV epitopes can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al. (1980); Hammerling et al. (1981); Kennett et al. (1980); see also, U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,466,917; 4,472,500; 4,491,632; and 4,493,890. Panels of monoclonal antibodies produced against HCV epitopes can be screened for various properties; i.e., for isotype, epitope affinity, etc.

Antibodies, both monoclonal and polyclonal, which are directed against HCV epitopes are particularly useful in diagnosis, and those which are neutralizing are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies.

Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired. See, for example, Nisonoff, A., et al. (1981) and Dreesman et al. (1985).

Techniques for raising anti-idiotypic antibodies are known in the art. See, for example, Grzych (1985), MacNamara et al. (1984), and Uytdehaag et al. (1985). These anti-idiotypic antibodies may also be useful for

## EP 0 388 232 A1

treatment and/or diagnosis of NANBH, as well as for an elucidation of the immunogenic regions of HCV antigens.

It would also be recognized by one of ordinary skill in the art that a variety of types of antibodies directed against HCV epitopes may be produced. As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one antibody combining site. An "antibody combining site" or "binding domain" is formed from the folding of variable domains of an antibody molecule(s) to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows an immunological reaction with the antigen. An antibody combining site may be formed from a heavy and/or a light chain domain (VH and VL, respectively), which form hypervariable loops which contribute to antigen binding. The term "antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, altered antibodies, univalent antibodies, the Fab proteins, and single domain antibodies.

A "single domain antibody" (dAb) is an antibody which is comprised of an VH domain, which reacts immunologically with a designated antigen. A dAb does not contain a VL domain, but may contain other antigen binding domains known to exist in antibodies, for example, the kappa and lambda domains. Methods for preparing dABs are known in the art. See, for example, Ward et al. (1989).

Antibodies may also be comprised of VH and VL domains, as well as other known antigen binding domains. Examples of these types of antibodies and methods for their preparation are known in the art (see, e.g., U.S. Patent No. 4,816,467, which is incorporated herein by reference), and include the following. For example, "vertebrate antibodies" refers to antibodies which are tetramers or aggregates thereof, comprising light and heavy chains which are usually aggregated in a "Y" configuration and which may or may not have covalent linkages between the chains. In vertebrate antibodies, the amino acid sequences of all the chains of a particular antibody are homologous with the chains found in one antibody produced by the lymphocyte which produces that antibody in situ, or in vitro (for example, in hybridomas). Vertebrate antibodies typically include native antibodies, for example, purified polyclonal antibodies and monoclonal antibodies. Examples of the methods for the preparation of these antibodies are described infra.

"Hybrid antibodies" are antibodies wherein one pair of heavy and light chains is homologous to those in a first antibody, while the other pair of heavy and light chains is homologous to those in a different second antibody. Typically, each of these two pairs will bind different epitopes, particularly on different antigens. This results in the property of "divalence", i.e., the ability to bind two antigens simultaneously. Such hybrids may also be formed using chimeric chains, as set forth below.

"Chimeric antibodies", are antibodies in which the heavy and/or light chains are fusion proteins. Typically the constant domain of the chains is from one particular species and/or class, and the variable domains are from a different species and/or class. Also included is any antibody in which either or both of the heavy or light chains are composed of combinations of sequences mimicking the sequences in antibodies of different sources, whether these sources be differing classes, or different species of origin, and whether or not the fusion point is at the variable/constant boundary. Thus, it is possible to produce antibodies in which neither the constant nor the variable region mimic known antibody sequences. It then becomes possible, for example, to construct antibodies whose variable region has a higher specific affinity for a particular antigen, or whose constant region can elicit enhanced complement fixation, or to make other improvements in properties possessed by a particular constant region.

Another example is "altered antibodies", which refers to antibodies in which the naturally occurring amino acid sequence in a vertebrate antibody has been varied. Utilizing recombinant DNA techniques, antibodies can be redesigned to obtain desired characteristics. The possible variations are many, and range from the changing of one or more amino acids to the complete redesign of a region, for example, the constant region. Changes in the constant region, in general, to attain desired cellular process characteristics, e.g., changes in complement fixation, interaction with membranes, and other effector functions. Changes in the variable region may be made to alter antigen binding characteristics. The antibody may also be engineered to aid the specific delivery of a molecule or substance to a specific cell or tissue site. The desired alterations may be made by known techniques in molecular biology, e.g., recombinant techniques, site directed mutagenesis, etc.

Yet another example are "univalent antibodies", which are aggregates comprised of a heavy chain/light chain dimer bound to the Fc (i.e., constant) region of a second heavy chain. This type of antibody escapes antigenic modulation. See, e.g., Glennie et al. (1982).

Included also within the definition of antibodies are "Fab" fragments of antibodies. The "Fab" region refers to those portions of the heavy and light chains which are roughly equivalent, or analogous, to the sequences which comprise the branch portion of the heavy and light chains, and which have been shown to exhibit immunological binding to a specified antigen, but which lack the effector Fc portion. "Fab" includes

## EP 0 388 232 A1

aggregates of one heavy and one light chain (commonly known as Fab'), as well as tetramers containing the 2H and 2L chains (referred to as F(ab)<sub>2</sub>), which are capable of selectively reacting with a designated antigen or antigen family. "Fab" antibodies may be divided into subsets analogous to those described above, i.e., "vertebrate Fab", "hybrid Fab", "chimeric Fab", and "altered Fab". Methods of producing "Fab" fragments of antibodies are known within the art and include, for example, proteolysis, and synthesis by recombinant techniques.

#### II.H. Diagnostic Oligonucleotide Probes and Kits

10

Using the disclosed portions of the isolated HCV cDNAs as a basis, oligomers of approximately 8 nucleotides or more can be prepared, either by excision or synthetically, which hybridize with the HCV genome and are useful in identification of the viral agent(s), further characterization of the viral genome(s), as well as in detection of the virus(es) in diseased individuals. The probes for HCV polynucleotides (natural or derived) are a length which allows the detection of unique viral sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of 10-12 nucleotides are preferred, and about 20 nucleotides appears optimal. Preferably, these sequences will derive from regions which lack heterogeneity. These probes can be prepared using routine methods, including automated oligonucleotide synthetic methods. Among useful probes, for example, are those derived from the newly isolated clones disclosed herein, as well as the various oligomers useful in probing cDNA libraries, set forth below. A complement to any unique portion of the HCV genome will be satisfactory. For use as probes, complete complementarity is desirable, though it may be unnecessary as the length of the fragment is increased.

For use of such probes as diagnostics, the biological sample to be analyzed, such as blood or serum, may be treated, if desired, to extract the nucleic acids contained therein. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample may be dot blotted without size separation. The probes are then labeled. Suitable labels, and methods for labeling probes are known in the art, and include, for example, radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent probes, and chemiluminescent probes. The nucleic acids extracted from the sample are then treated with the labeled probe under hybridization conditions of suitable stringencies, and polynucleotide duplexes containing the probe are detected.

The probes can be made completely complementary to the HCV genome. Therefore, usually high stringency conditions are desirable in order to prevent false positives. However, conditions of high stringency should only be used if the probes are complementary to regions of the viral genome which lack heterogeneity. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time, and concentration of formamide. These factors are outlined in, for example, Maniatis, T. (1982).

Generally, it is expected that the HCV genome sequences will be present in serum of infected individuals at relatively low levels, i.e., at approximately  $10^2$ - $10^3$  chimp infectious doses (CID) per ml. This level may require that amplification techniques be used in hybridization assays. Such techniques are known in the art. For example, the Enzo Biochemical Corporation "Bio-Bridge" system uses terminal deoxynucleotide transferase to add unmodified 3'-poly-dT-tails to a DNA probe. The poly dT-tailed probe is hybridized to the target nucleotide sequence, and then to a biotin-modified poly-A. PCT application 84/03520 and EPA124221 describe a DNA hybridization assay in which: (1) analyte is annealed to a single-stranded DNA probe that is complementary to an enzyme-labeled oligonucleotide; and (2) the resulting 45-tailed duplex is hybridized to an enzyme-labeled oligonucleotide. EPA 204510 describes a DNA hybridization assay in which analyte DNA is contacted with a probe that has a tail, such as a poly-dT tail, an amplifier strand that has a sequence that hybridizes to the tail of the probe, such as a poly-A sequence, and which is capable of binding a plurality of labeled strands. A particularly desirable technique may first involve amplification of the target HCV sequences in sera approximately 10,000 fold, i.e., to approximately  $10^6$  sequences/ml. This may be accomplished, for example, by the polymerase chain reactions (PCR) technique described which is by Saiki et al. (1986), by Mullis, U.S. Patent No. 4,683,195, and by Mullis et al., U.S. Patent No. 4,683,202. The amplified sequence(s) may then be detected using a hybridization assay which is described in EP 317,077, published May 24, 1989. These hybridization assays, which should detect sequences at the level of  $10^6$ /ml, utilize nucleic acid multimers which bind to single-stranded analyte 50-nucleic acid, and which also bind to a multiplicity of single-stranded labeled oligonucleotides. A suitable solution phase sandwich assay which may be used with labeled polynucleotide probes, and the methods for the preparation of probes is described in EPO 225,807, published June 16, 1987.

The probes can be packaged into diagnostic kits. Diagnostic kits include the probe DNA, which may be

## EP 0 388 232 A1

labeled; alternatively, the probe DNA may be unlabeled and the ingredients for labeling may be included in the kit in separate containers. The kit may also contain other suitably packaged reagents and materials needed for the particular hybridization protocol, for example, standards, as well as instructions for conducting the test.

5

Immunoassay and Diagnostic Kits

Both the polypeptides which react immunologically with serum containing HCV antibodies, for example, those detected by the antigenic screening method described infra. in the Examples, as well as those derived from or encoded within the isolated clones described in the Examples, and composites thereof, and the antibodies raised against the HCV specific epitopes in these polypeptides, are useful in immunoassays to detect presence of HCV antibodies, or the presence of the virus and/or viral antigens, in biological samples. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. For example, the immunoassay may utilize one viral epitope; alternatively, the immunoassay may use a combination of viral epitopes derived from these sources; these epitopes may be derived from the same or from different viral polypeptides, and may be in separate recombinant or natural polypeptides, or together in the same recombinant polypeptides. It may use, for example, a monoclonal antibody directed towards a viral epitope(s), a combination of monoclonal antibodies directed towards epitopes of one viral antigen, monoclonal antibodies directed towards epitopes of different viral antigens, polyclonal antibodies directed towards the same viral antigen, or polyclonal antibodies directed towards different viral antigens. Protocols may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

Some of the antigenic regions of the putative polyprotein have been mapped and identified by screening the antigenicity of bacterial expression products of HCV cDNAs which encode portions of the polyprotein. See the Examples. Other antigenic regions of HCV may be detected by expressing the portions of the HCV cDNAs in other expression systems, including yeast systems and cellular systems derived from insects and vertebrates. In addition, studies giving rise to an antigenicity index and hydrophobicity/hydrophilicity profile give rise to information concerning the probability of a region's antigenicity.

The studies on antigenic mapping by expression of HCV cDNAs showed that a number of clones containing these cDNAs expressed polypeptides which were immunologically reactive with serum from individuals with NANBH. No single polypeptide was immunologically reactive with all sera. Five of these polypeptides were very immunogenic in that antibodies to the HCV epitopes in these polypeptides were detected in many different patient sera, although the overlap in detection was not complete. Thus, the results on the immunogenicity of the polypeptides encoded in the various clones suggest that efficient detection systems may include the use of panels of epitopes. The epitopes in the panel may be constructed into one or multiple polypeptides.

Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the polypeptides of the invention containing HCV epitopes or antibodies directed against HCV epitopes in suitable containers, along with the remaining reagents and materials required for the conduct of the assay, as well as a suitable set of assay instructions.

Further Characterization of the HCV Genome, Virions, and Viral Antigens Using Probes Derived From cDNA to the Viral Genome

The HCV cDNA sequence information in the newly isolated clones described in the Examples may be used to gain further information on the sequence of the HCV genome, and for identification and isolation of the HCV agent, and thus will aid in its characterization including the nature of the genome, the structure of the viral particle, and the nature of the antigens of which it is composed. This information, in turn, can lead to additional polynucleotide probes, polypeptides derived from the HCV genome, and antibodies directed against HCV epitopes which would be useful for the diagnosis and/or treatment of HCV caused NANBH.

The cDNA sequence information in the abovementioned clones is useful for the design of probes for the

## EP 0 388 232 A1

Isolation of additional cDNA sequences which are derived from as yet undefined regions of the HCV genome(s) from which the cDNAs in clones described herein and in EP 0,316,218 are derived. For example, labeled probes containing a sequence of approximately 8 or more nucleotides, and preferably 20 or more nucleotides, which are derived from regions close to the 5'-termini or 3'-termini of the composite HCV cDNA sequence shown in Fig. 17 may be used to isolate overlapping cDNA sequences from HCV cDNA libraries. Alternatively, characterization of the genomic segments could be from the viral genome(s) isolated from purified HCV particles. Methods for purifying HCV particles and for detecting them during the purification procedure are described herein, *infra*. Procedures for isolating polynucleotide genomes from viral particles are known in the art, and one procedure which may be used is that described in EP 0,218,316. The isolated genomic segments could then be cloned and sequenced. An example of this technique, which utilizes amplification of the sequences to be cloned, is provided *infra*, and yielded clone 16jh.

Methods for constructing cDNA libraries are known in the art, and are discussed *supra* and *infra*; a method for the construction of HCV cDNA libraries in lambda-gt11 is discussed in EPO Pub. No. 318,216. However, cDNA libraries which are useful for screening with nucleic acid probes may also be constructed in other vectors known in the art, for example, lambda-gt10 (Huynh et al. (1985)).

#### Screening for Anti-Viral Agents for HCV

The availability of cell culture and animal model systems for HCV makes it possible to screen for anti-viral agents which inhibit HCV replication, and particularly for those agents which preferentially allow cell growth and multiplication while inhibiting viral replication. These screening methods are known by those of skill in the art. Generally, the anti-viral agents are tested at a variety of concentrations, for their effect on preventing viral replication in cell culture systems which support viral replication, and then for an inhibition of infectivity or of viral pathogenicity (and a low level of toxicity) in an animal model system.

The methods and compositions provided herein for detecting HCV antigens and HCV polynucleotides are useful for screening of anti-viral agents in that they provide an alternative, and perhaps more sensitive means, for detecting the agent's effect on viral replication than the cell plaque assay or ID<sub>50</sub> assay. For example, the HCV-polynucleotide probes described herein may be used to quantitate the amount of viral nucleic acid produced in a cell culture. This could be accomplished, for example, by hybridization or competition hybridization of the infected cell nucleic acids with a labeled HCV-polynucleotide probe. For example, also, anti-HCV antibodies may be used to identify and quantitate HCV antigen(s) in the cell culture utilizing the immunoassays described herein. In addition, since it may be desirable to quantitate HCV antigens in the infected cell culture by a competition assay, the polypeptides encoded within the HCV cDNAs described herein are useful in these competition assays. Generally, a recombinant HCV polypeptide derived from the HCV cDNA would be labeled, and the inhibition of binding of this labeled polypeptide to an HCV polypeptide due to the antigen produced in the cell culture system would be monitored. Moreover, these techniques are particularly useful in cases where the HCV may be able to replicate in a cell line without causing cell death.

The anti-viral agents which may be tested for efficacy by these methods are known in the art, and include, for example, those which interact with virion components and/or cellular components which are necessary for the binding and/or replication of the virus. Typical anti-viral agents may include, for example, inhibitors of virion polymerase and/or protease(s) necessary for cleavage of the precursor polypeptides. Other anti-viral agents may include those which act with nucleic acids to prevent viral replication, for example, anti-sense polynucleotides, etc.

Antisense polynucleotides molecules are comprised of a complementary nucleotide sequence which allows them to hybridize specifically to designated regions of genomes or RNAs. Antisense polynucleotides may include, for example, molecules that will block protein translation by binding to mRNA, or may be molecules which prevent replication of viral RNA by transcriptase. They may also include molecules which carry agents (non-covalently attached or covalently bound) which cause the viral RNA to be inactive by causing, for example, scissions in the viral RNA. They may also bind to cellular polynucleotides which enhance and/or are required for viral infectivity, replicative ability, or chronicity. Antisense molecules which are to hybridize to HCV derived RNAs may be designed based upon the sequence information of the HCV cDNAs provided herein. The antiviral agents based upon anti-sense polynucleotides for HCV may be designed to bind with high specificity, to be of increased solubility, to be stable, and to have low toxicity. Hence, they may be delivered in specialized systems, for example, liposomes, or by gene therapy. In addition, they may include analogs, attached proteins, substituted or altered bonding between bases, etc.

## EP 0 388 232 A1

Other types of drugs may be based upon polynucleotides which "mimic" important control regions of the HCV genome, and which may be therapeutic due to their interactions with key components of the system responsible for viral infectivity or replication.

5

General Methods

The general techniques used in extracting the genome from a virus, preparing and probing a cDNA library, sequencing clones, constructing expression vectors, transforming cells, performing immunological assays such as radioimmunoassays and ELISA assays, for growing cells in culture, and the like are known in the art and laboratory manuals are available describing these techniques. However, as a general guide, the following sets forth some sources currently available for such procedures, and for materials useful in carrying them out.

Both prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences which are compatible with the designated host are used. Among prokaryotic hosts, *E. coli* is most frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. Commonly used prokaryotic control sequences include the Beta-lactamase (penicillinase) and lactose promoter systems (Chang et al. (1977)), the tryptophan (*trp*) promoter system (Goeddel et al. (1980)) and the lambda-derived *P<sub>L</sub>* promoter and N gene ribosome binding site (Shimatake et al. (1981)) and the hybrid *tac* promoter (De Boer et al. (1983)) derived from sequences of the *trp* and *lac* UV5 promoters. The foregoing systems are particularly compatible with *E. coli*; if desired, other prokaryotic hosts such as strains of *Bacillus* or *Pseudomonas* may be used, with corresponding control sequences.

Eukaryotic hosts include yeast and mammalian cells in culture systems. *Saccharomyces cerevisiae* and *Saccharomyces carlsbergensis* are the most commonly used yeast hosts, and are convenient fungal hosts. Yeast compatible vectors carry markers which permit selection of successful transformants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2 micron origin of replication (Broach et al. (1983)), the combination of *CEN3* and *ARS1* or other means for assuring replication, such as sequences which will result in incorporation of an appropriate fragment into the host cell genome. Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes (Hess et al. (1968); Holland et al. (1978)), including the promoter for 3 phosphoglycerate kinase (Hitzeman (1980)). Terminators may also be included, such as those derived from the enolase gene (Holland (1981)). Particularly useful control systems are those which comprise the glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and if secretion is desired, leader sequence from yeast alpha factor. In addition, the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism. These systems are described in detail in EPO 120,551, published October 3, 1984; EPO 116,201, published August 22, 1984; and EPO 164,556, published December 18, 1985, all of which are assigned to the herein assignee, and are hereby incorporated herein by reference.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and a number of other cell lines. Suitable promoters for mammalian cells are also known in the art and include viral promoters such as that from Simian Virus 40 (SV40) (Fiers (1978)), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). Mammalian cells may also require terminator sequences and poly A addition sequences; enhancer sequences which increase expression may also be included, and sequences which cause amplification of the gene may also be desirable. These sequences are known in the art. Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences encoding NANBV epitopes into the host genome.

Transformation may be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host cell with the virus, and by direct uptake of the polynucleotide. The transformation procedure used depends upon the host to be transformed. For example, transformation of the *E. coli* host cells with lambda-gt11 containing BB-NANBV sequences is discussed in the Example section, infra. Bacterial transformation by direct uptake generally employs

## EP 0 388 232 A1

treatment with calcium or rubidium chloride (Cohen (1972); Maniatis (1982)). Yeast transformation by direct uptake may be carried out using the method of Hinnen et al. (1978). Mammalian transformations by direct uptake may be conducted using the calcium phosphate precipitation method of Graham and Van der Eb (1978), or the various known modifications thereof.

5 Vector construction employs techniques which are known in the art. Site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. In general, about 1 microgram of plasmid or DNA sequence is cleaved by 1 unit of enzyme in about 20 microliters buffer solution by incubation of 1-2 hr at 37° C. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction  
10 and the DNA recovered by precipitation with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis techniques, according to the general procedures found in Methods in Enzymology (1980) 65:499-560.

Sticky ended cleavage fragments may be blunt ended using *E. coli* DNA polymerase I (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with  
15 S1 nuclease may also be used, resulting in the hydrolysis of any single stranded DNA portions.

Ligations are carried out using standard buffer and temperature conditions using T4 DNA ligase and ATP; sticky end ligations require less ATP and less ligase than blunt end ligations. When vector fragments are used as part of a ligation mixture, the vector fragment is often treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5'-phosphate and thus prevent  
20 religation of the vector; alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation.

Ligation mixtures are transformed into suitable cloning hosts, such as *E. coli*, and successful transformants selected by, for example, antibiotic resistance, and screened for the correct construction.

Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer as described by Warner (1984). If desired the synthetic strands may be labeled with <sup>32</sup>P by treatment with  
25 polynucleotide kinase in the presence of <sup>32</sup>P-ATP, using standard conditions for the reaction.

DNA sequences, including those isolated from cDNA libraries, may be modified by known techniques, including, for example site directed mutagenesis, as described by Zoller (1982). Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA  
30 with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence. The resulting double stranded DNA is transformed into a phage supporting host bacterium. Cultures of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the mutated sequence, and the remaining 50%  
35 have the original sequence. Replicates of the plaques are hybridized to labeled synthetic probe at temperatures and conditions which permit hybridization with the correct strand, but not with the unmodified sequence. The sequences which have been identified by hybridization are recovered and cloned.

DNA libraries may be probed using the procedure of Grunstein and Hogness (1975). Briefly, in this procedure, the DNA to be probed is immobilized on nitrocellulose filters, denatured, and prehybridized with  
40 a buffer containing 0-50% formamide, 0.75 M NaCl, 75 mM Na citrate, 0.02% (wt/v) each of bovine serum albumin, polyvinyl pyrrolidone, and Ficoll, 50 mM Na Phosphate (pH 6.5), 0.1% SDS, and 100 micrograms/ml carrier denatured DNA. The percentage of formamide in the buffer, as well as the time and temperature conditions of the prehybridization and subsequent hybridization steps depends on the stringency required. Oligomeric probes which require lower stringency conditions are generally used with low  
45 percentages of formamide, lower temperatures, and longer hybridization times. Probes containing more than 30 or 40 nucleotides such as those derived from cDNA or genomic sequences generally employ higher temperatures, e.g., about 40-42° C, and a high percentage, e.g., 50%, formamide. Following prehybridization, <sup>32</sup>P-labeled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show  
50 the location of the hybridized probe; DNA in corresponding locations on the original agar plates is used as the source of the desired DNA.

For routine vector constructions, ligation mixtures are transformed into *E. coli* strain HB101 or other suitable host, and successful transformants selected by antibiotic resistance or other markers. Plasmids from the transformants are then prepared according to the method of Clewell et al. (1969), usually following  
55 chloramphenicol amplification (Clewell (1972)). The DNA is isolated and analyzed, usually by restriction enzyme analysis and/or sequencing. Sequencing may be by the dideoxy method of Sanger et al. (1977) as further described by Messing et al. (1981), or by the method of Maxam et al. (1980). Problems with band compression, which are sometimes observed in GC rich regions, were overcome by use of T-



## EP 0 388 232 A1

deazoguanosine according to Barr et al. (1986).

The enzyme-linked immunosorbent assay (ELISA) can be used to measure either antigen or antibody concentrations. This method depends upon conjugation of an enzyme to either an antigen or an antibody, and uses the bound enzyme activity as a quantitative label. To measure antibody, the known antigen is fixed to a solid phase (e.g., a microplate or plastic cup), incubated with test serum dilutions, washed, incubated with anti-immunoglobulin labeled with an enzyme, and washed again. Enzymes suitable for labeling are known in the art, and include, for example, horseradish peroxidase. Enzyme activity bound to the solid phase is measured by adding the specific substrate, and determining product formation or substrate utilization colorimetrically. The enzyme activity bound is a direct function of the amount of antibody bound.

To measure antigen, a known specific antibody is fixed to the solid phase, the test material containing antigen is added, after an incubation the solid phase is washed, and a second enzyme-labeled antibody is added. After washing, substrate is added, and enzyme activity is estimated colorimetrically, and related to antigen concentration.

### Examples

Described below are examples of the present invention which are provided only for illustrative purposes, and not to limit the scope of the present invention. In light of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art.

#### Isolation and Sequence of Overlapping HCV cDNA Clones 13i, 26j, CA59a, CA84a, CA156e and CA167b

The clones 13i, 26j, CA59a, CA84a, CA156e and CA167b were isolated from the lambda-gt11 library which contains HCV cDNA (ATCC No. 40394), the preparation of which is described in EPO Pub. No. 318,216 (published 31 May 1989), and WO 89/04669 (published 1 June 1989). Screening of the library was with the probes described infra., using the method described in Huynh (1985). The frequencies with which positive clones appeared with the respective probes was about 1 in 50,000.

The isolation of clone 13i was accomplished using a synthetic probe derived from the sequence of clone 12f. The sequence of the probe was:

5' GAA CGT TGC GAT CTG GAA GAC AGG GAC AGG 3'.

The isolation of clone 26j was accomplished using a probe derived from the 5'-region of clone K9-1. The sequence of the probe was:

5' TAT CAG TTA TGC CAA CGG AAG CGG CCC CGA 3'.

The isolation procedures for clone 12f and for clone K9-1 (also called K9-1) are described in EPO Pub. No. 318,216, and their sequences are shown in Figs. 1 and 2, respectively. The HCV cDNA sequences of clones 13i and 26j, are shown in Figs. 4 and 5, respectively. Also shown are the amino acids encoded therein, as well as the overlap of clone 13i with clone 12f, and the overlap of clone 26j with clone 13i. The sequences for these clones confirmed the sequence of clone K9-1. Clone K9-1 had been isolated from a different HCV cDNA library (See EP 0,218,316).

Clone CA59a was isolated utilizing a probe based upon the sequence of the 5'-region of clone 26j. The sequence of this probe was:

5' CTG GTT AGC AGG GCT TTT CTA TCA CCA CAA 3'.

A probe derived from the sequence of clone CA59a was used to isolate clone CA84a. The sequence of the probe used for this isolation was:

5' AAG GTC CTG GTA GTG CTG CTA TTT GCC 3'.

Clone CA156e was isolated using a probe derived from the sequence of clone CA84a. The sequence of the probe was:

5' ACT GGA CGA CGC AAG GTT GCA ATT GCT CTA 3'.

Clone CA167b was isolated using a probe derived from the sequence of clone CA 156e. The sequence of the probe was:

5' TTC GAC GTC ACA TCG ATC TGC TTG TCG GGA 3'.

The nucleotide sequences of the HCV cDNAs in clones CA59a, CA84a, CA156e, and CA167b, are shown Figs. 6, 7, 8, and 9, respectively. The amino acids encoded therein, as well as the overlap with the

**EP 0 388 232 A1**

sequences of relevant clones, are also shown in the Figs.

Creation of "pi" HCV cDNA Library

5

A library of HCV cDNA, the "pi" library, was constructed from the same batch of infectious chimpanzee plasma used to construct the lambda-gt11 HCV cDNA library (ATCC No. 40394) described in EPO Pub. No. 318,216, and utilizing essentially the same techniques. However, construction of the pi library utilized a primer-extension method, in which the primer for reverse transcriptase was based on the sequence of clone CA59A. The sequence of the primer was:  
5' GGT GAC GTG GGT TTC 3'.

10

15

Isolation and Sequence of Clone pi14a

Screening of the "pi" HCV cDNA library described supra., with the probe used to isolate clone CA167b (See supra.) yielded clone pi14a. The clone contains about 800 base pairs of cDNA which overlaps clones CA167b, CA156e, CA84a and CA59a, which were isolated from the lambda gt-11 HCV cDNA library (ATCC No. 40394). In addition, pi14a also contains about 250 base pairs of DNA which are upstream of the HCV cDNA in clone CA167b.

20

25

Isolation and Sequence of Clones CA216a, CA290a and ag30a

Based on the sequence of clone CA167b a synthetic probe was made having the following sequence:  
5' GGC TTT ACC ACG TCA CCA ATG ATT GCC CTA 3'  
The above probe was used to screen the lambda-gt11 library (ATCC No. 40394), which yielded clone CA216a, whose HCV sequences are shown in Fig. 10.

30

Another probe was made based on the sequence of clone CA216a having the following sequence:  
5' TTT GGG TAA GGT CAT CGA TAC CCT TAC GTG 3'  
Screening the lambda-gt11 library (ATCC No. 40394) with this probe yielded clone CA290a, the HCV sequences therein being shown in Fig. 11.

35

In a parallel approach, a primer-extension cDNA library was made using nucleic acid extracted from the same infectious plasma used in the original lambda-gt11 cDNA library described above. The primer used was based on the sequence of clones CA216a and CA290a:

40

5' GAA GCC GCA CGT AAG 3'  
The cDNA library was made using methods similar to those described previously for libraries used in the isolation of clones pi14a and k9-1. The probe used to screen this library was based on the sequence of clone CA290a:

45

5' CCG GCG TAG GTC GCG CAA TTT GGG TAA 3'  
Clone ag30a was isolated from the new library with the above probe, and contained about 670 basepairs of HCV sequence. See Fig. 12. Part of this sequence overlaps the HCV sequence of clones CA216a and CA290a. About 300 base-pairs of the ag30a sequence, however, is upstream of the sequence from clone CA290a. The non-overlapping sequence shows a start codon (T) and stop codons that may indicate the start of the HCV ORF. Also indicated in Fig. 12 are putative small encoded peptides (#) which may play a role in regulating translation, as well as the putative first amino acid of the putative polypeptide (I), and downstream amino acids encoded therein.

50

Isolation and Sequence of Clone CA205a

55

Clone CA205a was isolated from the original lambda gt-11 library (ATCC No. 40394), using a synthetic probe derived from the HCV sequence in clone CA290a (Fig. 11). The sequence of the probe was:  
5' TCA GAT CGT TGG TGG AGT TTA CTT GTT GCC 3'.

## EP 0 388 232 A1

The sequence of the HCV cDNA in CA205a, shown in Fig. 13, overlaps with the cDNA sequences in both clones ag30a and CA290a. The overlap of the sequence with that of CA290a is shown by the dotted line above the sequence (the figure also shows the putative amino acids encoded in this fragment).

As observed from the HCV cDNA sequences in clones CA205a and ag30a, the putative HCV polyprotein appears to begin at the ATG start codon; the HCV sequences in both clones contain an in-frame, contiguous double stop codon (TGATAG) forty two nucleotides upstream from this ATG. The HCV ORF appears to begin after these stop codons, and to extend for at least 8907 nucleotides (See the composite HCV cDNA shown in Fig. 17).

10

Isolation and Sequence of Clone 18g

Based on the sequence of clone ag30a (See Fig. 12) and of an overlapping clone from the original lambda gt-11 library (ATCC No. 40394), CA230a, a synthetic probe was made having the following sequence:

5' CCA TAG TGG TCT GCG GAA CCG GTG AGT ACA 3'.

Screening of the original lambda-gt11 HCV cDNA library with the probe yielded clone 18g, the HCV cDNA sequence of which is shown in Fig. 14. Also shown in the figure are the overlap with clone ag30a, and putative polypeptides encoded within the HCV cDNA.

The cDNA in clone 18g (C18g or 18g) overlaps that in clones ag30a and CA205a, described supra. The sequence of C18g also contains the double stop codon region observed in clone ag30a. The polynucleotide region upstream of these stop codons presumably represents part of the 5'-region of the HCV genome, which may contain short ORFs, and which can be confirmed by direct sequencing of the purified HCV genome. These putative small encoded peptides may play a regulatory role in translation. The region of the HCV genome upstream of that represented by C18g can be isolated for sequence analysis using essentially the technique described in EPO Pub. No. 318,216 for isolating cDNA sequences upstream of the HCV cDNA sequence in clone 12f. Essentially, small synthetic oligonucleotide primers of reverse transcriptase, which are based upon the sequence of C18g, are synthesized and used to bind to the corresponding sequence in HCV genomic RNA. The primer sequences are proximal to the known 5'-terminal of C18g, but sufficiently downstream to allow the design of probe sequences upstream of the primer sequences. Known standard methods of priming and cloning are used. The resulting cDNA libraries are screened with sequences upstream of the priming sites (as deduced from the elucidated sequence of C18g). The HCV genomic RNA is obtained from either plasma or liver samples from individuals with NANBH. Since HCV appears to be a Flavi-like virus, the 5'-terminus of the genome may be modified with a "cap" structure. It is known that Flavivirus genomes contain 5'-terminal "cap" structures. (Yellow Fever virus, Rice et al. (1988); Dengue virus, Hahn et al (1988); Japanese Encephalitis Virus (1987)).

40

Isolation and Sequence of Clones from the beta-HCV cDNA library

Clones containing cDNA representative of the 3'-terminal region of the HCV genome were isolated from a cDNA library constructed from the original infectious chimpanzee plasma pool which was used for the creation of the HCV cDNA lambda-gt11 library (ATCC No. 40394), described in EPO Pub. No. 318,216. In order to create the DNA library, RNA extracted from the plasma was "tailed" with poly (rA) using poly (rA) polymerase, and cDNA was synthesized using oligo(dT)<sub>12-18</sub> as a primer for reverse transcriptase. The resulting RNA:cDNA hybrid was digested with RNAase H, and converted to double stranded HCV cDNA. The resulting HCV cDNA was cloned into lambda-gt10, using essentially the technique described in Huynh (1985), yielding the beta (or b) HCV cDNA library. The procedures used were as follows.

An aliquot (12ml) of the plasma was treated with proteinase K, and extracted with an equal volume of phenol saturated with 0.05M Tris-Cl, pH 7.5, 0.05% (v/v) beta-mercaptoethanol, 0.1% (w/v) hydroxyquinoline, 1 mM EDTA. The resulting aqueous phase was re-extracted with the phenol mixture, followed by 3 extractions with a 1:1 mixture containing phenol and chloroform:isoamyl alcohol (24:1), followed by 2 extractions with a mixture of chloroform and isoamyl alcohol (1:1). Subsequent to adjustment of the aqueous phase to 200 mM with respect to NaCl, nucleic acids in the aqueous phase were precipitated overnight at -20°C, with 2.5 volumes of cold absolute ethanol. The precipitates were collected by centrifugation at 10,000 RPM for 40 min., washed with 70% ethanol containing 20 mM NaCl, and with 100% cold ethanol,

## EP 0 388 232 A1

dried for 5 min. in a dessicator, and dissolved in water.

The isolated nucleic acids from the infectious chimpanzee plasma pool were tailed with poly rA utilizing poly-A polymerase in the presence of human placenta ribonuclease inhibitor (HPRI) (purchased from Amersham Corp.), utilizing MS2 RNA as carrier. Isolated nucleic acids equivalent to that in 2 ml of plasma were incubated in a solution containing TMN (50 mM Tris HCl, pH 7.9, 10 mM MgCl<sub>2</sub>, 250 mM NaCl, 2.5 mM MnCl<sub>2</sub>, 2 mM dithiothreitol (DTT)), 40 micromolar alpha-[<sup>32</sup>P] ATP, 20 units HPRI (Amersham Corp.), and about 9 to 10 units of RNase free poly-A polymerase (BRL). Incubation was for 10 min. at 37° C, and the reactions were stopped with EDTA (final concentration about 250 mM). The solution was extracted with an equal volume of phenol-chloroform, and with an equal volume of chloroform, and nucleic acids were precipitated overnight at -20° C with 2.5 volumes of ethanol in the presence of 200 mM NaCl.

Isolation of Clone b5a

The beta HCV cDNA library was screened by hybridization using a synthetic probe, which had a sequence based upon the HCV cDNA sequence in clone 15e. The isolation of clone 15e is described in EPO Pub. No. 318,216, and its sequence is shown in Fig. 3. The sequence of the synthetic probe was:

5' ATT GCG AGA TCT ACG GGG CCT GCT ACT CCA 3'.

Screening of the library yielded clone beta-5a (b5a), which contains an HCV cDNA region of approximately 1000 base pairs. The 5'-region of this cDNA overlaps clones 35f, 19g, 26g, and 15e (these clones are described supra). The region between the 3'-terminal poly-A sequence and the 3'-sequence which overlaps clone 15e, contains approximately 200 base pairs. This clone allows the identification of a region of the 3'-terminal sequence the HCV genome.

The sequence of b5a is contained within the sequence of the HCV cDNA in clone 16jh (described infra). Moreover, the sequence is also present in CC34a, isolated from the original lambda-gt11 library (ATCC No. 40394). (The original lambda-gt11 library is referred to herein as the "C" library).

Isolation and Sequence of Clones Generated by PCR Amplification of the 3'-Region of the HCV Genome

Multiple cDNA clones have been generated which contain nucleotide sequences derived from the 3'-region of the HCV genome. This was accomplished by amplifying a targeted region of the genome by a polymerase chain reaction technique described in Salk et al. (1986), and in Saiki et al. (1988), which was modified as described below. The HCV RNA which was amplified was obtained from the original infectious chimpanzee plasma pool which was used for the creation of the HCV cDNA lambda-gt11 library (ATCC No. 40394) described in EPO Pub. No. 318,216. Isolation of the HCV RNA was as described supra. The isolated RNA was tailed at the 3'-end with ATP by *E. coli* poly-A polymerase as described in Sippel (1973), except that the nucleic acids isolated from chimp serum were substituted for the nucleic acid substrate. The tailed RNA was then reverse transcribed into cDNA by reverse transcriptase, using an oligo dT-primer adapter, essentially as described by Han (1987), except that the components and sequence of the primer-adapter were:

Stuffer	NotI	SP6 Promoter	Primer
AATTC	GCGGCCGC	CATACGATTTAGGTGACACTATAGAA	T <sub>15</sub>

The resultant cDNA was subjected to amplification by PCR using two primers:

Primer	Sequence
JH32 (30mer)	ATAGCGGCCGCCCTCGATTGCGAGATCTAC
JH11 (20mer)	AATTCGGCGGCCGCCATACGA

## EP 0 388 232 A1

The JH32 primer contained 20 nucleotide sequences hybridizable to the 5'-end of the target region in the cDNA, with an estimated  $T_m$  of 66°C. The JH11 was derived from a portion of the oligo dT-primer adapter; thus, it is specific to the 3'-end of the cDNA with a  $T_m$  of 64°C. Both primers were designed to have a recognition site for the restriction enzyme, NotI, at the 5'-end, for use in subsequent cloning of the amplified

5 HCV cDNA.

The PCR reaction was carried out by suspending the cDNA and the primers in 100 microliters of reaction mixture containing the four deoxynucleoside triphosphates, buffer salts and metal ions, and a thermostable DNA polymerase isolated from *Thermus aquaticus* (Taq polymerase), which are in a Perkin Elmer Cetus PCR kit (N801-0043 or N801-0055). The PCR reaction was performed for 35 cycles in a Perkin Elmer Cetus DNA thermal cycler. Each cycle consisted of a 1.5 min denaturation step at 94°C, an  
 10 annealing step at 60°C for 2 min, and a primer extension step at 72°C for 3 min. The PCR products were subjected to Southern blot analysis using a 30 nucleotide probe, JH34, the sequence of which was based upon that of the 3'-terminal region of clone 15e. The sequence of JH34 is:  
 5' CTT GAT CTA CCT CCA ATC ATT CAA AGA CTC 3'.

15 The PCR products detected by the HCV cDNA probe ranged in size from about 50 to about 400 base pairs.

In order to clone the amplified HCV cDNA, the PCR products were cleaved with NotI and size selected by polyacrylamide gel electrophoresis. DNA larger than 300 base pairs was cloned into the NotI site of pUC18S. The vector pUC18S is constructed by including a NotI polylinker cloned between the EcoRI and SalI sites of pUC18. The clones were screened for HCV cDNA using the JH34 probe. A number of positive  
 20 clones were obtained and sequenced. The nucleotide sequence of the HCV cDNA insert in one of these clones, 16jh, and the amino acids encoded therein, are shown in Fig. 15. A nucleotide heterogeneity, detected in the sequence of the HCV cDNA in clone 16jh as compared to another clone of this region, is indicated in the figure.

25

#### Compiled HCV cDNA Sequences

An HCV cDNA sequence has been compiled from a series of overlapping clones derived from the  
 30 various HCV cDNA libraries described supra. In this sequence, the compiled HCV cDNA sequence obtained from clones b114a, 18g, ag30a, CA205a, CA290a, CA216a, pi14a, CA167b, CA156e, CA84a, and CA59a is upstream of the compiled HCV cDNA sequence published in EPO Pub. No. 318,216, which is shown in Fig. 16. The compiled HCV cDNA sequence obtained from clones b5a and 16jh downstream of the compiled HCV cDNA sequence published in EPO Pub. No. 318,216.

35 Fig. 17 shows the compiled HCV cDNA sequence derived from the above-described clones and the compiled HCV cDNA sequence published in EPO Pub. No. 318,216. The clones from which the sequence was derived are b114a, 18g, ag30a, CA205a, CA290a, CA216a, pi14a, CA167b, CA156e, CA84a, CA59a, K9-1 (also called K9-1), 26j, 13i, 12f, 14i, 11b, 7f, 7e, 8h, 33c, 40b, 37b, 35, 36, 81, 32, 33b, 25c, 14c, 8f, 33f, 33g, 39c, 35f, 19g, 26g, 15e, b5a, and 16jh. In the figure the three dashes above the sequence indicate the  
 40 position of the putative initiator methionine codon.

Clone b114a was obtained using the cloning procedure described for clone b5a, supra., except that the probe was the synthetic probe used to detect clone 18g, supra. Clone b114a overlaps with clones 18g, ag30a, and CA205a, except that clone b114a contains an extra two nucleotides upstream of the sequence in clone 18g (i.e., 5'-CA). These extra two nucleotides have been included in the HCV genomic sequence  
 45 shown in Fig. 17.

It should be noted that although several of the clones described supra. have been obtained from libraries other than the original HCV cDNA lambda-gt11 C library (ATCC No. 40394), these clones contain HCV cDNA sequences which overlap HCV cDNA sequences in the original library. Thus, essentially all of the HCV sequence is derivable from the original lambda-gt11 C library (ATCC No. 40394) which was used  
 50 to isolate the first HCV cDNA clone (5-1-1). The isolation of clone 5-1-1 is described in EPO Pub. No. 318,216.

#### Purification of Fusion polypeptide C100-3 (Alternate method)

55

The fusion polypeptide, C100-3 (also called HCV c100-3 and alternatively, c100-3), is comprised of superoxide dismutase (SOD) at the N-terminus and an in-frame C100 HCV polypeptide at the C-terminus. A

## EP 0 388 232 A1

method for preparing the polypeptide by expression in yeast, and differential extraction of the insoluble fraction of the extracted host yeast cells, is described in EPO Pub. No. 318,216. An alternative method for the preparation of this fusion polypeptide is described below. In this method the antigen is precipitated from the crude cell lysate with acetone; the acetone precipitated antigen is then subjected to ion-exchange chromatography, and further purified by gel filtration.

5 The fusion polypeptide, C100-3 (HCV c100-3), is expressed in yeast strain JSC 308 (ATCC No. 20879) transformed with pAB24C100-3 (ATCC No. 67976); the transformed yeast are grown under conditions which allow expression (i.e., by growth in YEP containing 1% glucose). (See EPO Pub. No. 318,216). A cell lysate is prepared by suspending the cells in Buffer A (20 mM Tris HCl, pH 8.0, 1 mM EDTA, 1 mM PMSF. The cells are broken by grinding with glass beads in a Dymomill type homogenizer or its equivalent. The extent of cell breakage is monitored by counting cells under a microscope with phase optics. Broken cells appear dark, while viable cells are light-colored. The percentage of broken cells is determined.

10 When the percentage of broken cells is approximately 90% or greater, the broken cell debris is separated from the glass beads by centrifugation, and the glass beads are washed with Buffer A. After combining the washes and homogenate, the insoluble material in the lysate is obtained by centrifugation. The material in the pellet is washed to remove soluble proteins by suspension in Buffer B (50 mM glycine, pH 12.0, 1 mM DTT, 500 mM NaCl), followed by Buffer C (50 mM glycine, pH 10.0, 1 mM DTT). The insoluble material is recovered by centrifugation, and solubilized by suspension in Buffer C containing SDS. The extract solution may be heated in the presence of beta-mercaptoethanol and concentrated by ultrafiltration. The HCV c100-3 in the extract is precipitated with cold acetone. If desired, the precipitate may be stored at temperatures at about or below -15°C.

15 Prior to ion exchange chromatography, the acetone precipitated material is recovered by centrifugation, and may be dried under nitrogen. The precipitate is suspended in Buffer D (50 mM glycine, pH 10.0, 1 mM DTT, 7 M urea), and centrifuged to pellet insoluble material. The supernatant material is applied to an anion exchange column previously equilibrated with Buffer D. Fractions are collected and analyzed by ultraviolet absorbance or gel electrophoresis on SDS polyacrylamide gels. Those fractions containing the HCV c100-3 polypeptide are pooled.

20 In order to purify the HCV c100-3 polypeptide by gel filtration, the pooled fractions from the ion-exchange column are heated in the presence of beta-mercaptoethanol and SDS, and the eluate is concentrated by ultrafiltration. The concentrate is applied to a gel filtration column previously equilibrated with Buffer E (20 mM Tris HCl, pH 7.0, 1 mM DTT, 0.1% SDS). The presence of HCV c100-3 in the eluted fractions, as well as the presence of impurities, are determined by gel electrophoresis on polyacrylamide gels in the presence of SDS and visualization of the polypeptides. Those fractions containing purified HCV c100-3 are pooled. Fractions high in HCV c100-3 may be further purified by repeating the gel filtration process. If the removal of particulate material is desired, the HCV c100-3 containing material may be filtered through a 0.22 micron filter.

#### Expression and Antigenicity of Polypeptides Encoded in HCV cDNA

##### Polypeptides Expressed in E. coli

45 The polypeptides encoded in a number of HCV cDNAs which span the HCV genomic ORF were expressed in *E. coli*, and tested for their antigenicity using serum obtained from a variety of individuals with NANBH. The expression vectors containing the cloned HCV cDNAs were constructed from pSODc1 (Steimer et al. (1986). In order to be certain that a correct reading frame would be achieved, three separate expression vectors, pcf1AB, pcf1CD, and pcf1EF were created by ligating either of three linkers, AB, CD, and EF to a BamHI-EcoRI fragment derived by digesting to completion the vector pSODc1 with EcoRI and BamHI, followed by treatment with alkaline phosphatase. The linkers were created from six oligomers, A, B, C, D, E, and F. Each oligomer was phosphorylated by treatment with kinase in the presence of ATP prior to annealing to its complementary oligomer. The sequences of the synthetic linkers were the following.

## EP 0 388 232 A1

	Name	DNA Sequence (5' to 3')
5	A	GATC CTG AAT TCC TGA TAA
	B	GAC TTA AGG ACT ATT TTA A
	C	GATC CGA ATT CTG TGA TAA
10	D	GCT TAA GAC ACT ATT TTA A
	E	GATC CTG GAA TTC TGA TAA
15	F	GAC CTT AAG ACT ATT TTA A

Each of the three linkers destroys the original EcoRI site, and creates a new EcoRI site within the linker, but within a different reading frame. Hence, the HCV cDNA EcoRI fragments isolated from the clones when inserted into the expression vector, were in three different reading frames.

20 The HCV cDNA fragments in the designated lambda-gt11 clones were excised by digestion with EcoRI; each fragment was inserted into pcf1AB, pcf1CD, and pcf1EF. These expression constructs were then transformed into D1210 *E. coli* cells, the transformants were cloned, and recombinant bacteria from each clone were induced to express the fusion polypeptides by growing the bacteria in the presence of IPTG.

25 Expression products of the indicated HCV cDNAs were tested for antigenicity by direct immunological screening of the colonies, using a modification of the method described in Helfman et al. (1983). Briefly, as shown in Fig. 18, the bacteria were plated onto nitrocellulose filters overlaid on ampicillin plates to give approximately 1,000 colonies per filter. Colonies were replica plated onto nitrocellulose filters, and the replicas were regrown overnight in the presence of 2 mM IPTG and ampicillin. The bacterial colonies were lysed by suspending the nitrocellulose filters for about 15 to 20 min in an atmosphere saturated with CHCl<sub>3</sub> vapor. Each filter then was placed in an individual 100 mm Petri dish containing 10 ml of 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 3% (w/v) BSA, 40 micrograms/ml lysozyme, and 0.1 microgram/ml DNase. The plates were agitated gently for at least 8 hours at room temperature. The filters were rinsed in TBST (50 mM Tris HCl, pH8.0, 150 mM NaCl, 0.005% Tween 20). After incubation, the cell residues were rinsed and incubated in TBS (TBST without Tween) containing 10% sheep serum; incubation was for 1 hour. The filters were then incubated with pretreated sera in TBS from individuals with NANBH, which included: 3 chimpanzees; 8 patients with chronic NANBH whose sera were positive with respect to antibodies to HCV C100-3 polypeptide (described in EPO Pub. No. 318,216, and supra.) (also called C100); 8 patients with chronic NANBH whose sera were negative for anti-C100 antibodies; a convalescent patient whose serum was negative for anti-C100 antibodies; and 6 patients with community acquired NANBH. 40 Including one whose sera was strongly positive with respect to anti-C100 antibodies, and one whose sera was marginally positive with respect to anti-C100 antibodies. The sera, diluted in TBS, was pretreated by preabsorption with hSOD. Incubation of the filters with the sera was for at least two hours. After incubation, the filters were washed two times for 30 min with TBST. Labeling of expressed proteins to which antibodies in the sera bound was accomplished by incubation for 2 hours with <sup>125</sup>I-labeled sheep anti-human antibody. 45 After washing, the filters were washed twice for 30 min with TBST, dried, and autoradiographed.

A number of clones (see infra.) expressed polypeptides containing HCV epitopes which were immunologically reactive with serum from individuals with NANBH. Five of these polypeptides were very immunogenic in that antibodies to HCV epitopes in these polypeptides were detected in many different patient sera. The clones encoding these polypeptides, and the location of the polypeptide in the putative HCV polyprotein (wherein the amino acid numbers begin with the putative initiator codon) are the following: 50 clone 5-1-1, amino acids 1694-1735; clone C100, amino acids 1569-1931; clone 33c, amino acids 1192-1457; clone CA279a, amino acids 1-84; and clone CA290a amino acids 9-177. The location of the immunogenic polypeptides within the putative HCV polyprotein are shown immediately below.

55

## EP 0 388 232 A1

Clones encoding polypeptides of proven reactivity with sera from NANBH patients.		
Clone	Location within the HCV polyprotein	
	(amino acid no. beginning with putative initiator methionine)	
CA279a	1-84	
CA74a	437-582	
13i	511-690	
CA290a	9-177	
33c	1192-1457	
40b	1266-1428	
5-1-1	1694-1735	
81	1689-1805	
33b	1916-2021	
25c	1949-2124	
14c	2054-2223	
8f	2200-3325	
33f	2287-2385	
33g	2348-2464	
39c	2371-2502	
15e	2796-2886	
C100	1569-1931	

The results on the immunogenicity of the polypeptides encoded in the various clones examined suggest efficient detection and immunization systems may include panels of HCV polypeptides/epitopes.

#### Expression of HCV Epitopes in Yeast

Three different yeast expression vectors which allow the insertion of HCV cDNA into three different reading frames are constructed. The construction of one of the vectors, pAB24C100-3 is described in EPO Pub. No. 318,216. In the studies below, the HCV cDNA from the clones listed in supra. in the antigenicity mapping study using the *E. coli* expressed products are substituted for the C100 HCV cDNA. The construction of the other vectors replaces the adaptor described in the above *E. coli* studies with one of the following adaptors:

#### Adaptor 1

ATT TTG AAT TCC TAA TGA G  
AC TTA AGG ATT ACT CAG CT

#### Adaptor 2

AAT TTG GAA TTC TAA TGA G  
AC CTT AAG ATT ACT CAG CT.

The inserted HCV cDNA is expressed in yeast transformed with the vectors, using the expression



**EP 0 388 232 A1**

conditions described supra. for the expression of the fusion polypeptide, C100-3. The resulting polypeptides are screened using the sera from individuals with NANBH, described supra. for the screening of immunogenic polypeptides encoded in HCV cDNAs expressed in E. coli.

5

Comparison of the Hydrophobic Profiles of HCV Polyproteins with West Nile Virus Polyprotein and with Dengue Virus NS1

10 The hydrophobicity profile of an HCV polyprotein segment was compared with that of a typical Flavivirus, West Nile virus. The polypeptide sequence of the West Nile virus polyprotein was deduced from the known polynucleotide sequences encoding the non-structural proteins of that virus. The HCV polyprotein sequence was deduced from the sequence of overlapping cDNA clones. The profiles were determined using an antigen program which uses a window of 7 amino acid width (the amino acid in question, and 3 residues on each side) to report the average hydrophobicity about a given amino acid residue. The parameters giving the reactive hydrophobicity for each amino acid residue are from Kyte and Doolittle (1982). Fig. 19 shows the hydrophobic profiles of the two polyproteins; the areas corresponding to the non-structural proteins of West Nile virus, ns1 through ns5, are indicated in the figure. As seen in the figure, there is a general similarity in the profiles of the HCV polyprotein and the West Nile virus polyprotein.

20 The sequence of the amino acids encoded in the 5'-region of HCV cDNA shown in Fig. 16 has been compared with the corresponding region of one of the strains of Dengue virus, described supra., with respect to the profile of regions of hydrophobicity and hydrophilicity (data not shown). This comparison indicated that the polypeptides from HCV and Dengue encoded in this region, which corresponds to the region encoding NS1 (or a portion thereof), have a similar hydrophobic/hydrophilic profile.

25 The similarity in hydrophobicity profiles, in combination with the previously identified homologues in the amino acid sequences of HCV and Dengue Flavivirus in EP 0,218,316 suggests that HCV is related to these members of the Flavivirus family.

30

Characterization of the Putative Polypeptides Encoded Within the HCV ORF

The sequence of the HCV cDNA sense strand, shown in Fig. 17, was deduced from the overlapping HCV cDNAs in the various clones described in EPO Pub. No. 318,216 and those described supra. It may be deduced from the sequence that the HCV genome contains primarily one long continuous ORF, which encodes a polyprotein. In the sequence, nucleotide number 1 corresponds to the first nucleotide of the initiator MET codon; minus numbers indicate that the nucleotides are that distance away in the 5'-direction (upstream), while positive numbers indicate that the nucleotides are that distance away in the 3'-direction (downstream). The composite sequence shows the "sense" strand of the HCV cDNA.

40 The amino acid sequence of the putative HCV polyprotein deduced from the HCV cDNA sense strand sequence is also shown in Fig. 17, where position 1 begins with the putative initiator methionine.

Possible protein domains of the encoded HCV polyprotein, as well as the approximate boundaries, are the following (the polypeptides identified within the parentheses are those which are encoded in the Flavivirus domain):

45

50

55

## EP 0 388 232 A1

Putative Domain	Approximate Boundary
	(amino acid nos.)
"C" (nucleocapsid protein)	1-120
"E" (Virion envelope protein(s) and possibly matrix (M) proteins	120-400
"NS1" (complement fixation antigen?)	400-660
"NS2" (unknown function)	660-1050
"NS3" (protease?)	1050-1640
"NS4" (unknown function)	1640-2000
"NS5" (polymerase)	2000-? end

It should be noted, however, that hydrophobicity profiles (described *Infra*), indicate that HCV diverges from the Flavivirus model, particularly with respect to the region upstream of NS2. Moreover, the boundaries indicated are not intended to show firm demarcations between the putative polypeptides.

#### The Hydrophilic and Antigenic Profile of the Polypeptide

Profiles of the hydrophilicity/hydrophobicity and the antigenic Index of the putative polyprotein encoded in the HCV cDNA sequence shown in Fig. 16 were determined by computer analysis. The program for hydrophilicity/hydrophobicity was as described *supra*. The antigenic index results from a computer program which relies on the following criteria: 1) surface probability, 2) prediction of alpha-helicity by two different methods; 3) prediction of beta-sheet regions by two different methods; 4) prediction of U-turns by two different methods; 5) hydrophilicity/hydrophobicity; and flexibility. The traces of the profiles generated by the computer analyses are shown in Fig. 20. In the hydrophilicity profile, deflection above the abscissa indicates hydrophilicity, and below the abscissa indicates hydrophobicity. The probability that a polypeptide region is antigenic is usually considered to increase when there is a deflection upward from the abscissa in the hydrophilic and/or antigenic profile. It should be noted, however, that these profiles are not necessarily indicators of the strength of the immunogenicity of a polypeptide.

#### Identification of Co-linear Peptides in HCV and Flaviviruses

The amino acid sequence of the putative polyprotein encoded in the HCV cDNA sense strand was compared with the known amino acid sequences of several members of Flaviviruses. The comparison shows that homology is slight, but due to the regions in which it is found, it is probably significant. The conserved colinear regions are shown in Fig. 21. The amino acid numbers listed below the sequences represent the number in the putative HCV polyprotein (See Fig. 17.)

The spacing of these conserved motifs is similar between the Flaviviruses and HCV, and implies that there is some similarity between HCV and these flaviviral agents.

The following listed materials are on deposit under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 12301 Parklawn Dr., Rockville, Maryland 20852, and have been assigned the following Accession Numbers.

## EP 0 388 232 A1

lambda-gt11	ATCC No.	Deposit Date
HCV cDNA library	40394	1 Dec. 1987
clone 81	40388	17 Nov. 1987
clone 91	40389	17 Nov. 1987
clone 1-2	40390	17 Nov. 1987
clone 5-1-1	40391	18 Nov. 1987
clone 12f	40514	10 Nov. 1988
clone 35f	40511	10 Nov. 1988
clone 15e	40513	10 Nov. 1988
clone K9-1	40512	10 Nov. 1988
JSC 308	20879	5 May 1988
pS356	67683	29 April 1988

In addition, the following deposits were made on 11 May 1989.

Strain	Linkers	ATCC No.
D1210 (Cf1/5-1-1)	EF	67967
D1210 (Cf1/81)	EF	67968
D1210 (Cf1/CA74a)	EF	67969
D1210 (Cf1/35f)	AB	67970
D1210 (Cf1/279a)	EF	67971
D1210 (Cf1/C36)	CD	67972
D1210 (Cf1/131)	AB	67973
D1210 (Cf1/C33b)	EF	67974
D1210 (Cf1/CA290a)	AB	67975
HB101 (AB24/C100 #3R)		67976

The following derivatives of strain D1210 were deposited on 3 May 1989.

Strain Derivative	ATCC No.
pCF1CS/C8f	67956
pCF1AB/C12f	67952
pCF1EF/14c	67949
pCF1EF/15e	67954
pCF1AB/C25c	67958
pCF1EF/C33c	67953
pCF1EF/C33f	67050
pCF1CD/33g	67951
pCF1CD/C39c	67955
pCF1EF/C40b	67957
pCF1EF/CA167b	67959

The following strains were deposited on May 12, 1989.

## EP 0 388 232 A1

Strain	ATCC No.
Lambda gt11(C35)	40603
Lambda gt10(beta-5a)	40602
D1210 (C40b)	67980
D1210 (M16)	67981

The deposited materials mentioned herein are intended for convenience only, and are not required to practice the present invention in view of the descriptions herein, and in addition these materials are incorporated herein by reference.

#### Industrial Applicability

The invention, in the various manifestations disclosed herein, has many industrial uses, some of which are the following. The HCV cDNAs may be used for the design of probes for the detection of HCV nucleic acids in samples. The probes derived from the cDNAs may be used to detect HCV nucleic acids in, for example, chemical synthetic reactions. They may also be used in screening programs for anti-viral agents, to determine the effect of the agents in inhibiting viral replication in cell culture systems, and animal model systems. The HCV polynucleotide probes are also useful in detecting viral nucleic acids in humans, and thus, may serve as a basis for diagnosis of HCV infections in humans.

In addition to the above, the cDNAs provided herein provide information and a means for synthesizing polypeptides containing epitopes of HCV. These polypeptides are useful in detecting antibodies to HCV antigens. A series of immunoassays for HCV infection, based on recombinant polypeptides containing HCV epitopes are described herein, and will find commercial use in diagnosing HCV induced NANBH, in screening blood bank donors for HCV-caused infectious hepatitis, and also for detecting contaminated blood from infectious blood donors. The viral antigens will also have utility in monitoring the efficacy of anti-viral agents in animal model systems. In addition, the polypeptides derived from the HCV cDNAs disclosed herein will have utility as vaccines for treatment of HCV infections.

The polypeptides derived from the HCV cDNAs, besides the above stated uses, are also useful for raising anti-HCV antibodies. Thus, they may be used in anti-HCV vaccines. However, the antibodies produced as a result of immunization with the HCV polypeptides are also useful in detecting the presence of viral antigens in samples. Thus, they may be used to assay the production of HCV polypeptides in chemical systems. The anti-HCV antibodies may also be used to monitor the efficacy of anti-viral agents in screening programs where these agents are tested in tissue culture systems. They may also be used for passive immunotherapy, and to diagnose HCV caused NANBH by allowing the detection of viral antigen(s) in both blood donors and recipients. Another important use for anti-HCV antibodies is in affinity chromatography for the purification of virus and viral polypeptides. The purified virus and viral polypeptide preparations may be used in vaccines. However, the purified virus may also be useful for the development of cell culture systems in which HCV replicates.

Antisense polynucleotides may be used as inhibitors of viral replication.

For convenience, the anti-HCV antibodies and HCV polypeptides, whether natural or recombinant, may be packaged into kits.

#### Claims

1. A recombinant polynucleotide comprising a sequence derived from HCV cDNA, wherein the HCV cDNA is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156a, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 18jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

2. A recombinant polynucleotide according to claim 1, encoding an epitope of HCV.

3. A recombinant vector comprising the polynucleotide of claim 1 or claim 2.

4. A host cell transformed with the vector of claim 3.

## EP 0 388 232 A1

5. A recombinant expression system comprising an open reading frame (ORF) of DNA derived from the recombinant polynucleotide of claim 1 or claim 2, wherein the ORF is operably linked to a control sequence compatible with a desired host.

6. A cell transformed with the recombinant expression system of claim 5.

7. A polypeptide produced by the cell of claim 6.

8. A purified polypeptide comprising an epitope encoded within HCV cDNA wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

9. An immunogenic polypeptide produced by a cell transformed with a recombinant expression vector comprising an ORF of DNA derived from HCV cDNA, wherein the HCV cDNA is comprised of a sequence derived from the HCV cDNA sequence in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33C or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, and wherein the ORF is operably linked to a control sequence compatible with a desired host.

10. A peptide comprising an HCV epitope, wherein the peptide is of the formula

AA<sub>x</sub>-AA<sub>y</sub>,

wherein x and y designate amino acid numbers shown in Fig. 17, and wherein the peptide is selected from the group consisting of AA1-AA25, AA1-AA50, AA1-AA84, AA9-AA177, AA1-AA10, AA5-AA20, AA20-AA25, AA35-AA45, AA50-AA100, AA40-AA90, AA45-AA65, AA65-AA75, AA80-90, AA99-AA120, AA95-AA110, AA105-AA120, AA100-AA150, AA150-AA200, AA155-AA170, AA190-AA210, AA200-AA250, AA220-AA240, AA245-AA265, AA250-AA300, AA290-AA330, AA290-305, AA300-AA350, AA310-AA330, AA350-AA400, AA380-AA395, AA405-AA495, AA400-AA450, AA405-AA415, AA415-AA425, AA425-AA435, AA437-AA582, AA450-AA500, AA440-AA460, AA460-AA470, AA475-AA495, AA500-AA550, AA511-AA690, AA515-AA550, AA550-AA600, AA550-AA625, AA575-AA605, AA585-AA600, AA600-AA650, AA600-AA625, AA635-AA665, AA650-AA700, AA645-AA680, AA700-AA750, AA700-AA725, AA700-AA750, AA725-AA775, AA770-AA790, AA750-AA800, AA800-AA815, AA825-AA850, AA850-AA875, AA800-AA850, AA920-AA990, AA850-AA900, AA920-AA945, AA940-AA965, AA970-AA990, AA950-AA1000, AA1000-AA1060, AA1000-AA1025, AA1000-AA1050, AA1025-AA1040, AA1040-AA1055, AA1075-AA1175, AA1050-AA1200, AA1070-AA1100, AA1100-AA1130, AA1140-AA1165, AA1192-AA1457, AA1195-AA1250, AA1200-AA1225, AA1225-AA1250, AA1250-AA1300, AA1260-AA1310, AA1260-AA1280, AA1266-AA1428, AA1300-AA1350, AA1290-AA1310, AA1310-AA1340, AA1345-AA1405, AA1345-AA1365, AA1350-AA1400, AA1365-AA1380, AA1380-AA1405, AA1400-AA1450, AA1450-AA1500, AA1460-AA1475, AA1475-AA1515, AA1475-AA1500, AA1500-AA1550, AA1500-AA1515, AA1515-AA1550, AA1550-AA1600, AA1545-AA1560, AA1569-AA1931, AA1570-AA1590, AA1595-AA1610, AA1590-AA1650, AA1610-AA1645, AA1650-AA1690, AA1685-AA1770, AA1689-AA1805, AA1690-AA1720, AA1694-AA1735, AA1720-AA1745, AA1745-AA1770, AA1775-AA1800, AA1775-AA1810, AA1795-AA1850, AA1850-AA1900, AA1900-AA1950, AA1900-AA1920, AA1916-AA2021, AA1920-AA1940, AA1949-AA2124, AA1950-AA2000, AA1950-AA1985, AA1980-AA2000, AA2000-AA2050, AA2005-AA2025, AA2020-AA2045, AA2045-AA2100, AA2045-AA2070, AA2054-AA2223, AA2070-AA2100, AA2100-AA2150, AA2150-AA2200, AA2200-AA2250, AA2200-AA2325, AA2250-AA2330, AA2255-AA2270, AA2265-AA2280, AA2280-AA2290, AA2287-AA2385, AA2300-AA2350, AA2290-AA2310, AA2310-AA2330, AA2330-AA2350, AA2350-AA2400, AA2348-AA2464, AA2345-AA2415, AA2345-AA2375, AA2370-AA2410, AA2371-AA2502, AA2400-AA2450, AA2400-AA2425, AA2415-AA2450, AA2445-AA2500, AA2445-AA2475, AA2470-AA2490, AA2500-AA2550, AA2505-AA2540, AA2535-AA2560, AA2550-AA2600, AA2560-AA2580, AA2600-AA2650, AA2605-AA2620, AA2620-AA2650, AA2640-AA2660, AA2650-AA2700, AA2655-AA2670, AA2670-AA2700, AA2700-AA2750, AA2740-AA2760, AA2750-AA2800, AA2755-AA2780, AA2780-AA2830, AA2785-AA2810, AA2796-AA2886, AA2810-AA2825, AA2800-AA2850, AA2850-AA2900, AA2850-AA2865, AA2885-AA2905, AA2900-AA2950, AA2910-AA2930, AA2925-AA2950, AA2945-end(C' terminal).

11. A polypeptide comprised of the peptide of claim 10.

12. An immunogenic polypeptide attached to a solid substrate, wherein the polypeptide is according to claim 7, or claim 8, or claim 9, or claim 10, or claim 11, or wherein the polypeptide is comprised of an epitope encoded within HCV cDNA wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

13. A monoclonal antibody directed against an epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone p14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

14. A preparation of purified polyclonal antibodies directed against a polypeptide comprised of an epitope encoded within HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or

## EP 0 388 232 A1

clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

15. A polynucleotide probe for HCV, wherein the probe is comprised of an HCV sequence derived from an HCV cDNA sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or from the complement of the HCV cDNA sequence.

16. A kit for analyzing samples for the presence of polynucleotides from HCV comprising a polynucleotide probe containing a nucleotide sequence of about 8 or more nucleotides, wherein the nucleotide sequence is derived from HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, wherein the polynucleotide probe is in a suitable container.

17. A kit for analyzing samples for the presence of an HCV antigen comprising an antibody which reacts immunologically with an HCV antigen, wherein the antigen contains an epitope encoded within HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or wherein the HCV cDNA is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

18. A kit for analyzing samples for the presence of an HCV antibody comprising an antigenic polypeptide containing an HCV epitope encoded within HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh.

19. A kit for analyzing samples for the presence of an HCV antibody comprising an antigenic polypeptide expressed from HCV cDNA in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33C or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, wherein the antigenic polypeptide is present in a suitable container.

20. A method for detecting HCV nucleic acids in a sample comprising:

(a) reacting nucleic acids of the sample with a polynucleotide probe for HCV, wherein the probe is comprised of an HCV sequence derived from an HCV cDNA sequence is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, and wherein the reacting is under conditions which allow the formation of a polynucleotide duplex between the probe and the HCV nucleic acid from the sample.

(b) detecting a polynucleotide duplex which contains the probe, formed in step (a).

21. An immunoassay for detecting an HCV antigen comprising:

(a) incubating a sample suspected of containing an HCV antigen with an antibody directed against an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the incubating is under conditions which allow formation of an antigen-antibody complex; and (b) detecting an antibody-antigen complex formed in step (a) which contains the antibody.

22. An immunoassay for detecting antibodies directed against an HCV antigen comprising:

(a) incubating a sample suspected of containing anti-HCV antibodies with an antigen polypeptide containing an epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the incubating is under conditions which allow formation of an antigen-antibody complex; and

(b) detecting an antibody-antigen complex formed in step (a) which contains the antigen polypeptide.

23. An immunoassay for detecting antibodies directed against an HCV antigen comprising:

(a) incubating a sample suspected of containing anti-HCV antibodies with the polypeptide of claim 9, under conditions which allow formation of an antigen-antibody complex; and

(b) detecting an antibody-antigen complex formed in step (a) which contains the antigen polypeptide.

24. A vaccine for treatment of HCV infection comprising an immunogenic polypeptide containing an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17 or is the sequence present in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, and wherein the immunogenic polypeptide is present in a pharmacologically effective dose in a pharmaceutically acceptable excipient.

25. A method for producing antibodies to HCV comprising administering to an individual an isolated

## EP 0 388 232 A1

immunogenic polypeptide containing an HCV epitope encoded in HCV cDNA, wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, or is of the sequence present in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33c or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, and wherein the immunogenic polypeptide is present in a pharmacologically effective dose in a pharmaceutically acceptable excipient.

26. An antisense polynucleotide derived from HCV cDNA, wherein the HCV cDNA is that shown in Fig. 17.

27. A method for preparing purified fusion polypeptide C100-3 comprising:

(a) providing a crude cell lysate containing polypeptide C100-3,  
(b) treating the crude cell lysate with an amount of acetone which causes the polypeptide to precipitate,

(c) isolating and solubilizing the precipitated material,

(d) isolating the C100-3 polypeptide by anion exchange chromatography, and

(e) further isolating the C100-3 polypeptide of step (d) by gel filtration.

28. A method for preparing an HCV polypeptide comprising:

(a) providing a host cell transformed with a recombinant expression system comprising an open reading frame (ORF) of DNA derived from HCV cDNA, wherein the HCV cDNA is in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a; or clone 18g, or clone 16jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17, wherein the ORF is operably linked to a control sequence compatible with a desired host; and

(b) incubating the host cell under conditions which allow expression of the HCV polypeptide.

29. A method for preparing an immunogenic HCV polypeptide comprising:

(a) providing a host cell transformed with a recombinant expression vector comprising an ORF of DNA derived from HCV cDNA, wherein the HCV cDNA is comprised of a sequence derived from the HCV cDNA sequence in clone CA279a, or clone CA74a, or clone 13i, or clone CA290a, or clone 33c, or clone 40b, or clone 33b, or clone 25c, or clone 14c, or clone 8f, or clone 33f, or clone 33g, or clone 39c, or clone 15e, wherein the OEF is operably linked to a control sequence compatible with the desired host; and

(b) incubating the host cell under conditions which allow expression of the HCV polypeptide.

30. A method for preparing a host cell transformed with a recombinant polynucleotide comprising a sequence of HCV cDNA derived from the HCV cDNA in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17 comprising:

(a) providing a host cell capable of transformation;

(b) providing the recombinant polynucleotide; and

(c) incubating (a) with (b) under conditions which allow transformation of the host cell with the polynucleotide.

31. A method for preparing a recombinant polynucleotide comprised of a sequence of HCV cDNA derived from the HCV cDNA in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17 comprising:

(a) providing a host cell transformed with the recombinant polynucleotide; and

(b) isolating said polynucleotide from said host cell.

32. A method for preparing blood free of HCV comprising:

(a) providing a sample of blood suspected of containing HCV and anti-HCV antibodies;

(b) providing an immunogenic polypeptide prepared according to claim 28 or 29;

(c) incubating the sample of (a) with the immunogenic polypeptide of (b) under conditions which allow the formation of antibody-HCV polypeptide complexes;

(d) detecting the complexes formed in step (c); and

(e) saving the blood from which complexes were not detected in (d).

33. A method for preparing blood free of HCV comprising:

(a) providing nucleic acids from a sample of blood suspected of containing HCV polynucleotides;

(b) providing a probe for HCV, wherein the probe is comprised of an HCV sequence derived from an HCV cDNA which is of a sequence indicated by nucleotide numbers -319 to 1348 or 8659 to 8866 in Fig. 17.

## EP 0 388 232 A1

(c) reacting (a) with (b) under conditions which allow the formation of a polynucleotide duplex between the probe and the HCV nucleic acid from the sample;

(d) detecting a polynucleotide which contains the probe, formed in step (c); and

(e) saving the blood from which complexes were not detected in (d).

5 34. A method for producing a hybridoma which produces anti-HCV monoclonal antibodies comprising:

(a) immunizing an individual with an immunogenic polypeptide containing an epitope encoded in HCV cDNA, wherein the HCV cDNA is HCV cDNA in clone 13i, or clone 26j, or clone 59a, or clone 84a, or clone CA156e, or clone 167b, or clone pi14a, or clone CA216a, or clone CA290a, or clone ag30a, or clone 205a, or clone 18g, or clone 16jh, or wherein the HCV cDNA is of a sequence indicated by nucleotide numbers  
10 -319 to 1348 or 8659 to 8866 in Fig. 17; or

(b) immunizing an individual with an immunogenic polypeptide prepared according to claim 29;

(c) immortalizing antibody producing cells from the immunized individual;

(d) selecting an immortal cell which produces antibodies which react with an HCV epitope in the immunogenic polypeptide of (a) or (b); and

15 (e) growing said immortal cell.

20

25

30

35

40

45

50

55



EP 0 388 232 A1

## Translation of DNA 12f

IlePheLysIleArgMetTyrValGlyGlyValGluHisArgLeuGluAlaAlaCysAsn  
1 CCATATTTAAATCAGGATGTACGTGGGAGGGGTGGAACACAGGCTGGAAGCTGCCTGCA  
GGTATAAATTTTAGTCCTACATGCACCTCCCCAGCTTGTGTCCGACCTTCGACGGACGT

TrpThrArgGlyGluArgCysAspLeuGluAspArgAspArgSerGluLeuSerProLeu  
61 ACTGGACGCGGGGCGAACGTTGCGATCTGGAAGACAGGGACAGGTCCGAGCTCAGCCCT  
TGACCTGCGCCCGCTTGCAACGCTAGACCTTCTGTCCCTGTCCAGGCTCGAGTCGGGCA

LeuLeuThrThrThrGlnTrpGlnValLeuProCysSerPheThrThrLeuProAlaLeu  
121 TACTGCTGACCACTACACAGTGGCAGGTCTCCCGTGTTCCTTCACAACCTACCAGCCT  
ATGACGACTGGTGATGTGTACCGTCCAGGAGGGCACAAAGGAAGTGTGGGATGGTCGGA

SerThrGlyLeuIleHisLeuHisGlnAsnIleValAspValGlnTyrLeuTyrGlyVal  
181 TGTCACCGGCCTCATCCACCTCCACCAGAACATTGTGGACGTGCAGTACTTGTACGGGG  
ACAGGTGGCCGGAGTAGGTGGAGGTGGTCTTGTAACACCTGCACGTCATGAACATGCCCC

GlySerSerIleAlaSerTrpAlaIleLysTrpGluTyrValValLeuLeuPheLeuLeu  
241 TGGGGTCAAGCATCGCGTCTGGGCCATTAAAGTGGGAGTACGTGCTTCTCCTGTTCTCTC  
ACCCAGTTCGTAGCGCAGGACCCGGTAATTCACCTCATGCAGCAAGAGGACAAGGAAG

LeuAlaAspAlaArgValCysSerCysLeuTrpMetMetLeuLeuIleSerGlnAlaGlu  
301 TGCTTGACAGACGCGCGCTGTCTCCTGCTTGTGGATGATGCTACTCATATCCCAAGCGG  
ACGAACGTCTGCGCGCGCAGACGAGGACGAACACCTACTACGATGAGTATAGGGTTCGCC

-----Overlap with 14i-----  
AlaAlaLeuGluAsnLeuValIleLeuAsnAlaAlaSerLeuAlaGlyThrHisGlyLeu  
361 AGGCGGCTTTGGAGAACCTCGTAATACTTAATGCAGCATCCCTGGCCGGGACGCACGGTC  
TCCGCCGAAACCTCTTGGAGCATTATGAATTACGTGCTAGGGACCGGCCCTGCGTGCCAG

Val  
421 TTGTATC  
AACATAG

FIGURE 1

## EP 0 388 232 A1

## Translation of DNA k9-1

GlyCysProGluArgLeuAlaSerCysArgProLeuThrAspPheAspGlnGlyTrpGly  
1 CAGGCTGTCTCTGAGAGGCTAGCCAGCTGCCGACCCCTTACCGATTTTGACCGGGCTGGG  
GTCCGACAGGACTCTCCGATCGGTCGACGGCTGGGGAAATGGCTAAAACTGGTCCCCGACC

ProIleSerTyrAlaAsnGlySerGlyProAspGlnArgProTyrCysTrpHisTyrPro  
61 GCCCTATCAGTTATGCCAACGGAAGCGGCCCGACCGCCCTTACTGTGGCACTACC  
CGGGATAGTCAATACGGTTGCCTTCGCCGGGGCTGGTCGCGGGGATGACGACCGTGATGG

ProLysProCysGlyIleValProAlaLysSerValCysGlyProValTyrCysPheThr  
121 CCCCAAAACCTTGCGGTATTGTGCCCGGAAGAGTGTGTGGTCCGGTATATTGCTTCA  
GGGGTTTTGGAACGCCATAACACGGGCGCTTCTCACACACACCAGGCCATATAACGAAGT

ProSerProValValValGlyThrThrAspArgSerGlyAlaProThrTyrSerTrpGly  
181 CTCCACGCCCCGTGGTGGTGGGAACGACCGACAGGTCCGGCGCGCCACCTACAGCTGGG  
GAGGGTCGGGGCACCACCACCCCTTGCTGGCTGTCCAGCCCGCGGGGTGGATGCGACCC

GluAsnAspThrAspValPheValLeuAsnAsnThrArgProProLeuGlyAsnTrpPhe  
241 GTGAAATGATACGGACGCTCTTCGTCTTAACAATACCAGGCCACCGCTGGGCAATTGGT  
CACTTTTACTATGCCTGCAGAAGCAGGAATTGTTATGGTCCGGTGGCGACCCGTTAACCA

GlyCysThrTrpMetAsnSerThrGlyPheThrLysValCysGlyAlaProProCysVal  
301 TCGGTTGTACCTGGATGAATCAACTGGATTACCAAAGTGTGCGGAGCGCCTCCTTGTG  
AGCCAACATGGACCTACTTGAGTTGACCTAAGTGGTTTCACACGCCCTCGCGGAGGAACAC

IleGlyGlyAlaGlyAsnAsnThrLeuHisCysProThrAspCysPheArgLysHisPro  
361 TCATCGGAGGGCGGGCAACAACACCCCTGCCTGCCCACTGATTGCTCCGCAAGCATC  
AGTAGCCCTCCCCCGCCGTGTGTGGGACGTGACGGGGTGACTAACGAAGGCGTTCGTAG

AspAlaThrTyrSerArgCysGlySerGlyProTrpIleThrProArgCysLeuValAsp  
421 CGGACGCCACATACTCTCGGTGCGGCTCCGGTCCCTGGATCACACCCAGGTGCCTGGTCG  
GCCTGCGGTGTATGAGAGCCACGCCGAGGCCAGGGACCTAGTGTGGGTCCACGGACCAGC

-----  
TyrProTyrArgLeuTrpHisTyrProCysThrIleAsnTyrThrIlePheLysIleArg  
481 ACTACCCGTATAGGCTTTGGCATTATCCTTGTACCATCAACTACACTATATTTAAATCA  
TGATGGGCATATCCGAAACCGTAATAGGAACATGGTAGTTGATGTGATATAAATTTTAGT

-----  
MetTyrValGlyGlyValGluHisArgLeuGluAlaAlaCysAsnTrpThrArgGlyGlu  
541 GGATGTACGTGGGAGGGGTGAGCACAGGCTGGAAGCTGCCTGCAACTGGACGCGGGGGC  
CCTACATGCACCCCTCCCAGCTCGTGTCCGACCTTCGACGGACGTTGACCTGCGCCCCGC

-----  
ArgCysAspLeuGluAspArgAspArgSerGluLeuSerProLeuLeuLeuThrThrThr  
601 AACGTTGCGATCTGGAAGATAGGGACAGGTCCGAGCTCAGCCCGTTACTGTGACCACTA  
TTGCAACGCTAGACCTTCTATCCTGTCCAGGCTCGAGTCGGGCAATGACGACTGGTGAT

-----  
GlnTrpGlnValLeuProCysSerPheThrThrLeuProAlaLeuSerThrGlyLeuIle  
661 CACAGTGGCAGGTCTCTCCGTGTTCTTCAACCCCTGCCAGCCTGTCCACCGGCCTCA  
GTGTACCCGTCCAGGAGGGCACAGGAAGTGTGGGACGTCGGAACAGGTGGCCGGAGT

-----Overlap with Combined ORF of DNAs 12f through 15e-----  
HisLeuHisGlnAsnIleValAspValGlnTyrLeuTyrGlyValGlySerSerIleAla  
721 TCCACCTCCACCAGAACATTGTGGACGTGCAGTACTGTACGGGGTGGGGTCAAGCATCG  
AGGTGGAGGTGGTCTGTAAACACCTGCACGTCATGAACATGCCCCACCCAGTTCGTAGC

-----  
SerTrpAlaIleLysTrpGluTyrValValLeuLeuPheLeuLeuAlaAspAlaArg  
781 CGTCCTGGGCCATTAAAGTGGGAGTACGTCGTCCTCTGTTCTCTGCTGCAGACCCTGC  
CCAGGACCCGGTAATTCACCCCTCATGCAGCAGGAGGACAAGGAAGACGAACGTCCTCGCG

-----

FIGURE 2-1

EP 0 388 232 A1

ValCysSerCysLeuTrpMetMetLeuLeuIleSerGlnAlaGluAlaAlaLeuGluAsn  
841 GCGTCTGCTCCTGCTTGTGGATGATGCTACTCATATCCCAAGCGGAAGCGGCTTTGGAGA  
CGCAGACGAGGACGAACACCTACTACGATGAGTATAGGGTTTCGCCTTCGCCGAAACCTCT

-----  
LeuValIleLeuAsnAlaAlaSerLeuAlaGlyThrHisGlyLeuValSerPheLeuVal  
901 ACCTCGTAATACTTAATGCAGCATCCCTGGCCGGGACGCACGGTCTTGATCCTTCCTCG  
TGGAGCATTATGAATTACGTCGTAGGGACCGGCCCTGCGTGCCAGAACATAGGAAGGAGC

-----  
PhePheCysPheAlaTrpTyrLeuLysGlyLysTrpValProGlyAlaValTyrThrPhe  
961 TGTCTTCTGCTTTGCATGGTATCTGAAGGGTAAGTGGGTGCCCCGAGCGGTCTACACCT  
ACAAGAAGACGAAACGTACCATAGACTTCCCATTCACCCACGGCCCTCGCCAGATGTGGA

-----  
TyrGlyMetTrpProLeuLeuLeuLeuLeuAlaLeuProGlnArgAlaTyrAlaLeu  
1021 TCTACGGGATGTGGCCTCTCCTGCTCCTGTGGCGTTGCCCGAGCGGCGTACGCGC  
AGATGCCCTACACCGGAGAGGAGGACGAGGACAACCGCAACGGGTGCCCCGATGCGCG

-----  
AspThrGluValAlaAlaSerCysGlyGlyValValLeuValGlyLeuMetAlaLeuThr  
1081 TGGACACGGAGGTGGCCCGCTCGTGTGGCGGTGTGTTCTCGTGGGTGATGGCGCTAA  
ACCTGTGCCTCCACCGGCGCAGCACACCGCCACAACAAGAGCAGCCCACTACCGCGATT

-----  
LeuSerProTyrTyrLysArgTyrIleSerTrpCysLeuTrpTrpLeuGlnTyrPheLeu  
1141 CTCTGTCACCATATTACAAGCGCTATATCAGCTGGTGCTTGTTGGTGCGCTTCAGTATTTTC  
GAGACAGTGGTATAATGTTCCGATATAGTCGACCACGAACACCACCGAAGTCATAAAG

-----  
ThrArgValGluAlaGlnLeuHisValTrpIleProProLeuAsnValArgGlyGlyArg  
1201 TGACCAGAGTGGAGCGCAACTGCACGTGTGGATTCCCCCCTCAACGTCCGAGGGGGGC  
ACTGGTCTCACCTTCGCGTTGACGTGCACACCTAAGGGGGGAGTTGCAGGCTCCCCCG

-----  
AspAlaValIleLeuLeuMetCysAlaValHisProThrLeuValPheAspIleThrLys  
1261 GCGACGCTGTCATCTTACTCATGTGTGCTGTACACCGACTCTGGTATTTGACATCACCA  
CGCTGCGACAGTAGAATGAGTACACACGACATGTGGGCTGAGACCATAAACTGTAGTGGT

-----  
LeuLeuLeuAlaValPheGlyProLeuTrpIleLeuGlnAla  
1321 AATTGCTGCTGGCGTCTTCGGACCCCTTTGGATTCTTCAAGCCAG  
TTAACGACGACCGGCAGAACCTGGGGAAACCTAAGAAGTTTCGGTC

FIGURE 2-2

EP 0 388 232 A1

## Translation of DNA 15e

-----  
GlyAlaGlyLysArgValTyrTyrLeuThrArgAspProThrThrProLeuAlaArgAla  
1-- CGCGCGCTGGAAAGAGGGTCTACTACCTCAGCCGTGACCCCTACAACCCCTCGCGAGAGC  
GCCCGGACCTTTCTCCAGATGATGGAGTGGGCACTGGGATGTTGGGGGGAGCGCTCTCG  
-----Overlap with 26g-----  
AlaTrpGluThrAlaArgHisThrProValAsnSerTrpLeuGlyAsnIleIleMetPhe  
61 TCGGTGGGAGACAGCAAGACACACTCCAGTCAATTCCTGGCTAGGCAACATAATCATGTT  
ACGCACCCCTCTGTCGTTCTGTGTGAGGTCAGTTAAGGACCGATCCGTTGTATTAGTACAA  
-----  
AlaProThrLeuTrpAlaArgMetIleLeuMetThrHisPhePheSerValLeuIleAla  
121 TGCCCCCACACTGTGGGCGAGGATGATACTGATGACCCATTTCTTTAGCGTCCTTATAGC  
ACGGGGGTGTGACACCCGCTCCTACTATGACTACTGGGTAAAGAAATCGCAGGAATATCG  
-----  
ArgAspGlnLeuGluGlnAlaLeuAspCysGluIleTyrGlyAlaCysTyrSerIleGlu  
191 CAGGGACCAGCTTGAACAGGCCCTCGATTGCGAGATCTACGGGGCCTGCTACTCCATAGA  
GTCCCTGGTCTGAACCTGTCCGGGAGETAACGCTCTAGATGCCCGGACGATGAGGTATCT  
-----  
ProLeuAspLeuProProIleIleGlnArgLeu  
241 ACCACTTGATCTACCTCCAATCATTCAAAGACTC  
TGGTGAAC TAGATGGAGGTTAGTAAGTTTCTGAG

FIGURE 3

EP 0 388 232 A1

## Translation of DNA 131

ProSerProValValValGlyThrThrAspArgSerGlyAlaProThrTyrSerTrpGly  
1 CTCCCAGCCCCGTGGTGGTGGGAACGACCGACAGGTCGGGCGCGCCTACCTACAGCTGGG  
GAGGGTCGGGGCACCACCACCCTTGCTGGCTGTCCAGCCGCGCGGATGGATGTCGACCC

GluAsnAspThrAspValPheValLeuAsnAsnThrArgProProLeuGlyAsnTrpPhe  
61 GTGAAATGATACGGACGTCTTCGTCCTTAACAATACCAGGCCACCGCTGGGCAATTGGT  
CACTTTTACTATGCCTGCAGAAGCAGGAATTGTTATGGTCCGGTGGCGACCCGTTAACCA

GlyCysThrTrpMetAsnSerThrGlyPheThrLysValCysGlyAlaProProCysVal  
121 TCGGTTGTACCTGGATGAACCTCACTGGATTACCAAAGTGTGCGGAGCGCCTCCTTGTG  
AGCCAAACATGGACCTACTTGAGTTGACCTAAGTGGTTTCACACGCCTCGCGGAGGAACAC

IleGlyGlyAlaGlyAsnAsnThrLeuHisCysProThrAspCysPheArgLysHisPro  
181 TCATCGGAGGGGCGGGCAACAACACCCTGCACTGCCCCACTGATTGCTTCCGCAAGCATC  
AGTAGCCTCCCCGCCCGTTGTTGTGGGACGTGACGGGGTGACTAACGAAGCGTTTCGTAG

AspAlaThrTyrSerArgCysGlySerGlyProTrpLeuThrProArgCysLeuValAsp  
241 CGGACGCCACATACTCTCGGTGCGGCTCCGGTCCCTGGCTCACACCCAGGTGCCTGGTCG  
GCCTGCGGTGTATGAGAGCCACGCCGAGGCCAGGGACCGAGTGTGGGTCCACGGACCAGC

-----  
TyrProTyrArgLeuTrpHisTyrProCysThrIleAsnTyrThrIlePheLysIleArg  
301 ACTACCCGTATAGGCTTTGGCATTATCCTTGTACCATCAACTACACCATATTTAAATCA  
TGATGGGCATATCCGAAACCGTAATAGGAACATGGTAGTTGATGTGGTATAAATTTTAGT

-----  
MetTyrValGlyGlyValGluHisArgLeuGluAlaAlaCysAsnTrpThrArgGlyGlu  
361 GGATGTACGTGGGAGGGGTCGAGCACAGGCTGGAAGCTGCCTGCAACTGGACGCGGGGCG  
CCTACATGCACCCCTCCCAGCTCGTGTCCGACCTTCGACGGACGTTGACCTGCGCCCCGC

-----Overlap with 12f-----  
ArgCysAspLeuGluAspArgAspArgSerGluLeuSerProLeuLeuLeuThrThrThr  
421 AACGTTGCGATCTGGAAGACAGGGACAGGTCCGAGCTCAGCCCGTTACTGCTGACCACTA  
TTGCAACGCTAGACCTTCTGTCCCTGTCCAGGCTCGAGTCGGGCAATGACGACTGGTGAT

-----  
GlnTrpGlnValLeuProCysSerPheThrThrLeuProAlaLeuSerThrGlyLeu  
481 CACAGTGGCAGGTCCTCCCGTGTTCCTTCAACCCCTGCCAGCCTTGTCACCGGCCTCA  
GTGTCACCGTCCAGGAGGGCACAAGGAAGTGTGGGACGGTCGGAACAGGTGGCCGGAGT

FIGURE 4

EP 0 388 232 A1

## Translation of DNA 26j

LeuPheTyrHisHisLysPheAsnSerSerGlyCysProGluArgLeuAlaSerCysArg  
1 GCTTTTCTATCACCACAAGTTCAACTCTTCAGGCTGTCCTGAGAGGCTAGCCAGCTGCCG  
CGAAAAGATAGTGGTGTTCAAGTTGAGAAGTCCGACAGGACTCTCCGATCGGTCCGACGGC

ProLeuThrAspPheAspGlnGlyTrpGlyProIleSerTyrAlaAsnGlySerGlyPro  
61 ACCCCTTACCGATTTTGACCAGGGCTGGGGCCCTATCAGTTATGCCAACGGAAGCGGGCC  
TGGGGAATGGCTAAAACTGGTCCCGACCCCGGATAGTCAATACGGTTGCCTTCGCCGGG

AspGlnArgProTyrCysTrpHisTyrProProLysProCysGlyIleValProAlaLys  
121 CGACCAGCGCCCTACTGCTGGCACTACCCCCAAAACCTTGCGGTATTGTGCCCGCGAA  
GCTGGTCGCGGGGATGACGACCGTGATGGGGGGTTTTGGAACGCCATAACACGGGGCGCTT

---Overlap with 131---  
SerValCysGlyProValTyrCysPheThrProSerProValValVal  
181 GAGTGTGTGTGGTCCGGTATATTGCTTCACTCCAGCCCCGTGGTGGTGGG  
CTCACACACACCAGGCCATATAACGAAGTGAGGGTCGGGGCACCACCACC

FIGURE 5

EP 0 388 232 A1

## Translation of DNA CA59a

```
1  LeuValMetAlaGlnLeuLeuArgIleProGlnAlaIleLeuAspMetIleAlaGlyAla
   TTGGTAATGGCTCAGCTGCTCCGGATCCCACAAGCCATCTTGGACATGATCGCTGGTGCT
   AACCATTACCGAGTCGACGAGGCCCTAGGGTGTTCGGTAGAACCTGTACTAGCGACCACGA

61  HisTrpGlyValLeuAlaGlyIleAlaTyrPheSerMetValGlyAsnTrpAlaLysVal
   CACTGGGGAGTCCTGGCGGGCATAGCGTATTTCTCCATGGTGGGGAAGTGGGCGAAGGTC
   GTGACCCCTCAGGACCGCCCGTATCGCATAAAGAGGTACCACCCCTTGACCGCTTCCAG

121 LeuValValLeuLeuLeuPheAlaGlyValAspAlaGluThrHisValThrGlyGlySer
   CTGGTAGTGCTGCTGCTATTTGCCGGCGTCGACGCGGAAACCCACGTCACCGGGGGAAGT
   GACCATCAGACGACGATAAACGGCCGCAGCTGCGCCTTTGGGTGCAGTGGCCCCCTTCA

181 AlaGlyHisThrValSerGlyPheValSerLeuLeuAlaProGlyAlaLysGlnAsnVal
   GCCGGCCACACTGTGTCTGGATTTGTAGCCTCCTCGCACCAGGCGCCAAGCAGAACGTC
   CGGCCGGTGTGACACAGACCTAAACAATCGGAGGAGCGTGGTCCGCGGTTCGTCTTGACG

241 GlnLeuIleAsnThrAsnGlySerTrpHisLeuAsnSerThrAlaLeuAsnCysAsnAsp
   CAGCTGATCAACACCAACGGCAGTTGGCACCTCAATAGCACGGCCCTGAACGCAATGAT
   GTCGACTAGTTGTGGTTGCCGTCAACCGTGGAGTTATCGTGCCGGGACTTGACGTTACTA

301 SerLeuAsnThrGlyTrpLeuAlaGlyLeuPheTyrHisHisLysPheAsnSerSerGly
   AGCCTCAACACCGGCTGGTTGGCAGGGCTTTTCTATCACCACAAGTTCAACTCTTCAGGC
   TCGGAGTTGTGGCCGACCAACCGTCCCGAAAAGATAGTGGTGTCAAGTTGAGAAGTCCG
   -----Overlap with 26j-----

-----Overlap with K9-1-----
361 CysProGluArgLeuAlaSerCysArgPro
   TGTCTGAGAGGCTAGCCAGCTGCCGACCCC
   ACAGGACTGTCCSATCGGTCGACGGCTGGGG
   -----
```

FIGURE 6

EP 0 388 232 A1

## Translation of DNA CA84a

1 GlnGlyCysAsnCysSerIleTyrProGlyHisIleThrGlyHisArgMetAlaTrpAsp  
CGCAAGGTTGCAATTGCTCTATCTATCCCGGCCATATAACGGGTCACCGCATGGCATGGG  
GCGTTCCAACGTTAACGAGATAGATAGGGCCGGTATATTGCCAGTGGCGTACCGTACCC

-----  
61 MetMetMetAsnTrpSerProThrThrAlaLeuValMetAlaGlnLeuLeuArgIlePro  
ATATGATGATGAAGTGGTCCCCTACGACGGCGTTGGTAATGGCTCAGCTGCTCCGGATCC  
TATACTACTACTTGACCAGGGGATGCTGCCGCAACCATTACCGAGTCGACGAGGCCTAGG

-----  
121 GlnAlaIleLeuAspMetIleAlaGlyAlaHisTrpGlyValLeuAlaGlyIleAlaTyr  
CACAAGCCATCTTGGACATGATCGCTGGTGCTCACTGGGGAGTCCTGGCGGGCATAGCGT  
GTGTTTCGGTAGAACCTGTACTAGCGACCACGAGTGACCCCTCAGGACCGCCCGTATCGCA

-----Overlap with CA59a-----  
181 PheSerMetValGlyAsnTrpAlaLysValLeuValValLeuLeuLeuPheAlaGlyVal  
ATTTCTCCATGGTGGGGAAGTGGGCGAAGGTCTGGTAGTGCTGCTGCTATTGCGCGCG  
TAAAGAGGTACCACCCCTTGACCCGCTTCCAGGACCATCACGACGACGATAAACGGCCGC

-----  
241 AspAlaGluThrHisValThrGly  
TCGACGCGGAAACCCACGTCACCGGGG  
AGCTGCGCCTTTGGGTGCAGTGGCCCC

FIGURE 7



EP 0 388 232 A1

## Translation of DNA CA156e

1 CysTrpValAlaMetThrProThrValAlaThrArgAspGlyLysLeuProAlaThrGln  
GTGTTGGGTGGCGATGACCCCTACGGTGGCCACCAGGGATGGCAAAC TCCCCGCGACGCA  
CACAACCCACCGCTACTGGGGATGCCACCGGTGGTCCCTACCGTTTGAGGGGCGCTGCGT

61 LeuArgArgHisIleAspLeuLeuValGlySerAlaThrLeuCysSerAlaLeuTyrVal  
GCTTCGACGTCACATCGATCTGCTGTGCGGGAGCGCCACCCTCTGTTCCGGCCCTCTACGT  
CGAAGCTGCAGTGTAGCTAGACGAACAGCCCTCGCGGTGGGAGACAAGCCGGGAGATGCA

121 GlyAspLeuCysGlySerValPheLeuValGlyGlnLeuPheThrPheSerProArgArg  
GGGGGACCTATGCGGGTCTGTCTTTCTTGTGCGGCCAACTGTTACCTTCTCTCCAGGGCG  
CCCCCTGGATACGCCCAGACAGAAAGAACAGCCGGTTGACAAGTGAAGAGAGGGTCCGC

-----  
181 HisTrpThrThrGlnGlyCysAsnCysSerIleTyrProGlyHisIleThrGlyHisArg  
CCTGACCTGCTGCGTTCCAACGTTAACGAGATAGATAGGGCCGTTATATTGCCAGTGGC

-----Overlap with CA84a-----  
241 MetAlaTrpAspMetMetMetAsnTrpSerProThrThrAlaLeuValValAlaGlnLeu  
CATGGCATGGGATATGATGATGAACTGGTCCCCCTACGACGGCGTTGGTAGTGGCTCAGCT  
GTACCGTACCCTATACTACTACTTGACCAGGGGATGCTGCCGCAACCATCACCAGATCGA

-----  
301 LeuArgIleProGlnAla  
GCTCCGGATCCCACAAGCC  
CGAGGCCTAGGGTGTTCGG

FIGURE 8 •

EP 0 388 232 A1

## Translation of DNA CA167b

1 SerThrGlyLeuTyrHisValThrAsnAspCysProAsnSerSerIleValTyrGluAla  
CTCCACGGGGCTTTACCACGTCACCAATGATTGCCCTAACTCGAGTATTGTGTACGAGGC  
GAGGTGCCCCGAAATGGTGCAGTGGTTACTAACGGGATTGAGCTCATAACACATGCTCCG

61 AlaAspAlaIleLeuHisThrProGlyCysValProCysValArgGluGlyAsnAlaSer  
GGCCGATGCCATCCTGCACACTCCGGGGTGCCTCCCTTGCCTTCGTGAGGGCAACGCCTC  
CCGGCTACGGTAGGACGTGTGAGGCCCCACGCAGGGAACGCAAGCACTCCCGTTGCGGAG

-----

121 ArgCysTrpValAlaMetThrProThrValAlaThrArgAspGlyLysLeuProAlaThr  
GAGGTGTTGGGTGGCGATGACCCCTACGGTGGCCACCAGGGATGGCAAACCTCCCCGCGAC  
CTCCACAACCCACCGCTACTGGGGATGCCACCGGTGGTCCCTACCGTTTGAGGGGCGCTG

-----Overlap with CA156e-----

181 GlnLeuArgArgHisIleAspLeuLeuValGlySerAlaThrLeuCysSerAlaLeuTyr  
GCAGCTTCGACGTCACATCGATCTGCTTGTCTGGGAGCGCTACCCTCTGTTGGGCCCTCTA  
CGTCGAAGCTGCAGTGTAGCTAGACGAACAGCCCTCGCGATGGGAGACAAGCCGGGAGAT

-----

241 ValGlyAspLeuCysGlySerValPheLeu  
CGTGGGGGACTTGTGCGGGTCTGTCTTTCTTG  
GCACCCCTGAACACGCCACAGACAGAAAGAAC

FIGURE 9

EP 0 388 232 A1

## Translation of DNA CA216a

ArgArgArgSerArgAsnLeuGlyLysValIleAspThrLeuThrCysGlyPheAlaAsp  
1 CCOSCCGTAGGTGGCGCAATTTGGGTAAGGTCATCGATACCCTTACGTGCGGCTTGGCG  
GGGCGCATCCAGCGCGTTAAACCATTCAGTAGCTATGGGAATGCACCCCGAAGCGGC

LeuMetGlyTyrIleProLeuValGlyAlaProLeuGlyGlyAlaAlaArgAlaLeuAla  
61 ACCTCATGGGTACATACCCTCGTGGCGCCCTCTTGGAGGCGCTGCCAGGGCCCTGG  
TGGAGTACCCCATGTATGGCGAGCAGCGCGGGGAGAACCCTCGCGACGGTCCGGGACC

HisGlyValArgValLeuGluAspGlyValAsnTyrAlaThrGlyAsnLeuProGlyCys  
121 CGCATGGGCTCCGGGTTCTGGAGACGGCGTGAACATGCAACAGGGAACCTTCCTGGTT  
GCGTACCGCAGCCCAAGACCTTCTGCCGCACTTGATACGTTGTCCCTTGGAGGACCAA

SerPheSerIlePheLeuLeuAlaLeuLeuSerCysLeuThrValProAlaSerAlaTyr  
181 GCTCTTTCTCTATCTTCCTTCTGGCCCTGCTCTCTTGGCTTGAAGTGCCCGCTTCGGCT  
CGAGAAAGACATAGAAGGAAGACCGGACGACAGAACAACTGACACGCCCGAAGCCGA

GlnValArgAsnSerThrGlyLeuTyrHisValThrAsnAspCysProAsnSerSerIle  
241 ACCAAGTGCCCACTCCACGGGCTTACCACGTCAACCAATGATTGCCCTAACTCGAGTA  
TGGTTCACGCGTTGAGGTGCCCCGAAATGTTGCAGTGGTTACTAACGGGATTGAGCTCAT

-----Overlap with CA167b-----  
ValTyrGluAlaAlaAspAlaIleLeuHisThrProGlyCysValProCysValArgGlu  
301 TTGTGTACGAAGCGCGCATGCCATCCTGCACACTCCGGGTGCGTCCCTTGCCTTCGTG  
AACACATGCTTCGCGGCTACGGTAGGAGCTGTGAGGCTCCACGCAGGGAACGCAAGCAC

GlyAsnAlaSerArgCysTrpValAlaMetThrProThrValAla  
361 AAGGCAACCGCTCGAGGTGTTGGGTGGCGATGACCCCTACGGTGGCC  
TCCGCTTGGCGAGCTCCACACCCACCGCTACTGGGGAATGCCACCG

FIGURE 10

EP 0 388 232 A1

## Translation of DNA CA290a

LysLysAsnLysArgAsnThrAsnArgArgProGlnAspValLysPheProGlyGlyGly  
1 AAAAAAAAAACAAACGTAACACCAACCGTCGCCACAGGACSTCAAGTTCCCGGTGGCG  
TTTTTTTTTTGTTTCATTGTGGTTGGCAGCGGGTGCTGCAGTTCAAGCGCCACCGC

GlnIleValGlyGlyValTyrLeuLeuProArgArgGlyProArgLeuGlyValArgAla  
61 GTCAGATCGTTGGTGGAGTTTACTTGTTCGCCGCGCAGGGGCCCTAGATTGGGTGTGGCG  
CAGTCTAGCAACCACTCAATGAACAACGGCGCGTCCCCGGATCTAACCCACACCGC

ThrArgLysThrSerGluArgSerGlnProArgGlyArgArgGlnProIleProLysAla  
121 CCACGAGAAAGACTTCGACCGCTCCCAACCTCGACGACGCGGACCTATCCCCAAGC  
GCTGCTCTTCTGAAGGCTCGCCAGCGTTGGAGCTCCATCTGCGGTCCGATAGGGTTCC

ArgArgProGluGlyArgThrTrpAlaGlnProGlyTyrProTrpProLeuTyrGlyAsn  
181 CTGTCGGCCCCGAGGGCAGGACCTGGGCTCAGCCCGGTACCCCTGGCCCCCTCTATGGCA  
GACCAGCGGGCTCCGCTCCCTGACCCGAGTGGGGCCATGCGAACCGGCCAGTACCGT

GluGlyCysGlyTrpAlaGlyTrpLeuLeuSerProArgGlySerArgProSerTrpGly  
241 ATGAGGGCTGCGGGTGGCGGGATGGCTCCGTGCTCCCGTGGCTCTCGGCCCTAGCTGGG  
TACTCCCGACCGCCACCCGCCCTACCGAGGACAGCCGCCACCGAGAGCCGGATCCACCC

-----  
ProThrAspProArgArgArgSerArgAsnLeuGlyLysValIleAspThrLeuThrCys  
301 GCCCCACAGACCCCGCGTAGGTGGCGCAATTTGGGTAAAGTTCATCGATACCTTACCT  
CGGGGTGTCTGGGGCGCCATCCAGCGGTTAAACCCATTCCAGTAGCTATGGGAATGCA

-----  
GlyPheAlaAspLeuMetGlyTyrIleProLeuValGlyAlaProLeuGlyGlyAlaAla  
361 CCGCTTCGCCGAGCTCATGGCTACATACCGCTCGTCCGCCCCCTCTTCGAGCGGCTG  
CGCCGAGCGGCTGGAGTACCCCATGTATGGCGAGCAGCCGCGGGAGAACCTCCCGAC

-----Overlap with CA216a-----  
ArgAlaLeuAlaHisGlyValArgValLeuGluAspGlyValAsnTyrAlaThrGlyAsn  
421 CCAGGGCCCTCGCCCATCGCGTCCCGCTTCTGGAGACCGCGTGAACATATGCAACAGGCA  
GGTCCCGGACCGGTACCGCAGGCCCAAGACCTTCTGCCGCACCTGATAGGTTGTCCCT

-----  
LeuProGlyCysSerPheSerThrPhe  
481 ACCTTCCTGGTTGCTCTTTCTTACCTTC  
TGAAGGACCAACGAGAAAGAGATGGAG

FIGURE 11

EP 0 388 232 A1

## Translation of DNA ag30a

#MetSerValValGlnProProGlyProProLeu  
 #MetAlaLeuValOP  
 1 GCGCGAAGCGTCTAGCCATGCCCTTACTATGAGTGTCTGTCAGCCTCCAGGACCCCCC  
 GCGTCTTTCGAGATCGGTACCGCAATCATCTCACAGCACCTCGGAGGTCTTGGGGGGG  
 ProGlyGluProAM  
 61 TCCCGGGAGAGCCATAGTCTGCTGCGAACCCTGAGTACACCGGAATTGCCAGGACGAC  
 AGGGCCCTCTCGGTATCACCAGACGCCCTTGGCCACTCATGTGGCCTTAACGGTCTTGCTG  
 #MetProGlyAspLeuGlyValProProGlnAsp  
 121 CGGGTCCCTTCTTGGATCAACCTCGCTCAATGCCCTGGAGATTGGGGCTGCCCCCGCAAGA  
 GCCCAGGAAGAACCCTAGTTGGGCGAGTTACGGACCTCTAAACCCGACGGGGGGCGTTCT  
 Cy:AM OP AM GlyAlaCys  
 181 CTGCTAGCCGAGTAGTGTGGGTGCGAAAGGCCCTTGTGGTACTGCCCTGATAGGGTGTCTT  
 GACGATCGGCTCATCACAACCCAGCGCTTCCGGAACACCATACCGACTATCCACGAA  
 GluCysProGlyArgSerArgArgProCysThrMetSerThrAsnProLysProGlnLys  
 241 GCGAGTGGCCCCGGGAGGTCTCGTAGACCGTGCACCATGAGCAGGAATCCTAAACCTCAAA  
 CGCTACGGGGCCCTCCAGAGCATCTGSCACCTGGTACTCGTGCTTAGGATTTCGAGTTT  
 LysAsnLysArgAsnThrAsnArgArgProGlnAspValLysPheProGlyGlyGlyGln  
 301 AAAAAACAAACGTAACACCAACCGTCGCCACAGGACGTCAAGTTCCCGGGTGGCGGTC  
 TTTTCTTGTTCATTGTGTTGGCAGCGGGTCTCCTCCAGTTCAAGCGCCCAACCCAG  
 IleValGlyGlyValTyrLeuLeuProArgArgGlyProArgLeuGlyValArgAlaThr  
 361 AGATCGTTGGTGGAGTTTACTTGTTCGCGCGCAGGGGCCCTAGATTGGGTGTGCGCGGA  
 TCTAGCAACCACTCAATCAACAACCGCGCTCCCGGCATCTAACCCACAGCGCGCT  
 ArgLysThrSerGluArgSerGlnProArgGlyArgArgGlnProIleProLysAlaArg  
 421 CGAGAAAGACTTCCGAGCGGTGCAACCTCGAGGTAGACGTACGCTATCCCAAGGCTC  
 CCTCTTCTGAAGGCTCGCCAGCGTTGGAGCTCATCTGCAGTCCGATAGGGTTCCGAG  
 ArgProGluGlyArgThrTrpAlaGlnProGlyTyrProTrpProLeuTyrGlyAsnGlu  
 481 -----Overlap with CA290a-----  
 GTCGGCCCGAGGGCAGGACCTGGGCTCAGCCCGGTACCTTGGCCCCCTCTATGGCAATG  
 CAGCTGGGCTCCCGTCTCGACCCGAGTCGGGCCCATGGGAACCGGGAGATACCTTAC

FIGURE 12 -1

EP 0 388 232 A1

GlyCysGlyTrpAlaGlyTrpLeuLeuSerProArgGlySerArgProSerTrpGlyPro

541 AAGGCTGCGGGTGGGCGGGATGGCTCTGTCTCCCGTGGCTCTCGGCCTAGCTGGGGC  
TCCGACGCCCACCGCCCTACCGAGGACAGAGGGGCACCGAGAGCCGGATCGACCCCGG

ThrAspProArgArgArgSerArgAsnLeuGlyIysValIleAspThrLeuThrCysGly

601 CCACAGACCCCGGCGTAGGTCGCGCAATTTCGGTAAGGTCATCGATACCCCTACGTGCG  
GGTGTCTGGGGCCGCATCCAGCGCGTTAAACCCATTCCAGTAGCTATGGGAATGCACGC

Phe

661 GCTTC  
CGAAG

- \* - Start of long HCV ORF
- | - Putative first amino acid of large HCV polyprotein
- \* - Putative small encoded peptides( that may play a translational regulatory role)

FIGURE 12-2

EP 0 388 232 A1

## Translation of DNA CA205a

1 ValLeuGlyArgGluArgProCysGlyThrAlaOP AM GlyAlaCysGluCysProGly  
 GTCTTGGGTGCGAAAGGCCTTGTGGTACTGCCTGATAGGGTGCTTGCGAGTGCCCCGGG  
 CAGAACCAGCGCTTTCCGGAACACCATGACGGACTATCCACGAAACGCTCACGGGGCCC

---

61 ArgSerArgArgProCysThrMetSerThrAsnProLysProGlnArgLysThrLysArg  
 AGGTCTCGTAGACCGTGCACCATGAGCAGGAATCCTAAACCTCAAAGAAAAACCAACGT  
 TCCAGAGCATCTGGCAGCTGCTACTGCTGCTTAGCATTGGAGTTTCTTTTGGTTTCCA

---

121 AsnThrAsnArgArgProGlnAspValLysPheProGlyGlyGlyGlnIleValGlyGly  
 AACACCAACCGTCCGCCACAGGACGTCAAGTTCCCGGCTGGCGGTCAGATCGTTGGTGGG  
 TTGTGCTTGGCAGCGGCTCTCTGCACTTCAGGGGCCCCACCGCCAGTCTAGCAACCACT

---

181 ValTyrLeuLeuProArgArgGlyProArgLeuGlyValArgAlaThrArgLysThrSer  
 GTTIACTTGTGCGCGCAGCGCGCTAGATTGGGTGTGCGCGGACGAGAAAGACTTCC  
 CAAATGAACAACGGCGCTCCCGGGATCTAACCCACACGCGCGCTGCTTTCTGAAGG

---

-----Overlap with CA290a-----  
 241 GluArgSerGlnProArgGlyArgArgGlnProIleProLysAlaArgArgProGluGly  
 CAGCGGTGCGAACCTCGAGCTACACCTACCTATCCCCAACCTCTCTGCGCGGACGGC  
 CTCGCCAGCGTTGAGCTCCATCTGCAGTCGGATAGGGGTTCCGAGCAGCGGGGCTCCCG

---

301 ArgThrTrpAlaGlnProGlyTyrProTrpProLeuTyrGlyAsnGluGlyCys  
 AGCACCTGCGCTCAGCGCGGTACCTTGCGCCCTCTATCCCAATGAGCGCTCCG  
 TCCTGGACCGAGTCGGGCCCATGGGAACCGGGGAGATACCGTACTCCCGACGC

\* - putative initiator methionine codon

FIGURE 13

EP 0 388 232 A1

Translation of DNA 18g

```

#ProProOP
#SerThrMetAsnHisSerProValArgAsnTyrCysLeuHisAlaGluSerValAM
#LeuHisHisGluSerLeuProCysGluGluLeuLeuSerSerArgArgLysArgLeuAla
2 CTCCACCATGAATCACTCCCTGTGAGGAACCTACTGCTTCACGCAGAAAGCGTCTAGCC
CAGCTGCTACTTACTGAGGGGACACTCTTATGACAGAGTGCCTCTTTCCGAGATCGG

-----
#MetSerValValGlnProProGlyProProLeuProGlyGluProAM
MetAlaLeuValCP
61 ATGGCGTTAGTATGAGTGTGTCGTCAGCCTCCAGGACCCCTCCCGGGAGAGCCATAGT
TACCGCAATCATACTCACAGCACGTCGGAGGTCTGCGGGGAGGGCCCTCTCGGTATCA

-----

121 GGTCTGCGGAACCGGTGAGTACACCGSAATTGCCAGGACGACCGGGTCTTTCTTGGATC
CCAGACGCCTTGCCCACTCATGTGCCCTTAACGGTCTGCTGCCCCAGGAAGAACCTAG

-----Overlap with ag30a-----
#MetProGlyAspLeuGlyValProProGlnAspCysAM
181 AACCCGCTCAATGCCCTGGAGATTTGGGCGTGCCCCSCAASACTGCTAGCCGAGTAGTGT
TTCCCGGAGTTACCGACCTCTAAACCCGCACCGGGGCGTTCTGACGATCGGTCATCACA

-----
OP AM GlyAlaCysGluCysProGlyArgSer
241 TGGGTCCGGAAGGCCCTTGTGGTACTGCCTGATAGGGTGCTTGCAGTGTCCCCGGGAGGT
ACCCAGCGCTTTCCGGAACACCATGACGGACTATCCCACGAACGCTCACGGGGCCCTCCA

-----
ArgArg
301 CTCGTAGA
CAGCATCT

```

\* - Start of long HCV ORF  
 # - Putative small encoded peptides (that may play  
 a translational regulatory role).

FIGURE 14



EP 0 388 232 A1

## Translation of DNA 16jh

-----Overlap with 15e-----  
1 GlyAlaCysTyrSerIleGluProLeuAspLeuProProIleIleGlnArgLeuHisGly  
GGGGCCTGCTACTCCATAGAACCACTGGATCTACCTCCAATCATTCAAAGACTCCATGGC  
CCCCGGACGATGAGGTATCTTGGTGACCTAGATGGAGGTTAGTAAGTTTCTGAGGTACCG  
61 LeuSerAlaPheSerLeuHisSerTyrSerProGlyGluIleAsnArgValAlaAlaCys  
CTCAGCGCATTTCCTCCACAGTTACTCTCCAGGTGAAATTAATAGGGTGGCCGCATGC  
GAGTCGCGTAAAAGTGAGGTGTCAATGAGAGGTCCACTTTAATTATCCCACCGGCGTACG  
Gly\*  
G  
121 LeuArgLysLeuGlyValProProLeuArgAlaTrpArgHisArgAlaArgSerValArg  
CTCAGAAACTTGGGGTACCGCCCTTGCGAGCTTGGAGACACCGGGCCCGGAGCGTCCGC  
GAGTCTTTTGAACCCCATGGCGGGAACGCTCGAACCTCTGTGGCCCGGGCCTCGCAGGCG  
181 AlaArgLeuLeuAlaArgGlyGlyArgAlaAlaIleCysGlyLysTyrLeuPheAsnTrp  
GCTAGGCTTCTGGCCAGAGGAGGCAGGGCTGCCATATGTGGCAAGTACCTCTTCAACTGG  
CGATCCGAAGACCGGTCTCCTCCGTCCCGACGGTATACACCGTTCATGGAGAAGTTGACC  
241 AlaValArgThrLysLeuLys  
GCAGTAAGAACAAAGCTCAAAC  
CGTCATTCTTGTTTCGAGTTTG

\* = nucleotide heterogeneity

FIGURE 15

## EP 0 388 232 A1

## COMBINED ORF OF DNAs pil4a THROUGH 15e

(pil4a/CA167b/CA156e/CA84a/CA59a/K9-1/12f/141/11b/7f/7e/  
8h/33c/40b/37b/35/36/81/32/33b/25c/14c/8f/33f/33g/39c/  
35f/19g/26g & 15e)

1 ArgSerArgAsnLeuGlyLysValIleAspThrLeuThrCysGlyPheAlaAspLeuMet  
AGGTCGCGCAATTTGGGTAAGGTCATCGATACCCTTACGTGCGGCTTCGCCGACCTCATG  
TCCAGCGCGTTAAACCCATTCCAGTAGCTATGGGAATGCACGCCGAAGCGGCTGGAGTAC

61 GlyTyrIleProLeuValGlyAlaProLeuGlyGlyAlaAlaArgAlaLeuAlaHisGly  
GGGTACATACCGCTCGTCGGCGCCCTCTTGGAGGCGCTGCCAGGGCCCTGGCGCATGGC  
CCCATGTATGGCGAGCAGCCGCGGGGAGAACCCTCCGCGACGGTCCCGGGACCGCGTACCG

121 ValArgValLeuGluAspGlyValAsnTyrAlaThrGlyAsnLeuProGlyCysSerPhe  
GTCCGGGTTCTGGAAGACGGCGTGAACATATGCAACAGGGAACCTTCTGGTTGCTCTTC  
CAGGCCCAAGACCTTCTGCCGCACTTGATACGTTGTCCCTTGAAGGACCAACGAGAAAG

181 SerIlePheLeuLeuAlaLeuLeuSerCysLeuThrValProAlaSerAlaTyrGlnVal  
TCTATCTTCTTCTGGCCCTGCTCTTGTGCTTACTGTGCCCGCTTCGGCCTACCAAGTG  
AGATAGAAGGAAGACCGGGACGAGAGAACGAACCTGACACGGCGGAAGCCGGATGGTTAC

241 ArgAsnSerThrGlyLeuTyrHisValThrAsnAspCysProAsnSerSerIleValTyr  
CGCAACTCCACGGGGCTTTACCACGTCACCAATGATTGCCCTAACTCGAGTATTGTGTAC  
GCGTTGAGGTGCCCCGAAATGGTGAGTGTTACTAACGGGATTGAGCTCATAACACATG

301 GluAlaAlaAspAlaIleLeuHisThrProGlyCysValProCysValArgGluGlyAsn  
GAGGCGGGCGGATGCCATCCTGCACACTCCGGGGTGCGTCCCTTGGCTTCGTGAGGGCAAC  
CTCCGCGCGGTACGGTAGGACGTGTGAGGCCCCACGCAGGGAACGCAAGCACTCCCGTTG

361 AlaSerArgCysTrpValAlaMetThrProThrValAlaThrArgAspGlyLysLeuPro  
GCCTCGAGGTGTTGGGTGGCGATGACCCCTACGGTGGCCACCAGGGATGGCAAACCTCCCC  
CGGAGCTCCACAACCCACCGCTACTGGGGATGCCACCGGTGGTCCCTACCGTTTGAGGGG

421 AlaThrGlnLeuArgArgHisIleAspLeuLeuValGlySerAlaThrLeuCysSerAla  
GCGACGCAGCTTCGACGTCACATCGATCTGCTTGTGCGGGAGCGCCACCCTCTGTTGCGGC  
CGCTGCGTGAAGCTGCAGTGTAGCTAGACGAACAGCCCTCGCGGTGGGAGACAAGCCGG

481 LeuTyrValGlyAspLeuCysGlySerValPheLeuValGlyGlnLeuPheThrPheSer  
CTCTACGTGGGGGACCTATGCGGGTCTGTCTTTCTTGTGCGGCCAACTGTTACCTTCTCT  
GAGATGCACCCCTGGATACGCCAGACGAAAGAACAGCCGTTGACAAGTGAAGAGA

541 ProArgArgHisTrpThrThrGlnGlyCysAspCysSerIleTyrProGlyHisIleThr  
CCCAGGCGCCACTGGACGACGCAAGTTGCAATTGCTCTATCTATCCCGGCCATATAACG  
GGGTCCGCGGTGACCTGCTGCGTTCCAAACGTTAACGAGATAGATAGGGCCGGTATATTGC

601 GlyHisArgMetAlaTrpAspMetMetMetAsnTrpSerProThrThrAlaLeuValMet  
GGTCACCGCATGGCATGGGATATGATGATGAACCTGGTCCCTACGACGGCGTTGGTAATG  
CCAGTGGCGTACCGTACCCTATACTACTACTTGACCAGGGGATGCTGCCGCAACCATTAC

661 AlaGlnLeuLeuArgIleProGlnAlaIleLeuAspMetIleAlaGlyAlaHisTrpGly  
GCTCAGCTGTCTCCGGATCCCACAAGCCATCTTGGACATGATCGCTGGTGCTCACTGGGGA  
CGAGTCGACGAGGCCTAGGGTGTTCGGTAGAACCTGTACTAGCGACCACGAGTGACCCCT

721 ValLeuAlaGlyIleAlaTyrPheSerMetValGlyAsnTrpAlaLysValLeuValVal  
GTCCTGGCGGGCATAGCGTATTTCTCCATGGTGGGGAACTGGGCGAAGGTCCTGGTAGTG  
CAGGACCGCCCGTATCGCATAAAGAGGTACCACCCCTTGACCCGCTTCAGGACCATCAC

781 LeuLeuLeuPheAlaGlyValAspAlaGluThrHisValThrGlyGlySerAlaGlyHis  
CTGTGCTATTGCGGGCGTCGACGCGGAAACCCACGTCACCGGGGGAAGTGCCGGCCAC  
GACGACGATAAACGGCCGCGAGCTGCGCCTTGGGTGCACTGGCCCCCTTCACGGCCGGTG

[illegible]

EP 0 388 232 A1

TTCACCCCTCATGCAGCAAGAGGACAAGGAAGACGAACGTCTGCGCGCGCAGACGAGGACG

1861 LeuTrpMetMetLeuLeuIleSerGlnAlaGluAlaAlaLeuGluAsnLeuValIleLeu  
TTGTGGATGATGCTACTCATATCCCAAGCGGAGGCGGCTTTGGAGAACCCTCGTAATACTT  
AACACCTACTACGATGAGTATAGGGTTCGCCTCCGCCGAAACCTCTGGAGCATTATGAA

1921 AsnAlaAlaSerLeuAlaGlyThrHisGlyLeuValSerPheLeuValPhePheCysPhe  
AATGCAGCATCCCTGGCCGGGACGCACGGTCTGTATCCTTCCTCGTGTCTTCTGCTTT  
TTACGTCGTAGGGACCGGCCCTGCGTGCCAGAACATAGGAAGGAGCACAGAAGACGAA

1981 AlaTrpTyrLeuLysGlyLysTrpValProGlyAlaValTyrThrPheTyrGlyMetTrp  
GCATGGTATTTGAAGGSTAAGTGGGTGCCCCGAGCGGTCTACACCTTCTACGGGATGTGG  
CGTACCATAAACTTCCCATTCACCCACGGGCTCGCCAGATGTGGAAGATGCCCTACACC

2041 ProLeuLeuLeuLeuLeuAlaLeuProGlnArgAlaTyrAlaLeuAspThrGluVal  
CCTCTCCTCCTGCTCCTGTTGGCGTTGCCCGAGCGGGCGTACGCGCTGGACACGGAGGTG  
GGAGAGGAGGACGAGGACAACCGCAACGGGTCGCCCCGATGCGCGACCTGTGCCTCCAC

2101 AlaAlaSerCysGlyGlyValValLeuValGlyLeuMetAlaLeuThrLeuSerProTyr  
GCCGCGTCGTGTGGCGGTGTGTCTCGTGGGTGATGGCGCTGACTCTGTACCATAT  
CGGCGCAGCACACCGCCACAACAAGAGCAGCCCACTACCGCGACTGAGACAGTGGTATA

2161 TyrLysArgTyrIleSerTrpCysLeuTrpTrpLeuGlnTyrPheLeuThrArgValGlu  
TACAAGCGCTATATCAGCTGGTGTGGTGGCTTCAGTATTTCTGACCAGAGTGGAA  
ATGTTCCGGATATAGTCGACCACGAACACCACCGAAGTCATAAAAGACTGGTCTCACCTT

2221 AlaGlnLeuHisValTrpIleProProLeuAsnValArgGlyGlyArgAspAlaValIle  
GCGCAACTGCACGTGTGGATTCCCCCCTCAACGTCCGAGGGGGCGCGACGCCGTCATC  
CGCGTTGACGTGCACACCTAAGGGGGGAGTTGCAGGCTCCCCCGCGCTGCGGCAGTAG

2281 LeuLeuMetCysAlaValHisProThrLeuValPheAspIleThrLysLeuLeuLeuAla  
TTACTCATGTGTGCTGTACACCCGACTCTGGTATTTGACATCACCAATTGCTGCTGGCC  
AATGAGTACACACGACATGTGGGCTGAGACCATAAACTGTAGTGGTTTAACGACGACCGG

2341 ValPheGlyProLeuTrpIleLeuGlnAlaSerLeuLeuLysValProTyrPheValArg  
GTCTTCGGACCCCTTTGGATTCTTCAAGCCAGTTTGCTTAAAGTACCCTACTTTGTGCGC  
CAGAAGCCTGGGGAACCTAAGAAGTTCGGTCAAACGAATTCATGGGATGAAACACGCG

2401 ValGlnGlyLeuLeuArgPheCysAlaLeuAlaArgLysMetIleGlyGlyHisTyrVal  
GTCCAAGGCCTTCTCCGTTCTGCGCGTTAGCGCGGAAGATGATCGGAGGCCATTACGTG  
CAGGTTCCGGAAGAGGCCAAGACGCGCAATCGCGCTTCTACTAGCCTCCGTAATGCAC

2461 GlnMetValIleIleLysLeuGlyAlaLeuThrGlyThrTyrValTyrAsnHisLeuThr  
CAATGGTTCATCATTAGTTAGGGGCGCTTACTGGCACCTATGTTTATAACCATCTCACT  
GTTTACCAGTAGTAATTCAATCCCCGCAATGACCGTGATACAAATATGGTAGAGTGA

2521 ProLeuArgAspTrpAlaHisAsnGlyLeuArgAspLeuAlaValAlaValGluProVal  
CCTCTTCGGGACTGGGCGCACACGGCTTGCAGATCTGGCCGTGGCTGTAGAGCCAGTC  
GGAGAAGCCCTGACCCGCGTGTGCGGAACGCTCTAGACCGGCACCGACATCTCGGTCAG

2581 ValPheSerGlnMetGluThrLysLeuIleThrTrpGlyAlaAspThrAlaAlaCysGly  
GTCTTCTCCCAAATGGAGACCAAGCTCATCAGTGGGGGGCAGATACCGCCGCTGCGGT  
CAGAAGAGGGTTTACCTCTGGTTCGAGTAGTGACCCCCGCTCTATGGCGGCGCACGCCA

2641 AspIleIleAsnGlyLeuProValSerAlaArgArgGlyArgGluIleLeuLeuGlyPro  
GACATCATCAACGGCTTGCTGTTTCCGCCCGCAGGGGCGGGAGATACTGCTCGGGCCA  
CTGTAGTAGTTGCCGAACGGACAAGGCGGGCGTCCCCGGCCCTCTATGACGAGCCCGGT

2701 AlaAspGlyMetValSerLysGlyTrpArgLeuLeuAlaProIleThrAlaTyrAlaGln  
GCCGATGGAATGGTCTCCAAGGGGTGGAGGTTGCTGGCGCCCATCACGGCGTACGCCAG  
CGGCTACCTTACCAGAGGTTCCCCACCTCCAACGACCGCGGTAGTGCCGATGCGGGTC

2761 GlnThrArgGlyLeuLeuGlyCysIleIleThrSerLeuThrGlyArgAspLysAsnGln  
CAGACAAGGGGCTCCTAGGGTGCATAATCACCAGCCTAACTGGCCGGGACAAAACCAA  
GTCTGTTCCCGGAGGATCCACGTATTAGTGGTGGATTGACCGGCCCTGTTTTTGGTT

## EP 0 388 232 A1

2821 ValGluGlyGluValGlnIleValSerThrAlaAlaGlnThrPheLeuAlaThrCysIle  
GTGGAGGGTGAGGTCCAGATTGTGTCAACTGCTGCCCAAACCTTCCTGGCAACGTGCATC  
CACCTCCCACTCCAGGTCTAACACAGTTGACGACGGGTTTGGAGGACCGTTGCACGTAG

2881 AsnGlyValCysTrpThrValTyrHisGlyAlaGlyThrArgThrIleAlaSerProLys  
AATGGGGTGTGCTGGACTGTCTACCACGGGGCCGGAACGAGGACCATCGCGTCACCCAAG  
TTACCCACACGACCTGACAGATGGTGCCCCGGCCTTGCTCCTGGTAGCGCAGTGGGTTT

2941 GlyProValIleGlnMetTyrThrAsnValAspGlnAspLeuValGlyTrpProAlaPro  
GGTCTGTTCATCCAGATGTATACCAATGTAGACCAAGACCTTGTGGGCTGGCCCCGCTCCG  
CCAGGACAGTAGGTCTACATATGGTTACATCTGGTTCTGGAAACACCCGACCGGGCGAGGC

3001 GlnGlySerArgSerLeuThrProCysThrCysGlySerSerAspLeuTyrLeuValThr  
CAAGGTAGCCGCTCATTTGACACCCCTGCACCTGCGGGCTCCTCGGACCTTTACCTGGTCAAG  
GTTCCATCGGCGAGTAACGTGGGACGTGAACGCCGAGGAGCCTGGAAATGGACCAAGTGC

3061 ArgHisAlaAspValIleProValArgArgArgGlyAspSerArgGlySerLeuLeuSer  
AGGCACGCCGATGTTCATTCCTGTCGCCGGCGGGGTGATAGCAGGGGCACCGCTGTGTCTG  
TCCGTGCGGCTACAGTAAGGGCACGCGCGGCCCTTATCGTCCCGTCGGACGACAGC

3121 ProArgProIleSerTyrLeuLysGlySerSerGlyGlyProLeuLeuCysProAlaGly  
CCCCGGCCCATTTCTACTTGAAAGGCTCCTCGGGGGGTCCGCTGTGTGCCCCGCGGGG  
GGGGCCGGGTAAAGGATGAACCTTCCGAGGAGCCCCCAGGCGACAACACGGGGCGCCCC

3181 HisAlaValGlyIlePheArgAlaAlaValCysThrArgGlyValAlaLysAlaValAsp  
CACGCCGTGGCATATTTAGGGCCGCGGTGTGCACCCGTGGAGTGGCTAAGGCGGTGGAC  
GTGCGGCACCCGTATAAATCCCGCGGCCACAGTGGGCACCTCACCGATTCCGCCACCTG

3241 PheIleProValGluAsnLeuGluThrThrMetArgSerProValPheThrAspAsnSer  
TTTATCCCTGTGGAGAACCTAGAGACAACCATGAGGTCCCGGTTTCACGGATAACTCC  
AAATAGGGACACCTCTTGGATCTCTGTGTGTACTCCAGGGGCCACAAGTGCTATTGAGG

3301 SerProProValValProGlnSerPheGlnValAlaHisLeuHisAlaProThrGlySer  
TCTCCACCACTAGTGTCCCAAGAGCTTCCAGGTGGCTCACCTCCATGCTCCACAGGCAGC  
AGAGGTGGTCAACACGGGGTCTCGAAGGTCCACCGAGTGGAGGTACGAGGGTGTCCGTG

3361 GlyLysSerThrLysValProAlaAlaTyrAlaAlaGlnGlyTyrLysValLeuValLeu  
GGCAAAAGCACCAAGGTCCCGGCTGCATATGCAGCTCAGGGCTATAAGGTGCTAGTACTC  
CCGTTTTCTGTGTTCCAGGGCCGACGTATACGTGAGTCCCGATATTCCAGCATCATGAG

3421 AsnProSerValAlaAlaThrLeuGlyPheGlyAlaTyrMetSerLysAlaHisGlyIle  
AACCCCTCTGTGTGCTGCAACACTGGGCTTTGGTGCTTACATGTCCAAGGCTCATGGGATC  
TTGGGGAGACAACGACGTGTGACCCGAACCAAGTATACAGGTTCGAGTACCCCTAG

3481 AspProAsnIleArgThrGlyValArgThrIleThrThrGlySerProIleThrTyrSer  
GATCCTAACATCAGGACCGGGTGAGAACAATTACCACTGGCAGCCCCATCACGTACTCC  
CTAGGATTGTAGTCTCGGCCCACTCTTGTAAATGGTGACCGTCCGGGTAGTGCATGAGG

3541 ThrTyrGlyLysPheLeuAlaAspGlyGlyCysSerGlyGlyAlaTyrAspIleIleIle  
ACCTACGGCAAGTTCTTGGCGACGGCGGGTGCTCGGGGGGCGCTTATGACATAATAATT  
TGGATGCCGTTCAAGGAACGGCTGCGGCCACGAGCCCCCGGAATACTGTATTATTAA

3601 CysAspGluCysHisSerThrAspAlaThrSerIleLeuGlyIleGlyThrValLeuAsp  
TGTGACGAGTGCCACTCCACGGATGCCACATCCATCTGGGCATCGGCACCTGCTTGAC  
ACACTGCTCACGGTGAGGTGCTACGGTGTAGGTAGAACCGTAGCGTGACAGGAACCTG

3661 GlnAlaGluThrAlaGlyAlaArgLeuValValLeuAlaThrAlaThrProProGlySer  
CAAGCAGAGACTGCGGGGGCGAGACTGGTTGTGCTCGCCACCGCCACCCCTCCGGGCTCC  
GTTCTGTCTGACGCCCCGCTCTGACCAACACGAGCGGTGGCGGTGGGGAGGCCCGAGG

3721 ValThrValProHisProAsnIleGluGluValAlaLeuSerThrThrGlyGluIlePro  
GTCACTGTGCCCCATCCAACATCGAGGAGGTTGCTCTGTCCACACCGGAGAGATCCCT  
CAGTGACACGGGGTAGGGTTGTAGCTCCTCCAACGAGACAGGTGGTGGCCTCTCTAGGGA

3781 PheTyrGlyLysAlaIleProLeuGluValIleLysGlyGlyArgHisLeuIlePheCys  
TTTATCCCAAGCTATCCCGCTGCACTAATCAAGCGGGGACAGCTCTCTATCTCTCT

EP 0 388 232 A1

AAAATGCCGTTCCGATAGAGGGAGCTTCATTAGTTCCCCCCCCTGTGTAGAGTAGAAGACA  
HisSerLysLysLysCysAspGluLeuAlaAlaLysLeuValAlaLeuGlyIleAsnAla  
3841 CATTCAAAGAAGAAGTGCACGAACCTCGCCGCAAGCTGGTCGCATTGGGCATCAATGCC  
GTAAGTTTTCTTCTTCACGCTGCTTGAGCGGCGTTTTCGACCAGCGTAACCCGTAGTTACGG  
ValAlaTyrTyrArgGlyLeuAspValSerValIleProThrSerGlyAspValValVal  
3901 GTGGCCTACTACCGCGGTCTTGACGTGTCCGTCATCCGACCAGCGGCGATGTTGTCTGTC  
CACCGGATGATGGCGCCAGAATGCGACAGGCAGTAGGGCTGGTGC CGCTACAACAGCAG  
ValAlaThrAspAlaLeuMetThrGlyTyrThrGlyAspPheAspSerValIleAspCys  
3961 GTGGCAACCGATGCCCTCATGACCGGCTATACCGCGGACTTCGACTCGGTGATAGACTGC  
CACCGTTGGCTACGGGAGTACTGGCCGATAATGGCCGCTGAAGCTGAGCCACTATCTGACG  
AsnThrCysValThrGlnThrValAspPheSerLeuAspProThrPheThrIleGluThr  
4021 AATACGTGTGTCAACCCAGACAGTCGATTTCAGCCTTGACCCTACCTTCACCATTGAGACA  
TTATGCACACAGTGGGTCTGTTCAGCTAAAGTCGGAAC TGGGATGGAAGTGTA ACTCTGT  
IleThrLeuProGlnAspAlaValSerArgThrGlnArgArgGlyArgThrGlyArgGly  
4081 ATCACGCTCCCCCAGGATGCTGTCTCCCGCACTCAACGTCGGGGCAGGACTGGGCAGGGGG  
TAGTGCGAGGGGGTCTACGACAGAGGGCGTGAGTTGCAGCCCCGTCCTGACCGTCCCCC  
LysProGlyIleTyrArgPheValAlaProGlyGluArgProSerGlyMetPheAspSer  
4141 AAGCCAGGCATCTACAGATTGTGTGCACCGGGGGAGCGCCCCCTCGGGCATGTTTCGACTCG  
TTCGGTCCGTAGATGTCTAAACACCGTGCCCCCTCGCGGGGAGGCCGTACAAGCTGAGC  
SerValLeuCysGluCysTyrAspAlaGlyCysAlaTrpTyrGluLeuThrProAlaGlu  
4201 TCCGTCCTCTGTGAGTGCTATGACCGAGGCTGTGCTTGGTATGAGCTCAGCCCCGCCGAG  
AGGCAGGAGACACTCACGATACTGCGTCCGACACGAACCATACTCGAGTGC GGCGCGCTC  
ThrThrValArgLeuArgAlaTyrMetAsnThrProGlyLeuProValCysGlnAspHis  
4261 ACTACAGTTAGGCTACGAGCGTACATGAACACCCCGGGGCTTCCCGTGTGCCAGGACCAT  
TGATGTCAATCCGATGCTCGCATGTACTTGTTGGGGCCCCGAAGGGCACACGGTCTCGTA  
LeuGluPheTrpGluGlyValPheThrGlyLeuThrHisIleAspAlaHisPheLeuSer  
4321 CTTGAATTTTGGGAGGGCGTCTTTACAGGCCTCACTCATATAGATGCCCACTTTCTATCC  
GAACCTAAACCCCTCCCGCAGAAATGTCCGGAGTGAGTATATCTACGGGTGAAGATAGG  
GlnThrLysGlnSerGlyGluAsnLeuProTyrLeuValAlaTyrGlnAlaThrValCys  
4381 CAGACAAAGCAGAGTGGGGAGAACCTTCCTTACCTGGTAGCGTACCAAGCCACCGTGTGC  
GTCTGTTTCGTCTCACCCCTCTTGGGAAGGAATGGACCATCGCATGGTTCGGTGGCACACG  
AlaArgAlaGlnAlaProProProSerTrpAspGlnMetTrpLysCysLeuIleArgLeu  
4441 GCTAGGGCTCAAGCCCCCTCCCCCATCGTGGGACCAGATGTGGAAGTGTTTGATTTCGCCCTC  
CGATCCCGAGTTCGGGGAGGGGGTAGCACCCCTGGTCTACACCTTCAAACTAAGCGGAG  
LysProThrLeuHisGlyProThrProLeuLeuTyrArgLeuGlyAlaValGlnAsnGlu  
4501 AAGCCCACCCCTCCATGGGCCAACACCCCTGCTATACAGACTGGGCGCTGTTGAGAATGAA  
TTCGGGTGGGAGGTACCCGGTTGTGGGGACGATATGTC TGACCCCGCACAGTCTTACTT  
IleThrLeuThrHisProValThrLysTyrIleMetThrCysMetSerAlaAspLeuGlu  
4561 ATCACCCCTGACGCACCCAGTCACCAATACATCATGACATGCATGTCGGCCGACCTGGAG  
TAGTGGGACTGCGTGGGTCAGTGGTTTATGTAGTACTGTACGTACAGCCGGCTGGACCTC  
ValValThrSerThrTrpValLeuValGlyGlyValLeuAlaAlaLeuAlaAlaTyrCys  
4621 GTCGTACAGAGCACTGGGTGCTCGTTGGCGGCGCTCTGGCTGCTTTGGCCGCGTATTGC  
CAGCAGTGTCTGTGACCCACGAGCAACCGCCGAGACCAGCAAACCGGCGCATAACG  
LeuS rThrGlyCysValValIleValGlyArgValValLeuSerGlyLysProAlaIle  
4681 CTGTCAACAGGCTGCGTGGTTCATAGTGGGCAGGGTCTGCTTGTTCGGGAAGCCGGCAATC  
GACAGTTGTCCGACGCACCAGTATCACCCGTCCAGCAGAACAGGCCCTTCGGCCGTTAG  
IleProAspArgGluValLeuTyrArgGluPheAspGlu tGluGluCysSerGlnHis  
4741 ATACCTGACAGGGAAGTCTCTACCCAGAGTTCGATGACATGGAAGAGTGCTCTCAGCAC  
TATGGACTGTCCCTTCAGGAGATGGCTCTCAAGCTGCTCTG

## EP 0 388 232 A1

4801 LeuProTyrIleGluGlnGlyMetMetLeuAlaGluGlnPheLysGlnLysAlaLeuGly  
TTACCGTACATCGAGCAAGGGATGATGCTCGCCGAGCAGTTCAAGCAGAAGGCCCTCGGC  
AATGGCATGTAGCTCGTTCCCTACTACGAGCGGCTCGTCAAGTTCGTCTTCCGGGAGCCG

4861 LeuLeuGlnThrAlaSerArgGlnAlaGluValIleAlaProAlaValGlnThrAsnTrp  
CTCCTGCAGACCGCGTCCCGTCAGCAGAGGTTATCGCCCCGTCTGTCCAGACCAACTGG  
GAGGACGTCTGGCGCAGGGCAGTCCGTCTCCAATAGCGGGGACGACAGGTCTGGTTGACC

4921 GlnLysLeuGluThrPheTrpAlaLysHisMetTrpAsnPheIleSerGlyIleGlnTyr  
CAAAACTCGAGACCTTCTGGGCGAAGCATATGTGGAACCTTCATCAGTGGGATACAATAC  
GTTTTTGAGCTCTGGAAGACCGCTTCGTATACACCTGAAGTAGTCACCCCTATGTTATG

4981 LeuAlaGlyLeuSerThrLeuProGlyAsnProAlaIleAlaSerLeuMetAlaPheThr  
TTGGCGGGCTTGTCACGCTGCTCGTAACCCCGCCATTGCTTCATTGATGGCTTTTACA  
AACGCGCCGAACAGTTGCGACGGACCATTTGGGGCGGTAACGAAGTAACTACCGAAAATGT

5041 AlaAlaValThrSerProLeuThrThrSerGlnThrLeuLeuPheAsnIleLeuGlyGly  
GCTGCTGTCACCGCCCACTAACCCTAGCCAAACCCCTCCTCTTCAACATATTGGGGGGG  
CGACGACAGTGGTCTGGGTGATTGGTGATCGGTTTGGGAGGAGAAGTTGTATAACCCCCC

5101 TrpValAlaAlaGlnLeuAlaAlaProGlyAlaAlaThrAlaPheValGlyAlaGlyLeu  
TGGGTGGCTGCCCAGCTCGCCGCCCGGCTGCCGCTACTGCTTGTGGGGCGCTGGCTTA  
ACCCACCGACGGGTGCGAGCGGCGGGGCCACGGCGATGACGGAACACCCGCGACCGAAT

5161 AlaGlyAlaAlaIleGlySerValGlyLeuGlyLysValLeuIleAspIleLeuAlaGly  
GCTGGCGCGCCCATCGGCAGTGTGGACTGGGGAAGGTCTCATAGACATCCTTGACGGG  
CGACCGCGCGGTAGCCGTACAACCTGACCCCTTCCAGGAGTATCTGTAGGAACGTCCC

5221 TyrGlyAlaGlyValAlaGlyAlaLeuValAlaPheLysIleMetSerGlyGluValPro  
TATGGCGCGGGCGTGGCGGGAGCTTGTGGCATTCAAGATCATGAGCGGTGAGGTCCCC  
ATACCGCGCCCCGACCGCCCTCGAGAACACCGTAAGTTCTAGTACTCGCCACTCCAGGGG

5281 SerThrGluAspLeuValAsnLeuLeuProAlaIleLeuSerProGlyAlaLeuValVal  
TCCACGGAGGACCTGGTCAATCTACTGCCCGCCATCCTCTCGCCCGGAGCCCTCGTAGTC  
AGGTGCTCCTGGACCACTTAGATGACGGGCGGTAGGAGAGCGGGCCTCGGGAGCATCAG

5341 GlyValValCysAlaAlaIleLeuArgArgHisValGlyProGlyGluGlyAlaValGln  
GGCGTGCTGTGTCAGCAATACTGCGCCGGCACGTTGGCCCGGGCGAGGGGGCAGTGCAG  
CCGCACCAGACACGTCGTTATGACGCGCGCGTGCAACCGGGCCCGCTCCCCCGTCAAGTC

5401 TrpMetAsnArgLeuIleAlaPheAlaSerArgGlyAsnHisValSerProThrHisTyr  
TGGATGAACCGGCTGATAGCCTTCGCTTCCCGGGGAACCATGTTTCCCCACGCACTAC  
ACCTACTTGGCCGACTATCGGAAGCGGAGGGCCCCCTTGGTACAAAGGGGTGCGTGATG

5461 ValProGluSerAspAlaAlaAlaArgValThrAlaIleLeuSerSerLeuThrValThr  
GTGCCGGAGAGCGATGCAGCTGCCCGCTCACTGCCATACTCAGCAGCCTCACTGTAAAC  
CAGGCCCTCTCGCTACGTGACGGGCGCAGTGACGGTATGAGTCGTGCGAGTGACATTGG

5521 GlnLeuLeuArgArgLeuHisGlnTrpIleSerSerGluCysThrThrProCysSerGly  
CAGCTCCTGAGGCGACTGCACCACTGGATAAGCTCGGAGTGTACCACTCCATGCTCCGGT  
GTCGAGGACTCCGCTGACGTGGTCACCTATTCGAGCCTCACATGGTGAGGTACGAGGCCA

5581 SerTrpLeuArgAspIleTrpAspTrpIleCysGluValLeuSerAspPheLysThrTrp  
TCCTGGCTAAGGGACATCTGGGACTGGATATGCGAGGTGTTGAGCGACTTTAAGACCTGG  
AGGACCGATTCCCTGTAGACCTGACCTATACGCTCCCAACTCGCTGAAATCTTGAGCC

5641 LeuLysAlaLysLeuMetProGlnLeuProGlyIleProPheValSerCysGlnArgGly  
CTAAAGCTAAGCTCATGCCACAGCTGCCTGGGATCCCCCTTTGTGTCTGCCAGCGGGG  
GATTTTCGATTGAGTACGGTGTCGACGGACCCTAGGGGAAACACAGGACGGTTCGCGCCC

5701 TyrLysGlyValTrpArgValAspGlyIleMetHisThrArgCysHisCysGlyAlaGlu  
TATAAGGGGGTCTGGCGAGTGGACGGCATCATGCACACTCGCTGCCACTGTGGAGCTGAG  
ATATTTCCCCAGACCGCTCACCTGCCGTAGTACGTGTGAGCGACGGTGACACCTCGACTC

5761 IleThrGlyHisValLysAsnGlyThrMetArgIleValGlyProArgThrCysArgAsn

## EP 0 388 232 A1

TAGTGACCTGTACAGTTTTTGGCCCTGCTACTCCTAGCAGCCAGGATCCTGGACGTCCTTG

5821 MetTrpSerGlyThrPheProIleAsnAlaTyrThrThrGlyProCysThrProLeuPro  
ATGTGGAGTGGGACCTTCCCCATTAAATGCCTACACCACGGGCCCTGTACCCCCCTTCCT  
TACACCTCACCTGGAAGGGTAATTACGGATGTGGTGCCCGGGACATGGGGGGAAGGA

5881 AlaProAsnTyrThrPheAlaLeuTrpArgValSerAlaGluGluTyrValGluIleArg  
GCGCGAAGTACACGTTTCGCGCTATGGAGGGTGTCTGCAGAGGAATATGTGGAGATAAGG  
CGCGGCTTGATGTGCAAGCGGATACCTCCACAGACGTCTCCTTATACACCTCTATTCC

5941 GlnValGlyAspPheHisTyrValThrGlyMetThrThrAspAsnLeuLysCysProCys  
CAGTGGGGGACTTCCACTACGTGACGGGTATGACTACTGACAACTCTCAAATGCCCGTGC  
GTCACCCCCCTGAAGGTGATGACTGCCCATACTGATGACTGTAGAGTTTACGGGCACG

6001 GlnValProSerProGluPhePheThrGluLeuAspGlyValArgLeuHisArgPheAla  
CAGGTCCCATCGCCGAATTTTTCACAGAATTGGACGGGGTGCCTACATAGGTTTGGC  
GTCCAGGGTAGCGGGCTTAAAAAGTGTCTTAACCTGCCCCACGGGATGTATCCAAACGC

6061 ProProCysLysProLeuLeuArgGluGluValSerPheArgValGlyLeuHisGluTyr  
CCCCCTGCAAGCCCTTGCTGCGGGAGGAGGTATCATTACAGAGTAGGACTCCACGAATAC  
GGGGGACGTTTCGGGAACGACGCCCTCCTCCATAGTAAGTCTCATCCTGAGGTGCTTATG

6121 ProValGlySerGlnLeuProCysGluProGluProAspValAlaValLeuThrSerMet  
CCGGTAGGGTCGCAATTACCTTGCAGCCCCGAACCGGACGTGGCCGTGTTGACGTCCATG  
GGCCATCCACGCTTAATGGAACGCTCGGGCTTGGCCTGCACCGGCACAACCTGCAGGTAC

6181 LeuThrAspProSerHisIleThrAlaGluAlaAlaGlyArgArgLeuAlaArgGlySer  
CTCACTGATCCCTCCCATATAACAGCAGAGGCGGCGGGCGAAGGTGGCGAGGGGATCA  
GAGTACTAGGGAGGGTATATTGTCGTCTCCTCCCGGGCCGCTTCCAACCGCTCCCTAGT

6241 ProProSerValAlaSerSerSerAlaSerGlnLeuSerAlaProSerLeuLysAlaThr  
CCCCCTCTGTGGCCAGCTCCTCGGCTAGCCAGCTATCCGCTCCATCTCTCAAGGCAACT  
GGGGGAGACACCGGTCGAGGAGCCGATCGGTGATAGGCGAGGTAGAGAGTTCCGTTGA

6301 CysThrAlaAsnHisAspSerProAspAlaGluLeuIleGluAlaAsnLeuLeuTrpArg  
TGCACCGTAACCATGACTCCCCTGATGCTGAGCTCATAGAGGCCAACCTCCTATGGAGG  
ACGTGGCGATTGGTACTGAGGGGACTACGACTCGAGTATCTCCGGTTGGAGGATACCTCC

6361 GlnGluMetGlyGlyAsnIleThrArgValGluSerGluAsnLysValValIleLeuAsp  
CAGGAGATGGGCGGCAACATCACCAGGTTGAGTCAGAAAACAAAGTGGTGATTCTGGAC  
GTCTCTACCCGCCGTTGTAGTGGTCCCAACTCAGTCTTTTGTTCACCACTAAGACCTG

6421 SerPheAspProLeuValAlaGluGluAspGluArgGluIleSerValProAlaGluIle  
TCCTTCGATCCGCTTGTTGGCGGAGGAGGACGAGCGGGAGATCTCCGTACCCGCAGAAATC  
AGGAAGCTAGGCGAACACCGCCTCCTCCTGCTCGCCCTCTAGAGGCATGGGCGTCTTTAG

6481 LeuArgLysSerArgArgPheAlaGlnAlaLeuProValTrpAlaArgProAspTyrAsn  
CTGCGGAAGTCTCGGAGATTGCCCCAGGCCCTGCCCCGTTGGGCGCGGCCGACTATAAC  
GACGCCCTCAGAGCCTCTAAGCGGGTCCGGGACGGGCAAACCGCGCGGCCCTGATATTG

6541 ProProLeuValGluThrTrpLysLysProAspTyrGluProProValValHisGlyCys  
CCCCCGCTAGTGGAGACGTGGAAAAGCCCGACTACGAACCACCTGTGGTCCATGGCTGT  
GGGGGCGATCACCTCTGCACCTTTTTCGGGCTGATGCTTGGTGGACACCAGGTACCGACA

6601 ProLeuProProProLysSerProProValProProProArgLysLysArgThrValVal  
CCGCTTCCACCTCAAAGTCCCCCTCCTGTGCTCCGCCTCGGAAGAAGCGGACGGTGGTC  
GGCGAAGGTGGAGGTTTCAGGGGAGGACACGGAGGCGGAGCCTTCTTCGCCTGCCACCAG

6661 LeuThrGluSerThrLeuSerThrAlaLeuAlaGluLeuAlaThrArgSerPheGlySer  
CTCACTGAATCAACCTATCTACTGCCTTGGCCGAGCTCGCCACCAGAAGCTTTGGCAGC  
GAGTGAAGTTAGTTGGGATAGATGACGGAACCGGCTCGAGCGGTGGTCTTCGAAACCGTGC

6721 SerSerThrSerGlyIleThrGlyAspAsnThrThrThrSerSerGluProAlaProS r  
TCCTCAACTTCCGGCATTACGGGCGACAATACGACAACATCCTCTGAGCCCGCCCTTCT  
AGGAGTTGAACCGCTAATGCCCGCTGTTATCTGTTGTAAGGAGTCTGCGCCCGCCCAAG



## EP 0 388 232 A1

6781 GlyCysProProAspSerAspAlaGluSerTyrSerSerMetProProLeuGluGlyGlu  
GGCTGCCCCCGACTCCGACGCTGAGTCTATTCTCCATGCCCCCCTGGAGGGGGAG  
CCGACGGGGGGGCTGAGGCTCGACTCAGGATAAGGAGGTACGGGGGGGACCTCCCCCTC

6841 ProGlyAspProAspLeuSerAspGlySerTrpSerThrValSerSerGluAlaAsnAla  
CCTGGGGATCCGGATCTTAGCGACGGGTCATGGTCAACGGTCAGTAGTGAGGCCAACGCG  
GGACCCCTAGGCCTAGAATCGCTGCCAGTACCAGTTGCCAGTCATCACTCCGGTTGCGC

6901 GluAspValValCysCysSerMetSerTyrSerTrpThrGlyAlaLeuValThrProCys  
GAGGATGTCGTGTGCTCAATGTCTTACTCTTGGACAGGCGCACTCGTCACCCCGTGC  
CTCTACAGCACACGAGTTACAGAATGAGAACCCTGTCCGCGTGAGCAGTGGGGCAGC

6961 AlaAlaGluGluGlnLysLeuProIleAsnAlaLeuSerAsnSerLeuLeuArgHisHis  
GCCGCGGAAGAAGACGAACTGCCCATCAATGCCTAAGCAACTCGTTGCTACGTCACCAC  
CGGCGCCTTCTTGTCTTTGACGGGTAGTTACGTGATTCTGTTAGCAACGATGCAGTGGTG

7021 AsnLeuValTyrSerThrThrSerArgSerAlaCysGlnArgGlnLysLysValThrPhe  
AATTTGGTGATTCACACCTCACGCAGTGTGTCGCAAGGAGGAGAAAGTACATTT  
TTAAACCACATAAGGTGGTGGAGTGCCTCAGAACGGTTTCCGTCTTCTTTCAGTGTA

7081 AspArgLeuGlnValLeuAspSerHisTyrGlnAspValLeuLysGluValLysAlaAla  
GACAGACTGCAAGTTCTGGACAGCCATTACCAGGACGTACTCAAGGAGGTTAAAGCAGCG  
CTGTCTGACGTTCAAGACCTGTGCGTAATGGTCTGTCATGAGTTCTTCCAATTCGTGCG

7141 AlaSerLysValLysAlaAsnLeuLeuSerValGluGluAlaCysSerLeuThrProPro  
GCGTCAAAAGTGAAAGCTAAGTGTCTATCCGTAGAGGAAGCTTGACGCTGACGCCCCCA  
CGCAGTTTTCACTTCCGATTGAACGATAGGCATCTCTTCGAACGTGCGACTGCGGGGGT

7201 HisSerAlaLysSerLysPheGlyTyrGlyAlaLysAspValArgCysHisAlaArgLys  
CACTCAGCCAAATCCAAGTTTGGTTATGGGGCAAAAGACGTCCGTTGCCATGCCAGAAAG  
GTGAGTGGTTTAGGTTCAAACCAATACCCGTTTTCTGCAGGCAACGGTACGGTCTTTC

7261 AlaValThrHisIleAsnSerValTrpLysAspLeuLeuGluAspAsnValThrProIle  
GCCGTAACCCACATCAACTCCGTGTGGAAGACCTTCTGGAAGACAATGTAACACCAATA  
CGGCATTGGGTGTAGTTGAGGCACACCTTCTGGAAGACCTTCTGTTACATTGTGGTTAT

732P AspThrThrIleMetAlaLysAsnGluValPheCysValGlnProGluLysGlyGlyArg  
GACACTACCATCATGGCTAAGAAGCAGGTTTTCTGCGTTCAAGCTGAGAAGGGGGTCTGT  
CTGTGATGGTAGTACCGATTCTTGCTCCAAAGACGCAAGTGGACTCTTCCCCCAGCA

7381 LysProAlaArgLeuIleValPheProAspLeuGlyValArgValCysGluLysMetAla  
AAGCCAGCTCGTCTCATCGTGTTCCTCGATCTGGGCGTGCCTGTGCGAAAAGATGGCT  
TTCGGTTCGAGCAGTAGCACAAGGGGCTAGACCCGACGCGCACACGCTTTTCTACCGA

7441 LeuTyrAspValValThrLysLeuProLeuAlaValMetGlySerSerTyrGlyPheGln  
TTGTACGACGTGGTTACAAAGCTCCCCCTGGCCGTGATGGGAAGCTCTACGGATTCCAA  
AACATGCTGCACCAATGTTTCGAGGGGAACCGCACTACCCTTCGAGGATGCCTAAGGTT

7501 TyrSerProGlyGlnArgValGluPheLeuValGlnAlaTrpLysSerLysLysThrPro  
TACTCACCAGGACAGCGGTTGAATTCCTCGTGCAAGCGTGAAGTCCAAGAAAACCCCA  
ATGAGTGGTCTGTCGCCCACTTAAGGAGCAGTTTCGCACCTTCAGGTTCTTTTGGGGT

7561 MetGlyPheSerTyrAspThrArgCysPheAspSerThrValThrGluSerAspIleArg  
ATGGGGTTCTCGTATGATACCCGCTGCTTGACTCCACAGTCACTGAGAGCGACATCCGT  
TACCCCAAGAGCATACTATGGGCGACGAACTGAGGTGTCAGTGACTCTCGCTGTAGGCA

7621 ThrGluGluAlaIleTyrGlnCysCysAspLeuAspProGlnAlaArgValAlaIleLys  
ACGGAGGAGGCAATCTACCAATGTTGTGACCTCGACCCCCAAGCCCGCTGGCCATCAAG  
TGCCCTCCTCCGTTAGATGGTTACAACACTGGAGCTGGGGGTTCCGGCGCACCGGTAGTTC

7681 SerLeuThrGluArgLeuTyrValGlyGlyProLeuThrAsnS rArgGlyGluAsnCys  
TCCCTCACCGAGAGGCTTATGTTGGGGGCCCTCTTACCAATTCAAGGGGGGAGAACTGC  
AGGGAGTGGCTCTCCGAAATACAACCCCCGGGAGAATGGTTAAGTTCCCCCTCTTGACG

EP 0 388 232 A1

CCGATAGCGTCCACGGCGCGCTCGCCGCATGACTGTTGATCGACACCATTGTGGGAGTGA

7801 CysTyrIleLysAlaArgAlaAlaCysArgAlaAlaGlyLeuGlnAspCysThrMetLeu  
TGCTACATCAAGGCCCGGCAGCCTGTCTGAGCCGAGGGCTCCAGGACTGCACCATGCTC  
ACGATGTAGTTCGGGGCCCGTCGGACAGCTCGGCGTCCCGAGGTCTTGACGTGGTACGAG

7861 ValCysGlyAspAspLeuValValIleCysGluSerAlaGlyValGlnGluAspAlaAla  
GTGTGTGGCGACGACTTAGTCGTTATCTGTGAAAGCGGGGGTCCAGGAGGACGCGGCG  
CACACACCGCTGCTGAATCAGCAATAGACACTTTCGCGCCCCCAGGTCTCTGCGCCGCG

7921 SerLeuArgAlaPheThrGluAlaMetThrArgTyrSerAlaProProGlyAspProPro  
AGCCTGAGAGCCTTCACGGAGGCTATGACCAGGTACTCCGCCCCCCTGGGGACCCCCCA  
TCGGACTCTCGGAAGTGCTCCGATACTGGTCCATGAGGCGGGGGGACCCCTGGGGGGT

7981 GlnProGluTyrAspLeuGluLeuIleThrSerCysSerSerAsnValSerValAlaHis  
CAACCAGAATACGACTTGGAGCTCATAACATCATGCTCCTCCAACGTGTCAGTCGCCCCAC  
GTTGGTCTTATGCTGAACCTCGAGTATTGTAGTACGAGGAGGTTGCACAGTCAGCGGGTG

8041 AspGlyAlaGlyLysArgValTyrTyrLeuThrArgAspProThrThrProLeuAlaArg  
GACGGCGCTGGAAAGAGGGTCTACTACCTCACCCGTGACCCTACAACCCCTCGCGAGA  
CTGCCGCGACCTTCTCCAGATGATGGAGTGGGCACTGGGATGTTGGGGGAGCGCTCT

8101 AlaAlaTrpGluThrAlaArgHisThrProValAsnSerTrpLeuGlyAsnIleIleMet  
GCTGCGTGGGAGACAGCAAGACACACTCCAGTCAATTCCTGGCTAGGCAACATAATCATG  
CGACGCACCTCTGTCTGTTCTGTGTGAGGTCAGTTAAGGACCGATCCGTTGTATTAGTAC

8161 PheAlaProThrLeuTrpAlaArgMetIleLeuMetThrHisPhePheSerValLeuIle  
TTTGGCCCCACACTGTGGGCGAGGATGATACTGATGACCCATTTCTTTAGCGTCTTTATA  
AAACGGGGGTGTGACACCCGCTCTACTATGACTACTGGGTAAAGAAATCGCAGGAATAT

8221 AlaArgAspGlnLeuGluGlnAlaLeuAspCysGluIleTyrGlyAlaCysTyrSerIle  
GCCAGGGACAGCTTGAACAGGCCCTCGATTGCGAGATCTACGGGGCCTGCTACTCCATA  
CGGTCCCTGGTCAACTTGTCCGGGAGCTAACGCTCTAGATGCCCCGACGATGAGGTAT

8281 GluProLeuAspLeuProProIleIleGlnArgLeu  
GAACCACTTGATCTACCTCCAATCATTCAAAGACTC  
CTTGGTGAAGTAGATGGAGGTTAGTAAGTTTCTGAG

## EP 0 388 232 A1

-319 CACTCCACCATGAATCACTCCCCTGTGAGGAACACTACTGTCTTCACGCAGAAAGCGTCTAG  
GTGAGGTGGTACTTAGTGAGGGGACACTCCTTGATGACAGAAGTGCCTCTTTCGCAGATC

-259 CCATGGCGTTAGTATGAGTGTGCTGCAGCCTCCAGGACCCCCCTCCCGGGAGAGCCATA  
GGTACCGCAATCATACTCACAGCAGCTCGGAGGTCTTGGGGGGGAGGGCCCTCTCGGTAT

-199 GTGGTCTGCGGAACCGGTGAGTACACCGGAATTGCCAGGACGACCGGGTCCTTTCTTGGA  
CACCAGACGCTTGGCCACTCATGTGGCCTTAACGGTCCTGCTGGCCAGGAAAGAACCT

-139 TCAACCCGCTCAATGCCCTGGAGATTGGGGCTGCCCGCAAGACTGCTAGCCGAGTAGT  
AGTTGGGCGAGTTACGGACCTCTAAACCCGACGGGGGCGTTCTGACGATCGGCTCATCA

- 79 GTTGGGTGCGGAAAGGCCCTGTGGTACTGCTGATAGGGTGCTTGCGAGTGCCCCGGGAG  
CAACCCAGCGCTTTCGGAACACCATGACGGACTATCCACGAACGCTCACGGGGCCCTC

- 19 GTCTCGTAGACCGTGCACC  
CAGAGCATCTGGCAGTGG

Arg Thr  
1 MetSerThrAsnProLysProGlnLysLysAsnLysArgAsnThrAsnArgArgProGln  
ATGAGCACGAATCCTAAACCTCAAAAAAACAACGTAACACCAACCGTCGCCACAG  
TACTCGTGCTTAGGATTGGAGTTTTTTTTTGTGTTGCATTGTGTTGGCAGCGGGTGTCTC

61 AspValLysPheProGlyGlyGlyGlnIleValGlyGlyValTyrLeuLeuProArgArg  
GACGTCAAGTTCGCGGTGGCGGTGAGATCGTTGGTGGAGTTTACTGTTGCCGCGCAGG  
CTGCAGTTCAAGGGCCACCGCCAGTCTAGCAACCACCTCAAATGAACAACGGCGCGTCC

121 GlyProArgLeuGlyValArgAlaThrArgLysThrSerGluArgSerGlnProArgGly  
GGCCCTAGATTGGGTGTGCGCGCGACGAGAAAGACTTCCGAGCGGTGCAACCTCGAGGT  
CCGGGATCTAACCCACACGCGCGCTGCTCTTCTGAAGGCTCGCCAGCGTTGGAGCTCCA

181 ArgArgGlnProIleProLysAlaArgArgProGluGlyArgThrTrpAlaGlnProGly  
AGACGTGAGCCTATCCCAAGGCTCGTGGGCGGAGGACAGGACCTGGGCTCAGCCCGGG  
TCTGCAGTCGGATAGGGGTTCCGAGCAGCCGGGCTCCCGTCTGGACCCGAGTCGGGCCC

241 TyrProTrpProLeuTyrGlyAsnGluGlyCysGlyTrpAlaGlyTrpLeuLeuSerPro  
TACCCCTGGCCCTCTATGGCAATGAGGGCTGCGGGTGGCGGGATGGCTCCTGTCTCCC  
ATGGGAACCGGGGAGATACCGTTACTCCCGACGCCACCCGCCCTACCGAGGACAGAGGG

301 ArgGlySerArgProSerTrpGlyProThrAspProArgArgArgSerArgAsnLeuGly  
CGTGGCTCTCGGCCTAGCTGGGCCCCACAGACCCCGCGTAGGTGCGCAATTGGGGT  
GCACCGAGAGCCGGATCGACCCCGGGGTGTCTGGGGGCGCATCCAGCGGTTAAACCCA

361 LysValIleAspThrLeuThrCysGlyPheAlaAspLeuMetGlyTyrIleProLeuVal  
AAGGTGATCGATACCTTACGTGCGGCTTCGCCGACCTCATGGGGTACATACCGCTCGTC  
TTCCAGTAGCTATGGGAATGCACGCCGAAGCGGCTGGAGTACCCCATGTATGGCGAGCAG

421 GlyAlaProLeuGlyGlyAlaAlaArgAlaLeuAlaHisGlyValArgValLeuGluAsp  
GGCGCCCCCTTGGAGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTCTGGAAGAC  
CCGCGGGGAGAACCTCCGCGACGTTCCGGGACCGGTACCGCAGGCCCAAGACCTTCTG

481 GlyValAsnTyrAlaThrGlyAsnLeuProGlyCysSerPheSerIlePheLeuLeuAla  
GGCGTGAACATATGCAACAGGGAACCTTCTGTTGCTCTTCTCTATCTTCTCTGGCC  
CCGCACTTGATACGTTGCTTCCCTTGGAAGGACCAACGAGAAAGAGATAGAAGGAAGACCGG

541 LeuLeuSerCysLeuThrValProAlaSerAlaTyrGlnValArgAsnSerThrGlyLeu  
CTGCTCTCTTGTGCTTGTGCTGCGGCTTCGCGCTACCAAGTGGCGCAACTCCAGGGGCTT  
GACGAGAGAACGAACGACACGGGCGAAGCCGGATGGTTCACGCGTTGAGGTGCCCCGAA

601 TyrHisValThrAsnAspCysProAsnSerSerIleValTyrGluAlaAlaAspAlaIle  
TACCAGTCACCAATGATTGCCCTAACTCGAGTATTGTGTACGAGGCGGCGGTGCCATC  
ATGGTGCAGTGGTTACTAACGGGATTGAGCTCATAACACATGCTCCGCGGCTACGGTAG

661 LeuHisThrProGlyCysValProCysValArgGluGlyAsnAlaSerArgCysTrpVal  
CTGCACACTCCGGGGTGGTCCCTTGGCTTGGTGGAGGCAACGCTCGAGGTGTTGGGTG  
GACGTGTGAGGCCCCACGCGAGGAACGCAAGCACTCCCGTTGCGGAGCTCCACAACCCAC

Fig. 17-1

## EP 0 388 232 A1

721 AlaMetThrProThrValAlaThrArgAspGlyLysLeuProAlaThrGlnLeuArgArg  
GCGATGACCCCTACGGTGGCCACAGGGATGSCAACTCCCCGCGACGAGCTTCGACGT  
CGCTACTGGGGATGCCACCGGTGGTCCCTACCGTTTGAGGGGCGCTGCGTGAAGCTGCA

781 HisIleAspLeuLeuValGlySerAlaThrLeuCysSerAlaLeuTyrValGlyAspLeu  
CACATCGATCTGCTTGTGGGAGCGCCACCTCTGTTCCGGCCCTCTACGTGGGGGACCTA  
GTGTAGCTAGACGAACAGCCCTCGCGTGGGAGACAAGCCGGGAGATGCACCCCTGGAT

841 CysGlySerValPheLeuValGlyGlnLeuPheThrPheSerProArgArgHisTrpThr  
TGCGGGTCTGTCTTCTGTGCGGCCAACTGTTCACCTTCTCTCCAGGCGCCACTGGACG  
ACGCCCAGACAGAAAGAACAGCCGTTGACAAGTGAAGAGAGGGTCCGCGGTGACCTGC

901 ThrGlnGlyCysAsnCysSerIleTyrProGlyHisIleThrGlyHisArgMetAlaTrp  
ACGCAAGGTGCAATTGCTCTATCTATCCCGGCCATATAACGGGTACCGCATGGCATGG  
TGCGTTTCAACGTTAACAGATAGATAGGGCCGTTATATTGCCAGTGGCGTACCGTACC

961 Val  
AspMetMetMetAsnTrpSerProThrThrAlaLeuValMetAlaGlnLeuLeuArgIle  
GATATGATGATGAACGTGCTCCCTACGACGGCGTGGTAAATGGCTCAGCTGCTCCGGATC  
CTATACTACTACTTGACCAGGGGATGCTGCCGCAACCATTACCGAGTGCACGAGGCCTAG

1021 ProGlnAlaIleLeuAspMetIleAlaGlyAlaHisTrpGlyValLeuAlaGlyIleAla  
CCACAAGCCATCTTGGACATGATCGCTGGTCTACTGGGGAGTCTTGGCGGGCATAGCG  
GGTGTTCGGTAGAACCTGTACTAGCGACACGAGTGACCCCTCAGGACCGCCCGTATGCG

1081 TyrPheSerMetValGlyAsnTrpAlaLysValLeuValValLeuLeuPheAlaGly  
TATTTCTCCATGGTGGGGAAGTGGGCGAAGTCTGCTAGTGTCTGCTATTGTCGGGC  
ATAAAGAGGTACCAACCCCTTGACCCGCTTCCAGGACCATCAGACGACGATAAACGGCCG

1141 ValAspAlaGluThrHisValThrGlyGlySerAlaGlyHisThrValSerGlyPheVal  
GTGACGCGGAAACCCACGTCACCGGGGAAGTGGCGGCCACACTGTGTCTGGATTGTT  
CAGCTGCGCCTTTGGGTGCACTGGCCCCCTTACGGCCGTTGTGACACAGACCTAAACAA

1201 SerLeuLeuAlaProGlyAlaLysGlnAsnValGlnLeuIleAsnThrAsnGlySerTrp  
AGCCTCCTCGCACCAGGCGCCAAGCAGAAGCTCCAGCTGATCAACACCAACGGCAGTTGG  
TCGGAGGAGCGTGGTCCGCGGTTCTGCTTGCAGGTGCACTAGTTGTGGTTGCCGTCAACC

1261 HisLeuAsnSerThrAlaLeuAsnCysAsnAspSerLeuAsnThrGlyTrpLeuAlaGly  
CACCTCAATAGCACGGCCCTGAAGTCAATGATAGCCTCAACACCGGCTGGTTGGCAGGG  
GTGGAGTTATCGTGCAGGACTTGACGTTACTATCGGAGTTGTGGCCGACCAACCGTCCC

1321 LeuPheTyrHisHisLysPheAsnSerSerGlyCysProGluArgLeuAlaSerCysArg  
CTTTTCTATCACCACAAGTTCAACTCTTCAGGTGTCTCTGAGAGGCTAGCCAGCTGCCGA  
GAAAGATAGTGGTGTTCAGTTGAGAAGTCCGACAGGACTCTCCGATCGGTTCGACGGCT

1381 ProLeuThrAspPheAspGlnGlyTrpGlyProIleSerTyrAlaAsnGlySerGlyPro  
CCCCCTTACGATTTTGACAGGGCTGGGGCCCTATCAGTTATGCCAACGGAAGCGGCCCC  
GGGGAATGGCTAAACCTGGTCCCCGACCCCGGATAGTCAATACGGTTGCCTTCGCCGGGG

1441 AspGlnArgProTyrCysTrpHisTyrProProLysProCysGlyIleValProAlaLys  
GACCAGCGCCCTACTGTGGCACTACCCCCAAAACCTTGCGGTATTGTGCCCCGGAAG  
CTGGTCCGCGGGATGACGACCGTGATGGGGGTTTGGAAACCCATAACACGGCGCTTC

1501 SerValCysGlyProValTyrCysPheThrProSerProValValValGlyThrThrAsp  
AGTGTGTGTGGTCCGGTATATTGCTTCACTCCAGCCCCGTGGTGGTGGGAACGACGAC  
TCACACACACAGGCCATATAACGAAGTGAGGTGCGGGGACCAACACCTTGCTGGCTG

1561 ArgSerGlyAlaProThrTyrSerTrpGlyGluAsnAspThrAspValPheValLeuAsn  
AGGTGGGGCGCGCCACCTACAGCTGGGGTGAATGATACGGACGCTTCGTCTCTTAAC  
TCCAGCCCCGCGGGTGGATGTGACCCCACTTTTACTATGCTGCAGAAGCAGGAATTG

1621 AsnThrArgProProLeuGlyAsnTrpPheGlyCysThrTrpMetAsnSerThrGlyPhe  
AATACCAGGCCACCGCTGGGCAATTGGTTGCTTACCTGGATGAACCAACTGGATTTC  
TTATGGTCCGCTGGCGACCCGTTAACCAAGCCAACATGGACCTACTTGAGTTGACCTAAG

Fig. 17-2

EP 0 388 232 A1

1681 ThrLysValCysGlyAlaProProCysValIleGlyGlyAlaGlyAsnAsnThrLeuHis  
ACCAAAGTGTGCGGAGCGCCTCCTTGTGTATCGGAGGGGCGGCAACAACACCCTGCAC  
TGTTTTCACACGCCTCGCGGAGGAACACAGTAGCCTCCCCGCCGTGTTGTGGGACGTG

1741 CysProThrAspCysPheArgLysHisProAspAlaThrTyrSerArgCysGlySerGly  
TGCCCCACTGATTGCTTCCGCAAGCATCCGGACGCCACATACTCTCGGTGCGGCTCCGGT  
ACGGGGTGACTAACGAAGGCGTTCGTAGGCCTGCGGTGTATGAGAGCCACGCCGAGGCCA

1801 Leu  
ProTrpIleThrProArgCysLeuValAspTyrProTyrArgLeuTrpHisTyrProCys  
CCCTGGATCACACCAGGTGCCTGGTCGACTACCCGTATAGGCTTTGGCATTATCCTTGT  
GGGACCTAGTGTGGGTCCACGGACCAGCTGATGGGCATATCCGAAACCGTAATAGGAACA

1861 ThrIleAsnTyrThrIlePheLysIleArgMetTyrValGlyGlyValGluHisArgLeu  
ACCATCACTACACCATATTTAAATCAGGATGTACGTGGGAGGGTTCGAACACAGGCTG  
TGGTAGTTGATGTGGTATAAATTTTAGTCTACATGCACCTCCCCAGCTTGTGTCCGAC

1921 GluAlaAlaCysAsnTrpThrArgGlyGluArgCysAspLeuGluAspArgAspArgSer  
GAAGCTGCCTGCAACTGGACGCGGGCGAACGTTGCGATCTGGAAGACAGGGACAGGTCC  
CTTCGACGGACGTTGACCTGCGCCCCGCTTGCAACGCTAGACCTTCTGTCCCTGTCCAGG

1981 GluLeuSerProLeuLeuLeuThrThrThrGlnTrpGlnValLeuProCysSerPheThr  
GAGCTCAGCCCGTTACTGCTGACCACTACACAGTGGCAGGTCCTCCCGTGTTCCTTACA  
CTCGAGTCGGGCAATGACGACTGGTGATGTGTACCGTCCAGGAGGGCACAAGGAAGTGT

2041 ThrLeuProAlaLeuSerThrGlyLeuIleHisLeuHisGlnAsnIleValAspValGln  
ACCCTACCAGCCTTGTCCACCGGCCTCATCCACCTCCACCAGAACATTGTGGACGTGCAG  
TGGGATGTTCCGAACAGGTGGCCGGAGTAGGTGGAGGTGGTCTTGTAAACCTGCACGTC

2101 TyrLeuTyrGlyValGlySerSerIleAlaSerTrpAlaIleLysTrpGluTyrValVal  
TACTTGTACGGGGTGGGGTCAAGCATCGCGTCCTGGGCCATTAAGTGGGAGTACGTGCTT  
ATGAACATGCCCCACCCAGTTCTGTAGCGCAGGACCCGGTAATTCACCTCATGCAGCAA

2161 LeuLeuPheLeuLeuLeuAlaAspAlaArgValCysSerCysLeuTrpMetMetLeuLeu  
CTCCTGTTCTTCTGCTTGCAGACGCGCGCTCTGCTCCTGCTTGTGGATGATGCTACTC  
GAGGACAAGGAAGACGAACGTCTGCGCGCGCAGACGAGGACGAACACCTACTACGATGAG

2221 IleSerGlnAlaGluAlaAlaLeuGluAsnLeuValIleLeuAsnAlaAlaSerLeuAla  
ATATCCCAAGCGGAGGCGGCTTTGGAGAACCTCGTAATACTTAATGCAGCATCCCTGGCC  
TATAGGGTTTCGCTCCGCCGAAACCTCTTGAGCATTATGAATTACGTGCTAGGGACCGG

2281 GlyThrHisGlyLeuValSerPheLeuValPhePheCysPheAlaTrpTyrLeuLysGly  
GGGACGCACGGTCTTGTATCCTTCCTCGTGTCTTCTGCTTTGCATGGTATTTGAAGGGT  
CCCTGCGTGCCAGAACATAGGAAGGAGCACAAGAAGACGAAACGTACCATAAACTTCCCA

2341 LysTrpValProGlyAlaValTyrThrPheTyrGlyMetTrpProLeuLeuLeuLeuLeu  
AAGTGGGTGCCCCGAGCGGTCTACACCTTCTACGGGATGTGCCCTCTCTCCTGCTCCTG  
TTCACCCACGGGCTCGCCAGATGTGGAAGATGCCCTACACCGGAGAGGAGGACGAGGAC

2401 LeuAlaLeuProGlnArgAlaTyrAlaLeuAspThrGluValAlaAlaSerCysGlyGly  
TTGGCGTTGCCCCAGCGGCGTACGCGCTGGACACGGAGGTGGCCGCGTCTGTGGCGGT  
AACCGCAACGGGTCGCCCCATGCGCGACCTGTGCCTCCACCGGCGCAGCACACCGCCA

2461 ValValLeuValGlyLeuMetAlaLeuThrLeuSerProTyrTyrLysArgTyrIleSer  
GTTGTTCTCGTCGGGTGATGGCGCTGACTCTGTCAACATATTACAAGCGCTATATCAGC  
CAACAAGAGCAGCCCACTACCGCGACTGAGACAGTGGTATAATGTTGCGGATATAGTCG

Asn  
TrpCysLeuTrpTrpLeuGlnTyrPheLeuThrArgValGluAlaGlnLeuHisValTrp

Fig. 17-3

EP 0 388 232 A1

2641 HisProThrLeuValPheAspIleThrLysLeuLeuLeuAlaValPheGlyProLeuTrp  
CACCCGACTCTGGTATTTGACATCACCAAATTGCTGCTGGCCGTCTTCGGACCCCTTTGG  
GTGGGCTGAGACCATAAACTGTAGTGGTTTAACGACGACCGGCAGAAGCCTGGGGAAACC

2701 IleLeuGlnAlaSerLeuLeuLysValProTyrPheValArgValGlnGlyLeuLeuArg  
ATTCTTCAAGCCAGTTTGCTTAAAGTACCCTACTTTGTGCGCGTCCAAGGCCTTCTCCGG  
TAAGAAGTTCGGTCAAACGAATTCATGGGATGAAACACCGCAGGTTCCGGAAGAGGCC

2761 PheCysAlaLeuAlaArgLysMetIleGlyGlyHisTyrValGlnMetValIleIleLys  
TTCTGCGCGTTAGCGCGGAAGATGATCGGAGGCCATTACGTGCAAATGGTCATCATTAAG  
AAGACGCGCAATCGCGCCTTCTACTAGCCTCCGGTAATGCACGTTTACCAGTAGTAATTC

2821 LeuGlyAlaLeuThrGlyThrTyrValTyrAsnHisLeuThrProLeuArgAspTrpAla  
TTAGGGGCGCTTACTGGCACCTATGTTTATAACCATCTCACTCCTCTTCGGGACTGGGCG  
AATCCCCGGAATGACCGTGGATACAAATATTGGTAGAGTGAGGAGAAGCCCTGACCCGC

2881 HisAsnGlyLeuArgAspLeuAlaValAlaValGluProValValPheSerGlnMetGlu  
CACAACGGCTTGGCAGATCTGGCCGTGGCTGTAGAGCCAGTCGTCTTCTCCCAAATGGAG  
GTGTTGCCGAACGCTCTAGACCGGCACCGACATCTCGGTACAGCAGAAGAGGGTTTACCTC

2941 ThrLysLeuIleThrTrpGlyAlaAspThrAlaAlaCysGlyAspIleIleAsnGlyLeu  
ACCAAGCTCATCACGTGGGGGGCAGATACCGCCCGTGGCGTGACATCATCAACGGCTTG  
TGGTTCGAGTAGTGACCCCCCGTCTATGGCGGCGCACGCCACTGTAGTAGTTGCCGAAC

3001 ProValSerAlaArgArgGlyArgGluIleLeuLeuGlyProAlaAspGlyMetValSer  
CCTGTTTCCGCCCCGAGGGGCGGGAGATACTGCTCGGGCCAGCCGATGGAATGGTCTCC  
GGACAAAGGCGGGCGTCCCCGGCCCTCTATGACGAGCCCGGTTCGGCTACCTTACCAGAGG

3061 LysGlyTrpArgLeuLeuAlaProIleThrAlaTyrAlaGlnGlnThrArgGlyLeuLeu  
AAGGGGTGGAGGTGCTGGCGCCCATCACGGCGTACGCCAGCAGACAAGGGGCTCCTA  
TTCCCCACCTCCAACGACCGCGGGTAGTGCCGCATGCGGTCGTCTGTTCCCGGAGGAT

3121 GlyCysIleIleThrSerLeuThrGlyArgAspLysAsnGlnValGluGlyGluValGln  
GGGTGCATAATCACCAGCCTAACTGGCCGGGACAAAACCAAGTGGAGGGTGAGGTCCAG  
CCCACGTATTAGTGGTTCGGATTGACCGGCCCTGTTTTTGGTTCACCTCCCACTCCAGGTC

3181 IleValSerThrAlaAlaGlnThrPheLeuAlaThrCysIleAsnGlyValCysTrpThr  
ATTGTGTCAACTGCTGCCCAAACCTTCTGGCAACGTGCATCAATGGGGTGTGCTGGACT  
TAACACAGTTGACGACGGGTTTGAAGGACCGTTGCACGTAGTTACCCACACGACCTGA

3241 ValTyrHisGlyAlaGlyThrArgThrIleAlaSerProLysGlyProValIleGlnMet  
GTCTACCACGGGGCCGGAACGAGGACCATCGCGTCACCAAGGGTCTGTATCCAGATG  
CAGATGGTGCCCCGGCCTTGCTCCTGGTAGCGCAGTGGGTTCCAGGACAGTAGGTCTAC

3301 TyrThrAsnValAspGlnAspLeuValGlyTrpProAlaProGlnGlySerArgSerLeu  
TATACCAATGTAGACCAAGACCTTGTGGGCTGGCCCGCTCCGCAAGGTAGCCGCTCATTG  
ATATGGTTACATCTGTTCTGGAACACCCGACCGGGCGAGGCGTTCCATCGGCGAGTAAC

3361 ThrProCysThrCysGlySerSerAspLeuTyrLeuValThrArgHisAlaAspValIle  
ACACCCTGCACCTGCGGCTCCTCGGACCTTTACCTGGTCACGAGGCACGCCGATGTCAAT  
TGTGGGACGTGAACGCCGAGGAGCCTGGAAATGGACCAGTGCTCCGTGCGGCTACAGTAA

3421 ProValArgArgArgGlyAspSerArgGlySerLeuLeuSerProArgProIleSerTyr  
CCCGTGCGCCGGCGGGGTGATAGCAGGGGCAGCCTGCTGTGCCCCGCGCCATTTCCTAC  
GGGCACGCGGCGCCCACTATCGTCCCCGTGGACGACAGCGGGGCGGGTAAAGGATG

LeuLysGlySerSerGlyGlyProLeuLeuCysProAlaGlyHisAlaValGlyIlePhe

Fig. 17-4

## EP 0 388 232 A1

3601 LeuGluThrThrMetArgSerProValPheThrAspAsnSerSerProProValValPro  
CTAGAGACAACCATGAGGTCCCCGGTGTTCACGGATAACTCCTCTCCACCAGTAGTGCCC  
GATCTCTGTTGGTACTCCAGGGGCCACAAGTGCCATTGAGGAGAGGTGGTCATCACGGG

3661 GlnSerPheGlnValAlaHisLeuHisAlaProThrGlySerGlyLysSerThrLysVal  
CAGAGCTTCCAGGTGGCTCACCTCCATGCTCCACAGGCAGCGGCAAAAGCACCAAGGTC  
GTCTCGAAGGTCCACCGAGTGGAGGTACGAGGGGTGTCGGTCGCCGTTTTCGTGGTTCCAG

3721 ProAlaAlaTyrAlaAlaGlnGlyTyrLysValLeuValLeuAsnProSerValAlaAla  
CCGGCTGCATATGCAGCTCAGGGCTATAAGGTGCTAGTACTCAACCCCTCTGTGTGCTGCA  
GGCCGACGTATACGTGAGTCCCGATATTCCACGATCATGAGTTGGGGAGACAACGACGT

Leu

3781 ThrLeuGlyPheGlyAlaTyrMetSerLysAlaHisGlyIleAspProAsnIleArgThr  
ACACTGGGCTTTGGTGCTTACATGTCCAAGGCTCATGGGATCGATCCTAACATCAGGACC  
TGTGACCCGAAACCACGAATGTACAGSTTCCGAGTACCCTAGCTAGGATTGTAGTCCTGG

3841 GlyValArgThrIleThrThrGlySerProIleThrTyrSerThrTyrGlyLysPheLeu  
GGGGTGAGAACAATTACCACTGGCAGCCCCATCAGTACTCCACCTACGGCAAGTTCCTT  
CCCCACTCTTGTAAATGGTGACCGTCGGGGTAGTGTCATGAGGTGGATGCCGTTCAAGGAA

3901 AlaAspGlyGlyCysSerGlyGlyAlaTyrAspIleIleIleCysAspGluCysHisSer  
GCCGACGGCGGGTGCTCGGGGGCGCTTATGACATAATAATTGTGACGAGTGCCACTCC  
CGGCTGCCGCCACGAGCCCCCGCGAATACTGTATTATTAAACACTGCTCACGGTGAGG

3961 ThrAspAlaThrSerIleLeuGlyIleGlyThrValLeuAspGlnAlaGluThrAlaGly  
ACGGATGCCACATCCATCTTGGGCATCGGCCTGTCCTTGACCAAGCAGAGACTGCCGGG  
TGCTTACGGTGTAGGTAGAACCCGTAGCCGTGACAGGAAGTGGTTCGTCTCTGACGCCCC

4021 AlaArgLeuValValLeuAlaThrAlaThrProProGlySerValThrValProHisPro  
GCGAGACTGGTTGTGCTCGCCACCGCCACCCCTCCGGGCTCCGTCACTGTGCCCATCCC  
CGCTCTGACCAACACGAGCGGTGGCGGTGGGGAGGCCGAGCAGTGACACGGGGTAGGG

4081 AsnIleGluGluValAlaLeuSerThrThrGlyGluIleProPheTyrGlyLysAlaIle  
AACATCGAGGAGGTTGCTCTGTCCACCACCGAGAGATCCCTTTTACGGCAAGGCTATC  
TTGTAGCTCCTCCAACGAGACAGGTGGTGGCCTCTCTAGGGAAAAATGCCGTTCCGATAG

4141 ProLeuGluValIleLysGlyGlyArgHisLeuIlePheCysHisSerLysLysLysCys  
CCCCCGAAGTAATCAAGGGGGGAGACATCTCATCTTCTGTCAATTCAAAGAAGAAGTGC  
GGGAGCTTCATTAGTTCCCCCCTCTGTAGAGTAGAAGACAGTAAGTTCTTCTTCACG

4201 AspGluLeuAlaAlaLysLeuValAlaLeuGlyIleAsnAlaValAlaTyrTyrArgGly  
GACGAACCTCGCCGCAAGCTGGTTCGCATTGGGCATCAATGCCGTGGCCTACTACCGCGGT  
CTGCTTGAGCGGGCTTTCGACCAGCGTAACCCGTAGTTACGGCACCGGATGATGGCGCCA

4261 LeuAspValSerValIleProThrSerGlyAspValValValValAlaThrAspAlaLeu  
CTTGACGTGTCCGTCTATCCCGACAGCGCGATGTTGTCGTCTGGCAACCGATGCCCTC  
GAACTGCACAGGCAGTAGGGCTGGTTCGCCGCTACAACAGCAGCACCGTTGGCTACGGGAG

Tyr

4321 MetThrGlyTyrThrGlyAspPheAspSerValIleAspCysAsnThrCysValThrGln  
ATGACCGGCTATACCGCGGACTTCGACTCGGTGATAGACTGCAATACGTGTGTACCCAG  
TACTGGCCGATATGGCCGCTGAAGCTGAGCCACTATCTGACGTTATGCACACAGTGGGTC

Ser

4381 ThrValAspPheSerLeuAspProThrPheThrIleGluThrIleThrLeuProGlnAsp  
ACAGTCGATTTTCAGCCTTGACCCCTACCTTCACCATGAGACAATCAGCTCCCCCAGGAT  
TGTCAGCTAAAGTCGGAAGTGGGATGGAAGTGGTAACCTCTGTTAGTGGAGGGGGTCTTA

4441 AlaValSerArgThrGlnArgArgGlyArgThrGlyArgGlyLysProGlyIleTyrArg  
GCTGTCTCCCGCACTCAACGTCCGGGGCAGGACTGGCAGGGGGAAGCCAGGCATCTACAGA  
CGACAGAGGGCGTGAGTTGCAGCCCCGTCTGACCGTCCCCCTTCGTTCCGTAGATGTCT

Ser

4441 ThrValAspPheSerLeuAspProThrPheThrIleGluThrIleThrLeuProGlnAsp  
ACAGTCGATTTTCAGCCTTGACCCCTACCTTCACCATGAGACAATCAGCTCCCCCAGGAT  
TGTCAGCTAAAGTCGGAAGTGGGATGGAAGTGGTAACCTCTGTTAGTGGAGGGGGTCTTA

Fig. 17-5

## EP 0 388 232 A1

4561 TyrAspAlaGlyCysAlaTrpTyrGluLeuThrProAlaGluThrThrValArgLeuArg  
TATGACGCAGGCTGTGCTTGCTATGAGCTCAGCCCGCCGAGACTACAGTTAGGCTACGA  
ATACTGCGTCCGACACGAACCATACTCGAGTGCAGGGCGGCTCTGATGTCAATCCGATGCT

4621 AlaTyrMetAsnThrProGlyLeuProValCysGlnAspHisLeuGluPheTrpGluGly  
GCGTACATGAACACCCCGGGGCTTCCCGTGTGCCAGGACCATCTTGAATTTTGGGAGGGC  
CGCATGTACTTGTGGGGCCCCGAAGGGCACACGGTCCTGGTAGAACTTAAACCCCTCCCG

4681 ValPheThrGlyLeuThrHisIleAspAlaHisPheLeuSerGlnThrLysGlnSerGly  
GTCTTTACAGGCCTCACTCATATAGATGCCCACTTTCTATCCAGACAAAGCAGAGTGGG  
CAGAAATGTCGGGAGTGAGTATATCTACGGGTGAAAGATAGGGTCTGTTTCGTCTCACCC

4741 GluAsnLeuProTyrLeuValAlaTyrGlnAlaThrValCysAlaArgAlaGlnAlaPro  
GAGAACCTTCCTTACCTGGTAGCGTACCAAGCCACCGTGTGCGCTAGGGCTCAAGCCCT  
CTCTTGGAAGGAATGGACCATCGCATGGTTCGGTGGCACACGCGATCCCGAGTTCCGGGA

4801 ProProSerTrpAspGlnMetTrpLysCysLeuIleArgLeuLysProThrLeuHisGly  
CCCCCATCGTGGGACCAGATGTGGAAGTGTGTTGATTGCGCTCAAGCCCACCCTCCATGGG  
GGGGGTAGCACCCCTGGTCTACACCTTCACAACTAAGCGGAGTTCGGGTGGGAGGTACCC

4861 ProThrProLeuLeuTyrArgLeuGlyAlaValGlnAsnGluIleThrLeuThrHisPro  
CCAACACCCCTGCTATACAGACTGGGCGCTGTTTCTGAGTAAATCACCCTGACGCACCCA  
GGTTGTGGGGACGATATGTCTGACCCGCGACAAGTCTTACTTTAGTGGGACTGCGTGGGT

4921 ValThrLysTyrIleMetThrCysMetSerAlaAspLeuGluValValThrSerThrTrp  
GTCACCAAATACATCATGACATGCATGTCGGCCGACCTGGAGGTCGTCACGAGCACCTGG  
CAGTGGTTTATGTAGTACTGTACGTACAGCCGGCTGGACCTCCAGCAGTGCTCGTGGACC

4981 ValLeuValGlyGlyValLeuAlaAlaLeuAlaAlaTyrCysLeuSerThrGlyCysVal  
GTGCTCGTTGGCGGCGTCTTGCTGCTTTGGCCGCGTATTGCTGTCAACAGGCTGCGTG  
CACGAGCAACCGCCGAGGACCGACGAAACCGGCGCATAACGGACAGTTGTCCGACGCAC

5041 ValIleValGlyArgValValLeuSerGlyLysProAlaIleIleProAspArgGluVal  
GTCATAGTGGGCAGGGTCTGCTTGTCCGGGAAGCCGGCAATCATACCTGACAGGGAAGTC  
CAGTATCACCCGTCCAGCAGAACAGGCCCTTCGGCCGTTAGTATGGACTGTCCCTTCAG

5101 LeuTyrArgGluPheAspGluMetGluGluCysSerGlnHisLeuProTyrIleGluGln  
CTCTACCGAGAGTTTCTGATGAGATGGAAGAGTGCTCTCAGCACTTACCGTACATCGAGCAA  
GAGATGGCTCTCAAGCTACTCTACCTTCTCAGAGAGTCTGTAATGGCATGTAGCTCGTT

5161 GlyMetMetLeuAlaGluGlnPheLysGlnLysAlaLeuGlyLeuLeuGlnThrAlaSer  
GGGATGATGCTCGCCGAGCAGTTCAAGCAGAAGGCCCTCGGCCTCCTGCAGACCGCGTCC  
CCCTACTACGAGCGGCTCGTCAAGTTCGTCTTCCGGGAGCCGGAGGACGTCTGGCGCAGG

5221 ArgGlnAlaGluValIleAlaProAlaValGlnThrAsnTrpGlnLysLeuGluThrPhe  
CGTCAGGCAGAGGTTATCGCCCTGCTGTCCAGACCAACTGGCAAAACTCGAGACCTTC  
GCAGTCCGTCTCCAATAGCGGGGACGACAGGTCTGGTTGACCGTTTTTGGAGCTCTGGAAG

5281 TrpAlaLysHisMetTrpAsnPheIleSerGlyIleGlnTyrLeuAlaGlyLeuSerThr  
TGGGCGAAGCATATGTGGAACCTTCATCAGTGGGATACAATACTTGGCGGGCTTGTCAACG  
ACCCGCTTCGTATACACCTTGAAGTAGTACCCTATGTTATGAACCGCCCGAACAGTTGC

5341 LeuProGlyAsnProAlaIleAlaSerLeuMetAlaPheThrAlaAlaValThrSerPro  
CTGCCTGGTAACCCCGCCATTGCTTCATTGATGGCTTTTACAGCTGCTGTCACCAGCCCA  
GACGGACCATTTGGGGCGGTAACGAAGTAACACCGAAAATGTCGACGACAGTGGTCCGGT

5401 LeuThrThrSerGlnThrLeuLeuPheAsnIleLeuGlyGlyTrpValAlaAlaGlnLeu  
CTAACCACTAGCCAAACCTCCTCTTCAACATATTGGGGGGGTGGGTGGCTGCCAGCTC  
GATTGGTGATCGGTTTGGGAGGAGAAGTTGTATAACCCCCCACCACCGACGGGTCGAG

Fig. 17-6



## EP 0 388 232 A1

5521 AGTGTGGACTGGGGAAGGTCTCATAGACATCCTTGCAGGGTATGGCGGGCGTGGCG  
TCACAACCTGACCCCTCCAGGAGTATCTGTAGGAACGTCCCATACCGCGCCCGCACCGC

Gly

5581 GlyAlaLeuValAlaPheLysIleMetSerGlyGluValProSerThrGluAspLeuVal  
GGAGCTCTTGTGGCATTCAAGATCATGAGCGGTGAGGTCCCTCCACGGAGGACCTGGTC  
CCTCGAGAACACCGTAAGTTCTAGTACTCGCCACTCCAGGGGAGGTGCCTCCTGGACCAG

5641 AsnLeuLeuProAlaIleLeuSerProGlyAlaLeuValValGlyValValCysAlaAla  
AATCTACTGCCCGCCATCCTCTCGCCCGGAGCCCTCGTAGTCGGCGTGGTCTGTGCAGCA  
TTAGATGACGGGCGGTAGGAGAGCGGGCCTCGGGAGCATCAGCCGCACAGACACGTCGT

5701 IleLeuArgArgHisValGlyProGlyGluGlyAlaValGlnTrpMetAsnArgLeuIle  
ATACTGCGCCGGCACGTTGGCCCGGGCGAGGGGCAGTGCAGTGGATGAACCGGCTGATA  
TATGACGCGGCGGTGCAACCGGGCCCGTCCCCGTCACGTCACCTACTTGGCCGACTAT

5761 AlaPheAlaSerArgGlyAsnHisValSerProThrHisTyrValProGluSerAspAla  
GCCTTCGCCTCCCGGGGAACCATGTTTCCCCACGCACTACGTGCCGGAGAGCGATGCA  
CGGAAGCGGAGGGCCCCCTTGGTACAAAGGGGTGCGTGATGCACGGCCTCTCGCTACGT

HisCys

5821 AlaAlaArgValThrAlaIleLeuSerSerLeuThrValThrGlnLeuLeuArgArgLeu  
GCTGCCCCGCTCACTGCCATACTCAGCAGCCTCACTGTAACCCAGCTCCTGAGGCGACTG  
CGACGGGCGCAGTGACGGTATGAGTCGTGAGGTGACATTGGGTGCGAGGACTCCGCTGAC

5881 HisGlnTrpIleSerSerGluCysThrThrProCysSerGlySerTrpLeuArgAspIle  
CACCAGTGGATAAGCTCGGAGTGTACCACTCCATGCTCCGGTTCCTGGCTAAGGGACATC  
GTGGTCACCTATTTCGAGCCTCACATGTTGAGGTACGAGGCCAAGGACCGATTCCCTGTAG

5941 TrpAspTrpIleCysGluValLeuSerAspPheLysThrTrpLeuLysAlaLysLeuMet  
TGGGACTGGATATGCGAGGTGTTGAGCGACTTTAAGACCTGGCTAAAAGCTAAGCTCATG  
ACCCTGACCTATACGCTCCACAACCTCGCTGAAATTCTGGACCGATTTTCGATTGAGTAC

6001 ProGlnLeuProGlyIleProPheValSerCysGlnArgGlyTyrLysGlyValTrpArg  
CCACAGCTGCCTGGGATCCCTTTGTGTCTGCCAGCGCGGGTATAAGGGGGTCTGGCGA  
GGTGTGACGCGACCCCTAGGGGAACACAGGACGGTTCGCGCCCATATTCCCCAGACCGCT

Gly

6061 ValAspGlyIleMetHisThrArgCysHisCysGlyAlaGluIleThrGlyHisValLys  
GTGGACGGCATCATGCACACTCGCTGCCACTGTGGAGCTGAGATCACTGGACATGTCAA  
CACCTGCCGTAGTACGTGTGAGCGACGGTGACACCTCGACTCTAGTGACCTGTACAGTTT

6121 AsnGlyThrMetArgIleValGlyProArgThrCysArgAsnMetTrpSerGlyThrPhe  
AACGGGACGATGAGGATCGTCGGTCTTAGGACCTGCAGGAACATGTGGAGTGGGACCTTC  
TTGCCCTGCTACTCCTAGCAGCCAGGATCCTGGACGTCTTGTACACCTCACCTGGAAG

6181 ProIleAsnAlaTyrThrThrGlyProCysThrProLeuProAlaProAsnTyrThrPhe  
CCCATTAAATGCCTACACCAAGGGCCCCCTGTACCCCCCTTCTGCGCCGAACCTACAGTTC  
GGGTAATTACGGATGTGTTGCCCGGGGACATGGGGGAAGGACGCGGCTTGATGTGCAAG

6241 AlaLeuTrpArgValSerAlaGluGluTyrValGluIleArgGlnValGlyAspPheHis  
GCGCTATGGAGGGTGTCTGCAGAGGAATATGTGGAGATAAGGCAGGTGGGGGACTTCCAC  
CGGATACCTCCACAGACGTCTCCTTATACACCTCTATTCCGTCCACCCCTGAAGGTG

6301 TyrValThrGlyMetThrThrAspAsnLeuLysCysProCysGlnValProSerProGlu  
TACGTGACGGGTATGACTACTGACAATCTCAAATGCCCGTCCAGGTCCCATCGCCCGAA  
ATGCACTGCCCATACTGATGACTGTTAGAGTTTACGGGCACGGTCCAGGGTAGCGGGCTT

6361 PhePheThrGluLeuAspGlyValArgLeuHisArgPheAlaProProCysLysProLeu  
TTTTTACAGAATTGGACGGGGTGGCCTACATAGGTTTGGCCCCCTGCAAGCCCTTG  
AAAAAGTGTCTTAACCTGCCCCACGCGGATGTATCAAACGCGGGGGGACGTTCCGGGAAC

6421 LeuArgGluGluValSerPheArgValGlyLeuHisGluTyrProValGlySerGlnLeu  
CTGCGGGAGGAGGTATCATTCAGAGTAGGACTCCACGAATACCGGTAGGGTTCGAATTA  
--

Fig. 17-7

## EP 0 388 232 A1

6481 ProCysGluProGluProAspValAlaValLeuThrSerMetLeuThrAspProSerHis  
CCTTGCGAGCCCGAACCGGACGTGGCCGTGTTGACGTCCATGCTCACTGATCCCTCCCAT  
GGAACGCTCGGGCTTGGCCTGCACCGGCACAACCTGCAGGTACGAGTGACTAGGGAGGGTA

541 IleThrAlaGluAlaAlaGlyArgArgLeuAlaArgGlySerProProSerValAlaSer  
ATAACAGCAGAGGCGCGCCGGCGAAGGTTGGCGAGGGGATCACCCCTCTGTGGCCAGC  
TATTGTCGTCTCCGCCGCCGCTTCCAACCGCTCCCTAGTGGGGGAGACACCGGTG

6601 SerSerAlaSerGlnLeuSerAlaProSerLeuLysAlaThrCysThrAlaAsnHisAsp  
TCCTCGGCTAGCCAGCTATCCGCTCCATCTCTCAAGGCAACTGCACCGCTAACCATGAC  
AGGAGCCGATCGGTGATAGGCGAGGTAGAGAGTTCCGTTGAACGTGGCGATTGGTACTG

6661 SerProAspAlaGluLeuIleGluAlaAsnLeuLeuTrpArgGlnGluMetGlyGlyAsn  
TCCCTTGATGCTGAGCTCATAGAGGCCAACCTCCTATGGAGGCAGGAGATGGGCGGCAAC  
AGGGGACTACGACTCGAGTATCTCCGTTGGAGGATACCTCCGTCTCTACCCGCCGTTG

6721 IleThrArgValGluSerGluAsnLysValValIleLeuAspSerPheAspProLeuVal  
ATCACCAGGGTTGAGTCAGAAAACAAAGTGGTGATTCTGGACTCCTTCGATCCGCTTG  
TAGTGGTCCCAACTCAGTCTTTGTTTCACCACTAAGACCTGAGGAAGCTAGGCGAACAC

6781 AlaGluGluAspGluArgGluIleSerValProAlaGluIleLeuArgLysSerArgArg  
GCGGAGGAGGACGAGCGGGAGATCTCCGTACCCGACAGAAATCCTGCGGAAGTCTCGGAGA  
CGCTCTCTCTGCTCGCCCTCTAGAGGCATGGGCGTCTTTAGGACGCCTTCAGAGCCTCT

6841 PheAlaGlnAlaLeuProValTrpAlaArgProAspTyrAsnProProLeuValGluThr  
TTGCCCCAGGCCCTGCCCGTTTGGGCGCGGCGGACTATAACCCCGCTAGTGGAGACG  
AAGCGGTCCGGGACGGGCAACCCGCGCGGCGCTGATATTGGGGGGCGATCACCTCTGC

6901 TrpLysLysProAspTyrGluProProValValHisGlyCysProLeuProProProLys  
TGGAAAAGCCCCGACTACGAACCACCTGTGGTCCATGGCTGTCCGCTTCCACCTCCAAG  
ACCTTTTTTCGGGCTGATGCTTGGTGGACACCAGGTACCGACAGGCGAAGGTGGAGTTTC

6961 SerProProValProProProArgLysLysArgThrValValLeuThrGluSerThrLeu  
TCCCTCTCTGTGCTCCGCTCGGAAGAAGCGGACGGTGCTCCTCACTGAATCAACCTA  
AGGGGAGGACACGGAGGCGGAGCCTTCTTCGCTGOCACCAGGAGTGACTTAGTTGGGAT

Ser

7021 SerThrAlaLeuAlaGluLeuAlaThrArgSerPheGlySerSerSerThrSerGlyIle  
TCTACTGCCCTTGGCCGAGCTCGCCACCAGAAGCTTTGGCAGCTCCTCAACTTCCGGCATT  
AGATGACGGAACCGGCTCGAGCGGTGGTCTTCGAAACCGTCGAGGAGTTGAAGCCGTAA

7081 ThrGlyAspAsnThrThrThrSerSerGluProAlaProSerGlyCysProProAspSer  
ACGGGCGACAATACGACAACATCCTCTGAGCCCGCCCTTCTGGCTGCCCCCGGACTCC  
TGCCCGCTGTTATGCTGTTGTAGGAGACTCGGGCGGGGAAGACCGACGGGGGGCTGAGG

PheAla

7141 AspAlaGluSerTyrSerSerMetProProLeuGluGlyGluProGlyAspProAspLeu  
GACGCTGAGTCTTATTCCTCCATGCCCCCTGGAGGGGGAGCCTGGGGATCCGGATCTT  
CTGCGACTCAGGATAAGGAGGTACGGGGGGGACCTCCCCCTCGGACCCCTAGGCCTAGAA

7201 SerAspGlySerTrpSerThrValSerSerGluAlaAsnAlaGluAspValValCysCys  
AGCGACGGGTCAATGTTCAACGGTCAGTAGTGAGGCCAACGCGGAGGATGTCGTGTGCTGC  
TCGCTGCCCACTACCACTTGCCAGTCATCACTCCGTTGCGCCTCCTACAGCACACGACG

7261 SerMetSerTyrSerTrpThrGlyAlaLeuValThrProCysAlaAlaGluGluGlnLys  
TCAATGCTTACTCTTGGACAGGCGCACTCGTCACCCCGTGCGCCGCGGAAGAACAGAAA  
AGTTACAGAAATGAGAACCTTCCGCGTGAGCAGTGGGGCACGCGGCGCCTTCTTGTCTTT

7321 LeuProIleAsnAlaLeuSerAsnSerLeuLeuArgHisHisAsnLeuValTyrSerThr  
CTGCCCCATCAATGCACTAAGCAACTCGTTGCTACGTCACCACAATTTGGTGTATTCACC  
GACGGGTAGTTACGTGATTGCTTGGCAACGATGCAGTGGTGTAAACCACATAAGGTGG

7381 ThrSerArgSerAlaCysGlnArgGlnLysLysValThrPheAspArgLeuGlnValLeu  
ACCTCACGCAGTGTCTGCCAAAGGCAGAAGAAAGTCACATTTGACAGACTGCAAGTTCTG

Fig. 17-8

EP 0 388 232 A1

7441 AspSerHisTyrGlnAspValLeuLysGluValLysAlaAlaAlaSerLysValLysAla  
GACAGCCATTACCAGGACGTACTCAAGGAGGTTAAAGCAGCGGCGTCAAAAGTGAAGGCT  
CTGTCCGGTAATGGTCCTGCATGAGTTCCTCCAATTTGTCGCCGCAGTTTTCACCTCCGA

Phe  
7501 AsnLeuLeuSerValGluGluAlaCysSerLeuThrProProHisSerAlaLysSerLys  
AACTTGCTATCCGTAGAGGAAGCTTGCAGCCTGACGCCCCCACACTCAGCCAAATCCAAG  
TTGAACGATAGGCATCTCCTTCGAACGTCGGACTGCGGGGTGTGAGTCGGTTTAGGTTT

7561 PheGlyTyrGlyAlaLysAspValArgCysHisAlaArgLysAlaValThrHisIleAsn  
TTTGGTTATGGGGCAAAGACGTCCGTTGCCATGCCAGAAAGGCCGTAAACCCACATCAAC  
AAACCAATACCCCGTTTTCTGCAGGCAACGGTACGGTCTTTCCGGCATTGGGTGTAGTTG

7621 SerValTrpLysAspLeuLeuGluAspAsnValThrProIleAspThrThrIleMetAla  
TCCGTGTGGAAGACCTTCTGGAAGACAATGTAAACCAATAGACACTACCATCATGGCT  
AGGCACACCTTTCTGGAAGACCTTCTGTTACATTGTGGTTATCTGTGATGGTAGTACCGA

7681 LysAsnGluValPheCysValGlnProGluLysGlyGlyArgLysProAlaArgLeuIle  
AAGAACGAGGTTTTCTGCGTTCAGCCTGAGAAGGGGGGTGTAAGCCAGCTCGTCTCATC  
TTCTTGCTCCAAAAGACGCAAGTCGGACTCTTCCCCCAGCATTGGTTCGACAGAGTAG

7741 ValPheProAspLeuGlyValArgValCysGluLysMetAlaLeuTyrAspValValThr  
GTGTTCCCCGATCTGGGCGTGCCTGTGCGAAAAGATGGCTTTGTACGACGTGGTTACA  
CACAAGGGGCTAGACCGCACGCGCACACGCTTTTCTACCGAAACATGCTGCACCAATGT

7801 LysLeuProLeuAlaValMetGlySerSerTyrGlyPheGlnTyrSerProGlyGlnArg  
AAGCTCCCCCTTGGCCGTGATGGGAAGCTCCTACGGATTCCAATACTCACCAGGACAGCGG  
TTCGAGGGGAACCGGCACCTACCTTCGAGGATGCCTAAGGTTATGAGTGGTCTGTGCC

7861 ValGluPheLeuValGlnAlaTrpLysSerLysLysThrProMetGlyPheSerTyrAsp  
GTTGAATTCCTCGTGCAAGCGTGGAAGTCCAAGAAAACCCCAATGGGGTTCTCGTATGAT  
CAACTTAAGGAGCACGTTCCGACCTTCAGGTTCTTTTGGGGTTACCCCAAGAGCATACTA

7921 ThrArgCysPheAspSerThrValThrGluSerAspIleArgThrGluGluAlaIleTyr  
ACCCGCTGCTTTGACTCCACAGTCACTGAGAGCGACATCCGTACGGAGGAGGCAATCTAC  
TGGGCGACGAAACTGAGGTGTCACTGACTCTCGCTGTAGGCATGCCTCCTCCGTTAGATG

7981 GlnCysCysAspLeuAspProGlnAlaArgValAlaIleLysSerLeuThrGluArgLeu  
CAATGTTGTGACCTCGACCCCCAAGCCCGCTGGCCATCAAGTCCCTCACCAGAGGCTT  
GTTACAACACTGGAGCTGGGGGTTCCGGCCACCCGGTAGTTTCAGGGAGTGGCTCTCCGAA

Gly  
8041 TyrValGlyGlyProLeuThrAsnSerArgGlyGluAsnCysGlyTyrArgArgCysArg  
TATGTTGGGGGCCCTCTTACCAATTCAAGGGGGGAGAACTGCGGCTATCGCAGGTGCCGC  
ATACAACCCCCGGGAGAATGGTTAAGTTCCCCCTCTTGACGCCGATAGCGTCCACGGCG

8101 AlaSerGlyValLeuThrThrSerCysGlyAsnThrLeuThrCysTyrIleLysAlaArg  
GCGAGCGGCGTACTGACAACTAGCTGTGGTAACACCCTCACTTGCTACATCAAGGCCCGG  
CGCTCGCCGCATEACTGTTGATCGACACCATTGTGGGAGTGAACGATGTAGTTCCGGGCC

8161 AlaAlaCysArgAlaAlaGlyLeuGlnAspCysThrMetLeuValCysGlyAspAspLeu  
GCAGCCTGTGAGCCGCGAGGGCTCCAGGACTGCACCATGCTCGTGTGTGGCGACGACTTA  
CGTCGGACAGCTCGGCGTCCCGAGGTCTGACGTGGTACGAGCACACACCGCTGCTGAAT

8221 ValValIleCysGluSerAlaGlyValGlnGluAspAlaAlaSerLeuArgAlaPheThr  
GTCGTTATCTGTGAAAGCGCGGGGTCCAGGAGGACGCGGCGAGCCTGAGAGCCTTCACG  
CAGCAATAGACACTTTCGCGCCCCCAGGTCTCTGCGCCGCTCGGACTCTCGGAAGTGC

8281 GluAlaMetThrArgTyrSerAlaProProGlyAspProProGlnProGluTyrAspLeu  
GAGGCTATGACCAGGTACTCCGCCCCCCTGGGGACCCCCACAACCAGAATACGACTTG  
CTCCGATACTGGTCCATGAGGCGGGGGGACCCCTGGGGGGTGTGGTCTTATGCTGAAC

8341 GluLeuIleThrSerCysSerSerAsnValSerValAlaHisAspGlyAlaGlyLysArg  
GAGCTCATAACATCATGCTCCTCCAACGTGTGAGTCGCCACGACGGCGCTGGAAAGAGG

Fig. 17-9

EP 0 388 232 A1

ValTyrTyrLeuThrArgAspProThrThrProLeuAlaArgAlaAlaTrpGluThrAla  
8401 GTCTACTACCTCACCCGTGACCCTACAACCCCCCTCGCGAGAGCTGCGTGGGAGACAGCA  
CAGATGATGGAGTGGGCACTGGGATGTTGGGGGAGCGCTCTCGACGCACCCTCTGTCGT

ArgHisThrProValAsnSerTrpLeuGlyAsnIleIleMetPheAlaProThrLeuTrp  
8461 AGACACACTCCAGTCAATTCCTGGCTAGGCAACATAATCATGTTTCCCCCACACTGTGG  
TCTGTGTGAGGTCAGTTAAGGACCGATCCGTGTATTAGTACAAACGGGGGTGTGACACC

AlaArgMetIleLeuMetThrHisPhePheSerValLeuIleAlaArgAspGlnLeuGlu  
8521 GCGAGGATGATACTGATGACCCATTTCTTTAGCGTCCTTATAGCCAGGGACCAGCTTGAA  
CGCTCCTACTATGACTACTGGGTAAAGAAATCGCAGGAATATCGGTCCCTGGTCAACTT

GlnAlaLeuAspCysGluIleTyrGlyAlaCysTyrSerIleGluProLeuAspLeuPro  
8581 CAGGCCCTCGATTGCGAGATCTACGGGGCCTGCTACTCCATAGAACCACTTGATCTACCT  
GTCCGGGAGCTAACGCTCTAGATGCCCGGACGATGAGGTATCTTGGTGAACCTAGATGGA

ProIleIleGlnArgLeuHisGlyLeuSerAlaPheSerLeuHisSerTyrSerProGly  
8641 CCAATCATTCAAAGACTCCATGGCCTCAGCGCATTTTCACTCCACAGTTACTCTCCAGGT  
GGTTAGTAAGTTTCTGAGGTACCGGAGTCGCGTAAAAGTGAGGTGTCAATGAGAGGTCCA

GluIleAsnArgValAlaAlaCysLeuArgLysLeuGlyValProProLeuArgAlaTrp  
8701 GAAATTAATAGGGTGGCCGCATGCCCTCAGAAAACCTGGGGTACCGCCCTTGCGAGCTTGG  
CTTTAATTATCCCACCGCGTACGGAGTCTTTTGAACCCCATGGCGGGAACGCTCGAACC

Gly  
ArgHisArgAlaArgSerValArgAlaArgLeuLeuAlaArgGlyGlyArgAlaAlaIle  
8761 AGACACCGGGCCCGGAGCGTCCGCGCTAGGCTTCTGGCCAGAGGAGGCAGGGCTGCCATA  
TCTGTGGCCCGGGCCTCGCAGGCGCGATCCGAAGACCGGTCTCCTCCGTCCCGACGGTAT

CysGlyLysTyrLeuPheAsnTrpAlaValArgThrLysLeuLys  
8821 TGTGGCAAGTACCTCTTCAACTGGGCAGTAAGAACAAGCTCAAAC  
ACACCGTTCATGGAGAAGTTGACCCGTCATTCTTGTTCGAGTTTG

Fig. 17-10


EP 0 388 232 A1

IMMUNOLOGICAL SCREENING IN BACTERIA

Transform E coli with Recombinant Plasmids

↓ (Spot Bacteria on  
Nitrocellulose filter)


IPTG Plate




Lyse with Chloroform




BSA absorption/DNAse/Lysazyme

Incubate with primary  
antibody

Wash

Incubate with  
 $^{125}\text{I}$  secondary antibody


Wash




Autoradiograph

FIGURE 18

EP 0 388 232 A1





**U.S. DEPARTMENT OF JUSTICE**




EP 0 388 232 A1

**THE UNIVERSITY OF CHICAGO**






EP 0 388 232 A1



HCV (2001 - 2500)







European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 90 30 2866

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,P X	EP-A-0 318 216 (CHIRON CORP.) * Claims * ---	1-26,28 -34	C 12 N 15/51 A 61 K 39/29 G 01 N 33/576 C 12 Q 1/70
A	EP-A-0 293 274 (MITSUBISHI CHEMICAL INDUSTRIES) ---		
P,A	WO-A-9 000 597 (GENELABS INC.) ---		
P,A	CHEMICAL ABSTRACTS, vol. 112, no. 1, 1st January 1990, page 209, abstract no. 1980n, Columbus, Ohio, US; T. ARIMA et al.: "Cloning of a cDNA associated with acute and chronic hepatitis C infection generated from patients serum RNA", & GASTROENTEROL. JPN. 1989, 24(5), 540-4 * Abstract * ---		
P,A	CHEMICAL ABSTRACTS, vol. 112, no. 7, 12th February 1990, page 169, abstract no. 49584p, Clumbus, Ohio, US; T. ARIMA et al.: "A lambda gt11-cDNA clone specific for chronic hepatitis C generated from pooled serum presumably infected by hepatitis C virus", & GASTROENTEROL. JPN. 1989, 24(5), 545-8 * Abstract * ---		TECHNICAL FIELDS SEARCHED (Int. Cl.5)  C 12 N A 61 K G 01 N C 12 Q
P,A	CHEMICAL ABSTRACTS, vol. 112, no. 11, 12th March 1990, page 441, abstract no. 95311v, Columbus, Ohio, US; T. ARIMA et al.: "Cloning of serum RNA associated with hepatitis C infection suggesting heterogeneity of the agent(s) responsible for the infection", & GASTROENTEROL JPN. 1989, 24(6), 685-91 * Abstract * ---		
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 15-06-1990	Examiner SKELLY J.M.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application	

1500 03.82 (P0401)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 90 30 2866

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
P,X	<p>NUCLEIC ACIDS RESEARCH, vol. 17, no. 24, 1989, pages 10367-10372, IRL Press; Y. KUBO et al.: "A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan" * The whole document, especially page 10638, line 21 - page 10370, line 15 *</p> <p>-----</p>	1-26,28 -34	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 15-06-1990	Examiner SKELLY J.M.
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another</p>			

1501 03.82 (P0401)